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Klebsiella spp. are opportunistic pathogens that cause hospital and community 
acquired infections such as pneumonia, urinary tract infection, septicaemia, soft 
tissue infections, liver abscess, and meningitis. Multidrug-resistant strains possessing 
extended-spectrum β-lactamases (ESBLs) has become an increasing problem 
worldwide. The over use and, in some cases, misuse of antibiotics in humans and in 
animal husbandry has been cited as a responsible factor in the development of drug 
resistance in all bacterial species. The advancing age; female gender, hospital cross-
infection, the food chain trade and human migrations have contributed to increase the 
risk for community-acquired ESBL.  
 
A total of 223 isolates collected in 2006 and 2007 at Royal Infirmary of Edinburgh, 
Scotland, 219 K. pneumoniae, 2 K. oxytoca, 1 Enterobacter cloacae, and one isolate 
Salmonella enterica were identified by API 20E and confirmed genotypically with 
gyrA PCR-RFLP method. The antimicrobial susceptibility results showed that 34 
(15.2%), 36 (16.1%), 35 (15.7%), 45 (20.2%), 30 (13.5%) and 55 (24.7%) of these 
strains were found to be resistant to cefotaxime, ceftazidime, ceftriaxone, naladixic 
acid, ciprofloxacin and cefoxitin. None of the isolates were found resistant to 
meropenem keeping carbapenems the drug of choice for the treatment of multi-
resistant isolates. The overall frequency of ESBL producers observed in this study 
was 35 (15.7%) most of them 32/35 (91.4%) were from K. pneumoniae. The genetic 
analysis showed that SHV β-lactamases were detected in 32, whereas TEM and 
CTX-M were detected in 24 and 16 respectively. 
 
From the ESBL-producing isolates, molecular methods i entified nine strains 
possessing ESBL-SHV genes (1 strain blaSHV-5, 1 strain blaSHV-80 and 8 strains 
blaSHV-12), whereas the remaining were from the “non-ESBL” producing strains. 
Conjugation methods demonstrated that 29/32 isolates harboured transferable blaSHV 
genes. The large SHV transposon-borne promoters were amplified from only one 
non-transferable blaSHV-11, 15 isolates produced the small SHV transposon-bore 
promoters. Furthermore, the IS26 was found 73bp upstream of the blaSHV gene in all 
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small SHV transposon-borne promoters. A new blaLEN gene was identified from K. 
pneumoniae (KpII) phylogenetic group but remained susceptible to all 
cephalosporins. 
 
Sixteen (7.3%) of K. pneumoniae isolates were found to be producers of the CTX-M-
15 ESBL, of which two isolates (12.5%) were reported o be from community-
acquired infections. The insertion sequence ISEcp1 was detected by sequencing 48 
nucleotides upstream of blaCTX-M-15 in all isolates but one. Five different clones of 
CTX-M-15-producing isolates were identified by PFGE. 
 
The findings indicated a higher prevalence of qnr genes than in previous studies but 
still low in general. By PCR, 18 (8%) (11 qnrB1, 2 qnrB6 and 5 qnrA1) genes were 
identified from K. pneumoniae isolates. Also, the findings indicated the frequent co-
expression of fluoroquinolones and ESBLs resistance i  the same isolate. 
 
Two K. oxytoca strains were isolated from urine and blood specimens of hospitalized 
patients. Both strains were positive for the blaOXY-2 gene. One strain showed 
resistance to pencillins, monbactams, cephalosporins including cefotaxime and 
ceftazidime but was not inhibited by clavulanic acid. It differed by an amino acid 
substitution Ala237→Thr, which enhances the binding of cefotaxime.  
 
S1-nuclease plasmid profiles were obtained for some isolates. A total of one to two 
plasmids, ranging in size from approximately 40 to 210 kb, were observed per strain. 
The plasmids from 24 ESBL K. pneumoniae strains were assigned to be IncN or 
IncFII replicons. Analysis of phylogenetic groups showed that the majority of K. 
pneumoniae isolates were belonged to KpI-type. Both K. oxytoca strains were 
assigned to be KoII phylogenetic group based on rp B and gyrA sequencing. 
 
Integrons are capable of capturing and mobilizing genes called gene cassettes which 
play an important role in the dissemination of antimicrobial resistance through 
horizontal transmission. In fact, the present study indicated a high frequency of 
occurrence of class 1 integrons among ESBL-positive K pneumoniae. Three isolates 
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positive for class 1 integrons were found positive for class 2 integrons as well. Class 
1 integrons including dfr, aadA and ereA2 gene cassettes have been identified by 
sequencing, which confer resistance to trimethoprim, streptomycin/spectinomycin 
and erythromycin respectively.  
 
In conclusion, the results from this thesis report the emergence of hospital and 
community-acquired highly resistant CTX-15 β-lactamase in the Edinburgh, 
Scotland. The prevalence of ESBL-producing isolates in Scotland is still much lower 
than in many other European countries. The disseminatio  of SHV- and TEM- β-
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1.1. Antimicrobial Agents     
 
1.1.1 Historical perspective 
 
The initial discovery of antibiotics is generally begins with the Scottish scientist 
Alexander Fleming in 1928. He observed a mould of Penicillium notatum produced a 
diffusible antibacterial agent, penicillin, which inhibited the growth of 
Staphylococcus aureus. Fleming carried out a number of studies on the filtrate of 
liquid cultures of Penicillium notatum; he determined the antibacterial activity of this 
antibiotic in vitro, as well as its non-toxicity when injected into mice and rabbits. But 
Fleming failed to stabilise the active antibiotic (Rolinson 1998; Bennett and Chung 
2001; Goldsworthy and McFarlane 2002; Geddes 2008). Attempts to obtain purified 
penicillin in the 1930s were mostly unsuccessful; however, a study carried out by 
Howard Florey and Ernst Chain in 1940 showed that Penicillin was highly effective 
against a streptococcal infection in mice. They purified penicillin by freeze-drying 
sufficient for clinical use and they discovered a new strain of Penicillium which was 
able to produce high yields of penicillin that has led to the development of modern 
antibiotics (Goldsworthy and McFarlane 2002). 
 
In 1944, the Russian-born biochemist and soil microbiol gist Selman Abraham 
Waksman discovered an antibiotic product from soil bacterium Streptomyces griseus.  
The product, Streptomycin, was the first antibiotic useful for infections caused by 
Gram-negative bacteria (Kingston 2004). 
 
From this discovery, many new classes of antibiotic had been discovered by the 
1960s. The semisynthetic penicillins were introduced by Beecham in early 1960s 
included methicillin (1960), ampicillin (1961) and cloxacillin (1962). At the same 
time the cephalosporin C was established by Abraham and Newton (Rolinson 1998). 
 
1.1.2. Mechanism of action of Antimicrobial drugs 
 
Antimicrobial drugs have several mechanisms (Brooks 2007; Amyes 2010) include: 
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i) Interference with cell wall synthesis such as β-lactam antibiotics now 
include: penicillinase-resistant, amino-, carboxy-, indanyl-, and ureido-
penicillins; first- to fifth-generation cephalosporins; monobactams; and 
carbapenems. 
ii)  Interference of protein synthesis: Aminoglycosides, Macrolides, 
Tetracyclines, Lincomycins, Chloramphenicol, Linezolid, Streptogramins.  
iii)  Interference with nucleic acid (DNA) synthesis by interfering with DNA 
gyrase and topoisomerase IV: Quinolones, Metronidazole. 
iv) Inhibition of Ribonucleic acid (RNA) synthesis by acting on DNA-
directed RNA polymerase: Rifamycins.  
v) Inhibition of a metabolic pathway by acting on the synthesis of 
tetrahydropholic acid: Trimethoprim, Sulfamethoxazole. 
vi) Disruption of bacterial membrane structure: Polymyxins.  
 
 




The β-lactam antibiotics can be divided into six different groups, the penicillins, 
cephalosporins, carbapenems, cephamycins, monobactams, and β-lactamase 
inhibitors (Smet, Martel et al. 2008). β-lactam antibiotics contain a β-lactam ring 
which is a heteroatomic ring structure consisting of three carbon atoms and one 
nitrogen atom. The β-lactam ring of natural or semisynthetic penicillins is fused with 
a thiazolidine ring. In cephalosporins, the β-lactam ring is merged with a 
dihydrothiazine ring. In the carbapenems, the β-lactam ring is combined with a 
hydroxyethyl side chain, lacking an oxygen or sulphr atom in the bicyclic nucleus. 
In contrast to the antibiotics, clavulanic acid, a β-lactamase inhibitor, is composed of 
a β-lactam ring fused with an oxazolidine ring and does not possessed an amide 
function (Livermore and Williams 1996; Amyes 2010).   
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In general, modifications of the R and R’ groups alter the pharmacokinetic and 
antibacterial properties of β-lactam antibiotics; for example, substitutions at position 
7 of cephalosporins increase the penetration into the periplasmatic space and the 
stability against β-lactamases, but may reduce antibiotic activity (Donowitz and 
Mandell 1988). 
 
1.1.3.2. Mechanism of action of β-lactam antibiotics  
 
β-Lactam antibiotics act on bacteria by inhibiting the bacterial enzymes, 
transpeptidases and carboxypeptidases, located in the cytoplasmic membrane which 
catalyses synthesis of the cross-linked peptidoglycan. These enzymes are commonly 
called penicillin-binding-proteins (PBPs) (Spratt 1994).  
 
The cell wall of enterobacteria consists of an inner cytoplasmic membrane and outer 
layer consisting of lipopolysaccharides (LPS) and lipoproteins. LPS consists of lipid 
A, core polysaccharide, and O antigen. The periplasm is a space between the inner 
cytoplasmic membrane and outer lipid membrane. This space contains a loose 
network of peptidoglycan chains. A large layer of peptidoglycan found in the Gram-
positive bacteria; Gram-negative bacteria have a much thinner layer of peptidoglycan 
surrounded by a lipid bilayer outer membrane. The indiv dual peptidoglycan cell 
wall units are produced inside the cell, the final cross-linking is catalysed outside the 
cytoplasmic membrane by a group of membrane-anchored bacterial enzymes known 
as the cell-wall transpeptidases (Fisher, Meroueh et al. 2005; Wilke, Lovering et al. 
2005).  
 
Peptidoglycan is an essential component of the bacteri l cell wall. It protects the 
organism from osmotic rupture, determines cell shape, nd is integral to cell growth 
and division. The peptidoglycan is composed of a basic repeating unit of an 
alternating chains of disaccharide N-acetylglucosamine (NAG) and N-acetylmuramic 
acid (NAM) linked by β-(1,4)-glycoside units. The carboxyl group of muramic acid 
is usually replaced by an aminoacid chain composed of four aminoacids. The most 
common are L-alanine, D-alanine, D-glutamic acid, D-glutamine and L-lysine or 
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diaminopimelic acid (DAP) (Tipper and Strominger 1965; Livermore and Williams 
1996). 
 
In the cross-linking reaction in Gram-negative bacteria, a peptide bond is formed 
between the D-alanine on one chain and the free amino end of a diamino pimelic acid 
on the other chain causing the elimination of the terminal D-alanine and designated 
the transpeptidase reaction. The β-lactam antibiotics are analogues of the terminal 
amino acid (D-alanyl-D-alanine) residues on the precu sor NAM/NAG-peptide 
subunits of the peptidoglycan layer. In the presence of the β-lactam antibiotics, the 
transpeptidases and carboxypeptidases react with acyl-D-alanyl-D-alanine to form a 
lethal serine-ester-linked acyl (penicilloyl, cephalosporoyl) enzyme complex.  The β-
lactam-enzyme complex is very stable, and blocks the normal transpeptidation 
reaction. This result disrupts the synthesis of the cell wall and makes the growing 
bacteria highly susceptible to cell lysis and death (Tipper and Strominger 1965; 
Ghuysen 1988; Livermore and Williams 1996; Wilke, Lovering et al. 2005).  
 
1.1.3.3. Mechanisms of resistance to β-lactam antibiotics 
 
There are four major ways bacteria avoid the bactericidal effect of β-lactam 
antibiotics; alteration of penicillin binding proteins (PBPs), lack or diminished 
expression of outer membrane proteins (OMPs), active efflux pumps promoting the 
transport of the antibiotic from within the cell to the external environment, resulting 
in an intermediate level of resistance and finally, production of β-lactamases that 
hydrolyze the β-lactam ring and render the antibiotic inactive befor  it reaches the 
penicillin-binding protein (PBP) target.  
  
1.1.3.3.1. PBPs modifications 
 
PBPs are divided into two subgroups: low molecular mass (LMM) and high 
molecular mass (HMM) enzymes. The HMM enzymes are fu ther subdivided into 
the bifunctional class A enzymes and the monofunctio al transpeptidase class B 
enzymes (Wilke, Lovering et al. 2005). The penicillin-binding module contains three 
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conserved motifs that form the active cavity. They are the Ser-X-X-Lys (SXXK), the 
Ser-X-Asn (SXN), and the Lys-Thr/Ser-Gly (KT/SG) motifs (Hakenbeck 1998). 
 
Alterations of PBPs have been described in both Gram-negative and Gram-positive 
organisms, assuming a more important role in Gram-positive bacteria. There are 
several PBP-mediated mechanisms of β-lactam resistance, including: 
 
1- Point mutations altering an amino acid. In E. coli, at least three different 
amino acid substitutions within the transpeptidase domain of the PBP3, 
conferred at least seven-fold resistance to cephalexin but not to other 
cephalosporins, penicillins or monobactams. Amino acid modifications in one 
or two enzymes have very little effect on the resistance level (Hedge and 
Spratt 1985). Mutations in PBPs 1A, 2B, and 2X play an important role in the 
development of resistance to ß-lactam antibiotics by S. pneumoniae 
(Sanbongi, Ida et al. 2004). 
 
2- The acquisition of foreign PBP resistant to β-lactam antibiotics; for example, 
the acquisition of PBP2a by methicillin-resistant Staphylococcus aureus 
confers resistance to β-lactam antibiotics (Hackbarth and Chambers 1989). 
 
3- Recombination between susceptible PBPs and those of less susceptible 
species. This hybrid protein, originated in an intersp cies homologous 
recombination, presents slightly less susceptibility to β-lactams (Dougherty 
1986). 
 
4- Overexpression of a PBP. When PBP5 is overexpressed, it is responsible for 
both natural insensitivity and acquired intrinsic resistance to penicillin in 






1.1.3.3.2. Permeability-based resistance 
  
The outer membrane of Gram-negative bacteria plays an important role serving as a 
diffusion barrier for penetration of hydrophilic compounds and interacts with the 
bacterial environment. In Gram-positive bacteria the β-lactam can easily reach the 
cytoplasmic membrane, whereas in Gram-negative the crossing of the outer 
membrane is essentially done through protein channels, the porins (Nikaido 1989).  
 
The porins are divided into two classes: specific and non-specific. In E. coli, OmpC, 
and OmpF, represent the non-specific porins that permit the general diffusion of 
small polar molecules. A loss of either of these porins has been related to antibiotic 
resistance (Nikaido 1989). The OmpA protein in E. coli is a homologue of the major 
porin of P. aeruginosa OprF (Nikaido 2003). In Klebsiella spp. OmpK36, OmpK35 
and OmpK34 are the homologues of OmpC, OmpF and OmpA (Alberti, Rodriquez-
Quinones et al. 1995; Domenech-Sanchez, Martinez-Martinez et al. 2003). K. 
pneumoniae strains usually express OmpK35 and OmpK36, the ESBL-producing 
strains commonly express only one of these, normally OmpK36, or no porin at all 
(Martinez-Martinez, Hernandez-Alles et al. 1996; Hernandez-Alles, Conejo et al. 
2000). In addition to the major porins, minor porins have been described including 
OmpK37 from K. pneumoniae, OmpN from E. coli and OmpS2 from Salmonella 
typhi. The percentages of identity and similarity of OmpK37 with the OmpS2 and 
OmpN porins are 80 and 88% and 77 and 85%, respectively (Domenech-Sanchez, 
Hernandez-Alles et al. 1999). The outer membrane alterations in K. pneumoniae are 
not decisive factors in increasing resistance to animicrobial agents, but porin loss co-
operates with beta-lactamase production to increase re istance to beta-lactams 
(Hernandez-Alles, Conejo et al. 2000). 
 
1.1.3.3.3. Efflux pump 
 
The third mechanism involved in resistance to β-lactam antibiotics is the expression 
of efflux pumps. These proteins transport the antibiotic from within the cell to the 
external environment. A characteristic of efflux pumps is the variety of molecules 
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they may transport, due to poor substrate specificity. Thus, this multidrug efflux 
system plays an important role in providing resistance to a very wide range of 
compounds in Gram-negative bacteria (Nikaido 1998; Poole 2004). 
 
Efflux  was first described as a mechanism of resistance to tetracycline in Escherichia 
coli (McMurry, Petrucci et al. 1980); reviewed by Poole (2005). Bacterial efflux 
systems capable of accommodating a timicrobials generally fall into five classes, the 
major facilitator (MF) superfamily, the ATP-binding cassette (ABC) family, the 
resistance-nodulation-division (RND) family, the small multidrug resistance (SMR) 
family and the multidrug and toxic compound extrusion (MATE) family (Poole 
2004; Poole 2005). 
 
One of these multidrug efflux pumps is the resistance odulation division (RND). 
Examples of this superfamily include the AcrAB system of E. coli and the MexAB-
OprM system of Pseudomonas aeruginosa. The substrates of this family is diverse 
and includes antibiotics, dyes, and detergents (Nikaido 1998). However, members of 
the MFS, MATE and SMR families also show a limited ability to promote resistance 
to some biocides and antibiotics (Poole 2004). 
 
1.1.3.3.4. Enzyme production 
 
The fourth and most important mechanism of resistance to β-lactam antibiotics is the 
production of β-lactamase enzymes. The β-lactamases confer significant antibiotic 
resistance to their bacterial hosts by hydrolysis of the amide bond of the β-lactam 
ring. Classes A, C, and D include enzymes that hydrolyze their substrates by forming 
an acyl (penicilloic or cephalosporoic) enzyme through an active site serine, whereas 
class B β-lactamases are metalloenzymes that utilize at l ast one active-site zinc ion. 
These enzymes are especially important in Gram-negativ  bacteria as they constitute 
the major defence mechanism against β-lactam-based drugs (Livermore 1995; Wilke, 
Lovering et al. 2005). Beta-lactamases have been designated as ‘‘enzymes 
hydrolysing amides, amidines and other C-N bonds . . . separated on the basis of the 
substrate: . . . cyclic amides’’ (Bush, Jacoby et al. 1995).  
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Emergence of resistance to β-lactam antibiotics began even before the development 
of penicillin. The first identification of β-lactamase enzyme was isolated in E. coli 
before the use of penicillin in medical practice (Abraham and Chain 1940). Many 
genera of Gram-negative bacteria naturally possess chromosomal-mediated β-
lactamase. These enzymes and penicillin-binding proteins (PBPs) are thought to have 
evolved from a common ancestor, which probably assist the bacteria in competition 
with other naturally producing β-lactams bacteria (Ghuysen 1991). The first plasmid-
mediated β-lactamase in Gram-negatives, TEM-1, was described in 1965 (the 
designation “TEM” came from the patient’s name, Temoniera) (Datta and 
Kontomichalou 1965). At the same time, another plasmid-mediated β-lactamase, 
known as “SHV-1” (sulfhydryl variable), was found in K. pneumoniae and E. coli. 
(Paterson and Bonomo 2005). The genes encoding β-lactamases can be located on 
the bacterial chromosome, on plasmids, on transposons, r on integrons. These 
mobile genetic elements enable β-lactamases dissemination to other members of the 
Enterobacteriaceae family, H. influenzae, N. gonorrhoeae, and P. aeruginosa, and 
rise the incidence of multi-drug resistant bacteria w th complex resistance patterns 
(Bradford 2001; Weldhagen 2004; Paterson and Bonomo 2005). The mutations in 
TEM and SHV β-lactamases gave them expanded spectrum of activity against 
oxyimino-β-lactams (oxyimino-cephalosporins), and then these enzymes were called 
extended-spectrum β-lactamases (ESBLs) (Bradford 2001; Gniadkowski 2008). 
 
1.1.4. Extended spectrum β-lactamases 
 
Extended spectrum β-lactamases (ESBLs) are “β-lactamases capable of conferring 
bacterial resistance to the penicillins, first-, second-, and third-generation 
cephalosporins, and aztreonam (but not the cephamycins or carbapenems) by 
hydrolysis of these antibiotics, and which are inhibited by β-lactamase inhibitors 
such as clavulanic acid” (Paterson and Bonomo 2005). ESBLs are located in two 
subgroups of group 2, namely subgroups 2be (extended sp ctrum β-lactamases; 
Ambler’s class A enzymes) and 2d (cloxacillin-hydrolyzing β-lactamases; Ambler’s 
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class D ESBLs) according to the β-lactamase functional classification scheme 
(Ambler, Coulson et al. 1991; Bush, Jacoby et al. 1995).  
 
The first ESBL was identified by Knothe, Shah et al. (1983) in a nosocomial K. 
pneumoniae strain isolated in Germany in 1983; since then, over 500 variants of the 
clavulanic acid-inhibited form (TEM, SHV, CTX-M, OXA) have been described 
worldwide (http://www.lahey.org/studies/webt.htm). They are most prevalent in 
Klebsiella spp., and their epidemiology reflects a mixture of mutations, plasmid 
transfer and or clonal spread (Livermore and Woodford 2006). A single clone has 
spread among 14 French hospitals, including a serotype K25 K. pneumoniae with 
SHV-4 (Arlet, Rouveau et al. 1994).  
 
The most common ESBL phenotypes arise from point muations in the blaTEM, 
blaSHV, or blaCTX genes resulting in alterations of the primary amino acid sequence of 
the enzyme (Bradford 2001; Gniadkowski 2001; Paterson and Bonomo 2005; 
Paterson 2006). These mutations usually occurred at position 104 (TEM), 146 
(SHV), 156 (SHV), 164 (TEM), 167 (CTX-M), 169 (SHV), 179 (SHV and TEM), 
205 (TEM), 237 (TEM), 238 (SHV and TEM) and 240 (TEM, SHV and CTX-M) 
(Gniadkowski 2008). Many of the organisms that harbou  ESBLs are also resistant to 
other classes of antibiotics, such as aminoglycosides, fluoroquinolones, tetracyclines, 
chloramphenicol, and sulfonamides (Bonnet 2004).  
 
1.1.4.1. Classification and nomenclature of β-lactamases 
 
Several attempts have been developed to classify β-lactamases. The first scheme to 
classify β-lactamases was proposed in 1968 to group it into penicillinases and 
cephalosporinases (Sawai, Mitsuhashi et al. 1968). In 1970, another classification 
scheme proposed by Jack and Richmond (1970), which was updated in 1973 by 
Richmond and Sykes (1973). This scheme classifies th  β-lactamases from Gram-
negative into five groups based on whether this enzyme hydrolysed penicillin more 
or less rapidly than cephaloridine and whether its activity was inhibited by 
cloxacillin and/or p-chloromercuribenzoate. In 1976, Sykes and Matthew (1976) 
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extended this last scheme to include plasmid-mediat β-lactamases differentiated by 
isoelectric focusing (IEF). After that, Mitsuhashi and Inoue (1981) proposed a 
scheme where they added the category cefuroxime-hydrolyzing β-lactamase to the 
penicillinase and cephalosporinase. Molecular structu e classification was first 
proposed by Ambler (1980) with two classes. Class A including PC1 β-lactamase 
from S. aureus and class B metallo-β lactamase II from B. cereus. Furthermore, 
Jaurin and Grundstrom (1981) described class C cephalosporinases from E. coli K-
12. The designation of class D β-lactamase were segregated from the other serine β-
lactamases after sequencing of PSE-2 and OXA-1 hydrolyzing carbencillin and 
oxacillin (Ouellette, Bissonnette et al. 1987; Huovinen, Huovinen et al. 1988).  
 
One of the most used classification schemes is Ambler’s (Ambler, Coulson et al. 
1991) based upon amino acid sequences. He classified the β-lactamases into four 
molecular classes, A, B, C and D. Moreover, Bush, Jacoby et al. (1995) extended his 
classification scheme of 1989 (Bush 1989a; Bush 1989b; Bush 1989c) attempted to 
correlate the functional characteristics with the molecular structure recognizes four 
major β-lactamase classes, one of which (Group 2) is split into eight subgroups. 
Finally, Bush and Jacoby (2010) updated his classificat on scheme of 1995 by adding 
new functional subgroups to the scheme as a result of identification of new major β-
lactamase families variants (Table 1.1).  
 
β-lactamases are categorized based on similarity in amino acid sequence (Ambler 
classes A through D) or on substrate and inhibitor pr file (Bush-Jacoby-Medeiros 
Groups 1 through 4) classification schemes are widely accepted. As such, this work 









Table 1.1: β-lactamase classification schemes modified from (Bush and Jacoby 
2010): 
 




Distinctive substrates Inhibited by 
Representative 
enzymes 
   CA / TZB EDTA  
C 1 Cephalosporins - - 
AmpC, P99, ACT-1, 
CMY-2, FOX-1, 
MIR-1 
C 1e Cephalosporins - - GC-1, CMY-37 













Ms, PER, VEB 





- - TEM-50 
A 2c Carbencillin + - PSE-1, CARB-3 
A 2ce Carbencillin, cefepime + - RTG-4 




V - OXA-11, OXA-15 




+ - CEPA 
A 2f Carbapenems V - KPC-2, IMI-1, SME-1 
B 3a  (B1) Carbapenems - + 
IMP-1, VIM-1, IND-
1, CcrA 
 (B2)    
L1, CAU-1, GOB-1, 
FEZ-1 
B 3b (B3) Carbapenems - + CphA, Sfh-1 
Unkown 4 -    
(V), Variable, (+), Yes, (-), No, CA, Clavulanic acid, TZB, Tazobact m 
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1.1.4.2. Active site 
 
The β-lactamases are divided into two classes; serine and metallo β-lactamases that 
do not share sequence or structural homology. In classes A, C and D an active site 
serine and a molecular mass of approximately 29,000 Da, is responsible for the β-
lactam hydrolysis (Bradford 2001). The three classes of serine β-lactamases, A, C 
and D share similarity on the protein structure leve , which proves that they are 
derived a common ancestor (Hall and Barlow 2004). In class B metallo β-lactamases 
need a bivalent cation, usually zinc, to be able to catalyse the β-lactam ring (Garau, 
Garcia-Saez et al. 2004; Walsh 2005; Bebrone 2007) 
 
1.1.5. The clinically most important β-lactamases 
 
1.1.5.1. Class A β-lactamases 
 
1.1.5.1.1. TEM β-lactamases 
 
The TEM family of ESBLs constitutes the largest and wi ely disseminated group of 
these enzymes. Their evolutionary precursors are th TEM-1 and TEM-2 
penicillinases (Livermore 1995; Medeiros 1997; Bradfor  2001). TEM-1, was first 
reported in 1965 from an E. coli isolate (Datta and Kontomichalou 1965). Plasmid-
mediated TEM-1 is the most prevalent β-lactam inactivating enzyme found in enteric 
bacilli especially in E. coli and K. pneumoniae, they are also found with increasing 
frequency in other Gram-negative species (Liu, Gur et al. 1992; Bradford 2001). 
TEM-1, is able to hydrolyse ampicillin more than carbenicillin, oxacillin, or 
cephalothin, and is inhibited by clavulanic acid. TEM-1 is encoded by a series of 
gene alleles, blaTEM-1A to blaTEM-1F, which differ from each other by specific silent 
mutations. Each of these genes could initiate a separate evolutionary lineage of 
mutant derivatives (Leflon-Guibout 2000).   
 
TEM-2, the first derivative of TEM-1, had a single amino acid substitution at 
position 39 (Gln39→Lys) from the original TEM-1 β-lactamase. This substitution 
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changes the isoelectric point from 5.4 in TEM-1 to 5.6 in TEM-2. The blaTEM-2 gene 
possesses a stronger promoter than the promoter of he blaTEM-1 gene which confers a 
higher enzymatic activity when compared to TEM-1 producing strains (Jacoby and 
Carreras 1990). TEM-1a, TEM-1b and TEM-2 are encoded in transposable elements 
such as transposons, Tn3, Tn2 and Tn1, respectively (Datta and Kontomichalou 
1965; Partridge and Hall 2005). 
 
TEM-3, originally reported in 1987, was the first TEM-type β-lactamase that 
displayed the ESBLs phenotype. Sequencing of TEM-3 revealed that the enzyme 
was related to TEM-2 and differed by two amino acids from its parent TEM-2 
enzyme: Lys→Glu at position 102 and Ser→Gly at position of 236 (Sougakoff, 
Goussard et al. 1988).   
 
One to five point mutations are especially important for producing the ESBL 
phenotype and extend their hydrolytic spectra; they include amino acid substitutions 
at positions Asp104, Arg164, Ala237, Gly238 and Glu240 (Bradford 2001; Bonnet 
2004). The mutations at position Gly238 in the active site pushes the β-strand out 
and away from the reactive Ser70 residue, resulting in a slightly expanded active site, 
which could improve binding and accommodate cephalosporins with bulky side-
chains. Ser238 is critical for cefotaxime hydrolysis whereas both Ser238 and Lys240 
are needed for strong ceftazidime hydrolysis (Huletsky, Knox et al. 1993). Although 
mutation Glu104→Lys improves the ability of the enzyme to hydrolyse 
cephalosporins and monobactams, it is not sufficient to confer true resistance and is 
always found in clinical isolates associated with at le st one mutation at another part 
of the active site. The Glu104→Lys substitution modifies the precise positioning of 
the SDN loop, which is involved in the binding and catalysis of the substrate (Petit, 
Maveyraud et al. 1995). Moreover, amino acid substitutions at positi n Arg164 are 
the most common mutations in TEM enzymes. Substitutions with either serine or 
histidine remove the ionic bonds that arginine has m de with acidic residues and this 
allows the Ω loop to move to one side thus opening the active site for bulky β-lactam 
variants and increased catalytic efficiency for cefotaxime, ceftazidime and aztreonam 
(Sowek, Singer et al. 1991). In addition, the substitution Ala237→Thr is found in 
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TEM-5 and TEM-24 and it improves binding of the enzyme to cefotaxime by 
facilitating the creation of a hydrogen bond between the Thr237 and the cefotaxime 
molecule (Knox 1995). 
 
TEM enzymes confer a phenotype of resistance to β-lactamase inhibitors conferring 
an inhibitor resistant TEM (IRT) phenotype. Currently, more than 28 blaTEM gene 
variants are resistant to inhibitors like clavulanic acid 
(http://www.lahey.org/studies/). Amino acid substitutions in TEM at positions 
Met69, Ser130, Arg244, Arg275 and Asn276 are usually ssociated with the 
resistance to β-lactamase inhibitors (Canton, Morosini et al. 2008; Drawz and 
Bonomo 2010). 
 
Although inhibitor-resistant TEM (IRT) enzymes generally confer less resistance to 
oxyimino-cephalosporins than parental enzymes, a few enzymes have hydrolytic 
activity against oxyimino-cephalosporins together with inhibitor resistance. These 
enzymes are referred to as complex mutants of TEM (C T). A CMT enzyme 
possesses both of the amino acid substitutions observed in TEM ESBLs and those 
observed in inhibitor-resistant TEMs (Canton, Morosini et al. 2008). First enzyme of 
this group described in France in 1997, CMT-1 (TEM-50), presented the ESBL 
substitutions of TEM-15 and the IRT-substitutions of IRT-4 (Sirot, Recule et al. 
1997). Another example, TEM-125 (CMT-) enzyme combines the amino acid 
substitutions of TEM-12 (ESBL) and those of inhibitor-resistant TEM-39 (Robin, 
Delmas et al. 2006). Other enzymes presenting amino acid substittions of ESBL 
and IRT enzymes were also described in Poland, Portugal and other regions of 
France (Fiett, Palucha et al. 2000; Poirel, Mammeri et al. 2004; Machado, Coque et
al. 2007). Currently, about 9 CMT gene variants are repo ted 
(http://www.lahey.org/studies/). CMT-type β-lactamases are a great challenge in 
detection of ESBLs in clinical laboratories because ph notypic detection methods of 
ESBLs depend on the inhibition of ESBLs by β-lactamase inhibitors, which is absent 




1.1.5.1.2. SHV β-lactamases 
 
SHV enzymes are classified in groups 2b and 2be of the Bush-Jacoby-Medeiros 
classification scheme and in Ambler class A (Ambler, Coulson et al. 1991; Bush, 
Jacoby et al. 1995). SHV refers to sulfhydryl variable. “This designation was made 
because it was thought that SHV hydrolysed cephaloridine but not benzylpencillin in 
the presence of p-chloromercuribenzoate, inhibitory sulfhydryl binding chemical 
(Matthew 1979; Tzouvelekis and Bonomo 1999). This activity was never confirmed 
in later studies with purified enzyme of the SHV-type β-lactamases (Paterson and 
Bonomo 2005). SHV-1 was first described in 1972 andcalled Pit-2 from the author’s 
name Pitton (Pitton 1972). SHV-1 confers resistance to ampicillin, amoxicillin, 
carbenilcillin and ticarcillin (Livermore 1995).  
 
SHV-1 share 84-88.9% and 91.8% amino acid sequence similarity with LEN-1 (a 
chromosomally encoded β-lactamase and K. pneumoniae species-specific 
penicillinase) and OHIO-1 (a plasmid encoded β-lactamase) respectively. Whereas 
the amino acid sequence identity between SHV-1 and TEM-1 is 63.7-67%. The 
SHV-1 substrate binding cavity is 0.7-1.2 Å larger than in TEM-1 (Heritage, M'Zali 
et al. 1999; Kuzin, Nukaga et al. 1999; Tzouvelekis and Bonomo 1999; Reynolds, 
Thomson et al. 2006). 
 
A chromosomal copy of blaSHV-1 or blaSHV-11 or close relatives, encoding non-
extended-spectrum enzymes, considered as native to the great majority of K. 
pneumoniae strains (Babini and Livermore 2000; Ford and Avison 2004; Lee, Cho et 
al. 2006). Other reports considered the SHV-1 β-lactamase is most commonly found 
in K. pneumoniae and is responsible for up to 20% of the plasmid-mediat  
ampicillin resistance in this species (Tzouvelekis and Bonomo 1999). SHV enzymes 
were also detected in other Enterobacteriaceae as a plasmid-mediated β-lactamases 
(Matthew 1979; Sabate, Miro et al. 2002).  
 
Plasmid-mediated blaSHV genes are possibly mobilized from genome to plasmid 
mediated by IS26 (Ford and Avison 2004). IS26 is widely distributed among 
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plasmids facilitating the mobilization of chromosomal sequences containing 
resistance genes. Also, IS26 was found associated with a class 1 integrons which is 
considered as a critical step in the evolution of diverse multiresistance plasmids 
found in clinical enterobacteria (Miriagou, Carattoli et al. 2005). IS26 is an 820-bp 
long insertion sequence that typically generates 8 bp target duplication upon 
transposition (Mollet, Iida et al. 1983). It is demonstrated for IS1 that the length of 
target site duplication sequences may vary according to the sequence of the 
integrated site (Machida and Machida 1987). It is believed that the IS26 insertion 
increases promoter strength through the introduction of a different –35 region 
(Podbielski, Schonling et al. 1991a). IS26 insertion was found 2 kbp upstream in the 
plasmid-mediated SHV-5 enzyme (Gutmann, Ferre t al. 1989). In plasmid-mediated 
SHV-2a, SHV-11 and SHV-12, IS26 insertion was identified into the blaSHV 
promoter (Podbielski, Schonling et al. 1991b; Nuesch-Inderbinen, Kayser et al. 
1997).  
 
The first of these enzymes capable of hydrolyzing the newer beta-lactams, SHV-2, 
was found in a single strain of K. ozaenae isolated in Germany (Knothe, Shah et al. 
1983). Sequencing of the SHV-2 gene showed that only e amino-acid substitution 
of Gly238→Ser was differed from SHV-1 (Kliebe, Nies t al. 1985). The majority of 
SHV variants possessing an ESBL phenotype are charaterized by the substitution of 
a glycine for serine at position 238, glutamic acid for lysine at position 240 
(Huletsky, Knox et al. 1993; Kurokawa, Yagi et al. 2000; Bradford 2001; Hujer, 
Hujer et al. 2002).  
 
The serine residue at position 238 is crucial for effective hydrolysis of ceftazidime. 
The Gly238→Ser pushes the β-strand out and away from the active site Ser70, which 
expands the active site even more when compared to TEM, and permits greater 
substrate versatility against penicillins and cephalosporins. These findings were 
confirmed by site-directed mutagenesis studies (Huletsky, Knox et al. 1993; Hujer, 
Hujer et al. 2002).  Furthermore, the lysine residue at position 240 is responsible for 
hydrolysis of cefotaxime. Resistance to this antibio c is increased in enzymes such 
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as SHV-5 and SHV-12, which possess at least both Gly238→Ser and Glu240→Lys 
substitutions (Huletsky, Knox et al. 1993; Nuesch-Inderbinen, Kayser et al. 1997).  
 
Also, the residue Asp179 is positioned in the Ω loop of the SHV active site. Amino 
acid substitution of Asp179→Ala (SHV-6), Asn (SHV-8) and Gly(SHV-24) possibly 
increase the movement of the Ω loop, expanding the binding site and destabilizing 
the Glu166 (Knox 1995). This substitution conferred high-level resistance to 
ceftazidime but not to cefotaxime (Kurokawa, Yagi et al. 2000). 
  
Contrary to TEM β-lactamases, there are few SHV that confer resistance to β-
lactamase inhibitors. Until now, only few (five) enzymes were detected which 
present mutations that can confer loss of susceptibility to β-lactamase inhibitors 
(Drawz and Bonomo 2010). For example, amino acid substit tions of residues 
Met69→Ile (SHV-49) (Dubois, Poirel et al. 2004), Ser130→Gly (SHV-10) 
(Prinarakis, Miriagou et al. 1997) and Ala187→Thr (SHV-26) (Chang, Siu et al. 
2001) confer an increase of resistance against clavulanic acid associated with the loss 
of affinity to penicillins and narrow-spectrum cephalosporins. By site-saturation 
mutagenesis, SHV enzymes in vitro do no benefit propo tionally from the 
simultaneous presence of amino acid substitutions in residues 69, 244 and 276 of 
naturally occurring in TEM enzymes (Randegger and Hachler 2001). 
 
1.1.5.1.3. CTX-M β-lactamases 
 
In the second half of the 1980s, non-TEM and non-SHV plasmid class A ESBLs 
enzymes have been reported, among them the CTX-M type β-lactamases (active on 
Cefotaxime) (Bonnet 2004). CTX-M first detected in Japan in 1986 from a 
cefotaxime-resistant E. coli (the enzyme was named FEC-1) (Matsumoto, Ikeda et al. 
1988). A few years later in 1989, a similar cefotaxime-resistant clinical E. coli strain 
from Germany was reported to produce β-lactamase enzyme designated CTX-M-1 
(Bauernfeind, Grimm et al. 1990). In 1992, a new plasmid-mediated cefotaximase, 
designated CTX-M-2, was described from multidrug-resistant Salmonella 
typhimurium isolated in 1990 in Argentina (Bauernfeind, Casellas et al. 1992). At the 
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same year, the same type of ESBL was reported in clinical E. coli strain MEN, 
isolated at the beginning of 1989 in France and designated MEN-1 (Barthelemy, 
Peduzzi et al. 1992). The CTX-M β-lactamases constitute one of the most rapidly 
growing ESBL families. Over the last decade CTX-M types have replaced TEM and 
SHV mutants as the predominant ESBLs in numerous contries of Africa, Europe, 
South America and Asia. The CTX-M enzymes have been id tified worldwide 
(Baraniak, Fiett et al. 2002; Saladin, Cao et al. 2002; Livermore and Woodford 2006; 
Livermore, Canton et al. 2007).  
 
The CTX-M family now contains 96 enzymes (http://ww.lahey.org/studies/) and 
subclassified by amino acid similarities into 5 groups: CTX-M-1, CTX-M-2, CTX-
M-8, CTX-M-9 and CTX-M-25 in which the members of each group share 94% 
identity (Bonnet 2004). In contrast to TEM and SHV families, which were originated 
by amino acid substitutions of their parent enzymes TEM-1, TEM-2 and SHV-1, the 
CTX-M ESBLs were acquired by the horizontal gene transfer from other bacteria. 
The gene sequences encoding the regions surrounding the plasmid-mediated CTX-M 
enzymes show high identities to those of the regions surrounding kluyvera georgiana 
chromosomal blaKLUG genes or the K. ascorbata chromosomal blaKLUA  genes 
suggesting the mobilization of this type of β-lactamase-encoding gene from the 
chromosome to plasmids. Thus, it is considered that t e CTX-M-8 and CTX-M-9 
probably originated from Kluyvera georgiana blaKLUG (Poirel, Kampfer et al. 2002; 
Olson, Silverman et al. 2005), whereas the CTX-M-1 and CTX-M-2 family evolved 
from K. ascorbata chromosomal genes blaKLUA (Humeniuk, Arlet et al. 2002; 
Rodriguez, Power et al. 2004).  
 
The CTX-M enzymes confer higher level resistance to cefotaxime, ceftriaxone and 
aztreonam than to ceftazidime (Dutour, Bonnet et al. 2002; Saladin, Cao et al. 2002). 
However, some point mutations produced enzymes witha much stronger activity 
against ceftazidime. For example, CTXM-15 was derived from CTX-M-3 by a 
Asp240→Gly substitution, which increased catalytic activity to ceftazidime (Poirel, 
Gniadkowski et al. 2002). The Asp240→Gly substitution was observed in CTX-M-
32 and CTX-M-53 (CTX-M group 1) presenting higher catalytic activity against 
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ceftazidime (Cartelle, del Mar Tomas et al. 2004; Doublet, Granier et al. 2009). 
CTX-M-27 and CTX-M-16, differing from CTX-M-9 and CTX-M-14 respectively 
by the Asp240→Gly mutation, also present higher catalytic efficiencies against 
ceftazidime (Bonnet, Dutour et al. 2001; Bonnet, Recule t al. 2003). Asp240→Gly 
substitution appears to increase the flexibility of B3 β-strand and synchronized 
motions of the β3 strand with the reactive Ser70 and residues 167 to 170 of the Ω-
loop. These modifications allow a deep insertion of ce tazidime in the catalytic 
pocket and increase activity against ceftazidime (Chen, Delmas et al. 2005; Delmas, 
Chen et al. 2008).  
 
Another substitution responsible for higher levels of resistance to ceftazidime, as 
compared to cefotaxime, is the Pro167→Ser mutation, which differentiates CTX-M-
19 from CTX-M-14 (Poirel, Naas et al. 2001). The mutation at Pro167 in the Ω-loop 
modifies the interaction between β-lactams with Ser237 on the β3 strand and Ser130 
on the SXN loop sites, which are fairly distant from the mutation site. The ydrogen 
bond of the C-4 carboxylate of ceftazidime with Ser130 of CTX-M-19 may well 
correlate with the strong ability of CTX-M-19 to hydrolyze ceftazidime (Kimura, 
Ishiguro et al. 2004). 
 
CTX-M enzymes are susceptibile to β-lactamase inhibitors, although a low-level of 
resistance to the combination of clavulanic acid with amoxicillin and ticarcillin could 
be observed (Bonnet 2004). CTX-M-14 was able to hydrol e sulbactam, clavulanate 
and tazobactam retain their ability to inactivate this enzyme (Ishii, Galleni et al. 
2007).  
 
The ability of insertion sequences (ISEcp1, ISCR, IS26, IS10 and IS903) to mobilize 
and to promote the expression of β-lactamase genes may explain the current spread 
of CTX-M-type enzymes worldwide. The insertion sequnce ISEcp1 was firstly 
identified upstream of blaCMY-4 from an E. coli isolate from the United Kingdom 
(Eckert, Gautier et al. 2006)The insertion sequences ISEcp1 or ISEcp1-like are 
involved in the mobilization of blaCTX-M genes and have repeatedly been observed 
upstream of ORFs encoding the several bl CTX-M genes belonging to the CTX-M-1, 
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CTXM-2, CTX-M-9, and CTX-M-25 subgroups. Also, the ISEcp1 element provides 
the promoter for expression of blaCTX-M genes (Karim, Poirel et al. 2001; Saladin, 
Cao et al. 2002; Poirel, Decousser et al. 2003; Eckert, Gautier et al. 2006; Poirel, 
Naas et al. 2008). The ISEcp1 belongs to the IS1380 family and is capable of 
mobilizing the neighboring genes by one-ended transposition mechanism. The 
mobilization of blaCTX-M-2 from K. ascorbata to E. coli was achievable in the 
presence of ISEcp1 (Lartigue, Poirel et al. 2006).  
 
The ISCR (IS common regions) (formerly called orf513) was identified as being 
closely associated with the spread of many antibiotic resistance genes (Canton and 
Coque 2006; Toleman, Bennett  al. 2006; Poirel, Naas et al. 2008). The blaCTX-M-2 
gene was possibly acquired by a plasmid through Orf513, the so-called CR (common 
region) element. The ISCR1 is strongly associated with the emergence and 
dissemination of the blaCTX-M-2 gene in all blaCTX-M-2-containing Gram-negative 
isolates in Argentina (Arduino, Roy et al. 2002; Arduino, Catalano et al. 2003). In 
Europe, blaCTX-M-9 is most commonly associated with ISCR1 elements as part of a 
complex class 1 integron, In60 (Toleman, Bennett et al. 2006). ISCR elements can 
mobilize large sections of adjacent DNA via a rolling circle replication mechanism. 
Different bla genes, including blaCTX-M, blaCMY, blaDHA-1, blaIMP-1, blaVEB, blaVIM-1 
and qnrA as well as other resistance genes have been associted with ISCR1. ISCRs 
are also associated with Salmonella enterica serovar Typhimurium pathogenecity 
genomic islands (SGIs) and on conjugative transposons encoding sulfamethoxazole, 
trimethoprim and streptomycin resistance genes from Vibrio cholerae (Toleman, 
Bennett et al. 2006). ISCR elements can be divided into two groups: ISCRs1 are 
those that form complex class 1 integrons and ISCRs-2 to -13 are those associated 
with non-class 1 integrons (Bebrone 2007).  
 
The insertion sequence IS26 was described by Saladin, Cao et al. (2002) to be 
upstream of a blaCTX-M-1 gene. The presence of IS26 in all isolates probably due to 
the presence of this insertion sequence on known plasmids, such as IncFII, IncN, and 
IncL/M (Novais, Canton et al. 2007). In addition, IS10 mobile element has been 
observed upstream of blaCTX-M-8 (Bonnet, Sampaio et al. 2000), an IS903-like 
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element was observed downstream of the blaCTX-M-14 and blaCTX-M-17 genes (Pai, Choi 
et al. 2001; Cao, Lambert et al. 2002). Furthermore, the presence of a phage-related 
sequence was identified immediately upstream of blaCTX-M-10 in several CTX-M-10-
producing isolates in Spain suggesting that bacteriophage might be involved in an 
acquisition of blaCTX-M-10 (Oliver, Coque et al. 2005). 
 
Plasmids encoding CTX-M enzymes are often highly transmissible that enable the 
genes to be transferred from one bacterial species to another and from one genus to 
another. The genes responsible for CTX-M β-lactamases are encoded by plasmids 
belonging to the narrow host-range incompatibility types (IncFI, IncFII, IncHI2 and 
IncI) or the broad host-range incompatibility types (IncN, IncP1, IncL/M and 
IncA/C) (Canton and Coque 2006; Novais, Canton et al. 2007; Coque, Novais et al. 
2008; Carattoli 2009) 
 
Isolates producing CTX-M enzymes were reported worldwide, especially CTX-M-
15, CTX-M-14, CTX-M-3, CTX-M-2, and CTX-M-9. In the United Kingdom the 
CTX-M-15 has become the most prevalent enzyme among E. coli strains during the 
last couple of years. CTX-M-1 co-existed initially with isolates harbouring CTX-M-
9, CTXM- 14, and SHV-12, and to some extent with TEM (Livermore, Canton et al. 
2007). In Spain the high prevalence of CTX-M-9, CTX-M-14, CTX-M-15 and CTX-
M-10 has been reported in several studies of the E. coli, K. pneumoniae and 
Salmonella spp. isolates (Hernandez, Martinez-Martinez et al. 2005; Oliver, Coque 
et al. 2005; Valverde, Coque t al. 2008; Oteo, Cuevas et al. 2009). A great variety 
of CTX-M enzymes has been identified in French hospitals including CTX-M-1, 
CTX-M-2, CTX-M-3, CTX-M-9 CTX-M-14, CTX-M-15, CTX-M-21 and CTX-M-
27 ESBLs characterized (Dutour, Bonnet et al. 2002; Saladin, Cao et al. 2002; Arpin, 
Dubois et al. 2003; Eckert, Gautier et al. 2004; Arpin, Quentin et al. 2009). In the 
eastern European countries blaCTX-M-3 is the predominant enzyme. CTX-M-15 also 
identified with a lesser extent (Gniadkowski, Schneider et al. 1998; Edelstein, 
Pimkin et al. 2003; Empel, Baraniak et al. 2008). Additionally, the CTX-M-15 is the 
most-reported CTX-M type in Scandinavian countries (Lytsy, Sandegren et al. 2008). 
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In Canada, a similar CTX-M prevalence to the European countries with a degree of 
diversity among CTX-M enzyme types, with CTX-M-14 and CTX-M-15 being the 
most abundant, while isolates producing CTX-M-2, -3, -24, 13 and -27 were 
relatively rare (Mulvey, Bryce et al. 2004; Pitout, Church et al. 2007). CTX-M 
ESBLs were first reported in 2002 in five states (Virginia, Idaho, Ohio, Washington, 
and Texas) in the United States (Moland, Black et al. 2003). However, CTX-M-
encoding genes including CTX-M-14, CTX-M-15 and CTX-M-3 considered rare in 
the United States (Castanheira, Mendes et al. 2008; Hanson, Moland et al. 2008). 
 
In South America, CTX-M-2, was described from multidrug-resistant Salmonella 
typhimurium isolated in 1990 in Argentina (Bauernfeind, Casellas et al. 1992).  
CTX-M-2 is the most common and has been broadly found in Argentina, Uruguay, 
Paraguay and Brazil. Also, CTX-M-8 and -9 have been found in Brazil (Bonnet 
2004). E. coli producing CTX-M-15 and CTX-M-9 variants (CTX-M-14 and CTX-
M-24) were predominant among community isolates from Bolivia and Peru 
(Pallecchi, Bartoloni et al. 2007).  
 
In the Far East, CTX-M-2 and CTX-M-3 were predominant from Japan (Yamasaki, 
Komatsu et al. 2003), while in China, CTX-M-9, CTX-M-13 and CTX-M-14 
enzymes were already the most frequent ESBL in 1997 and 1998 (Chanawong, 
M'Zali et al. 2002). In India, the CTX-M-15 considered as the most successful and 
widespread CTX-M among others. CTX-M-15 was detected in a two month period 
of the year 2000 from E. coli, K. pneumoniae and Enterobacter aerogenes (Karim, 
Poirel et al. 2001). 
 
1.1.5.2. Class A carbapenemases 
 
The molecular class A carbapenemases, including the plasmid-mediated serine β-
lactamases KPC (for “K. pneumoniae carbapenemase”) and GES (Guiana extended 
spectrum) and the chromosomally encoded SME (for “Se ratia marcescens enzyme) 
and IMI/NMC (imipenem-hydrolyzing β-lactamase/not metalloenzyme 
carbapenemase) enzymes. The class A carbapenem enzymes have the ability to 
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hydrolyze a broad spectrum of antibiotics, including carbapenems, cephalosporins, 
penicillins, and aztreonam, and all are inhibited by clavulanic acid and tazobactam 
(Queenan and Bush 2007). 
 
The chromosomal β-lactamases SME and IMI/NMC enzymes have been detected in 
rare clinical isolates among Serratia marcescens and Enterobacter cloacae isolates 
(Queenan and Bush 2007).  
 
Plasmid-mediated KPC was first detected in a K. pneumoniae clinical isolate from 
North Carolina in 1996 (Yigit, Queenan et al. 2001). KPC has become common in 
the east coast of the United States especially after new variants KPC-2 and KPC-3 
were reported from isolates of K. pneumoniae in Baltimore, MD and New York, NY 
respectively (Moland, Hanson et al. 2003; Woodford, Tierno et al. 2004). Out side 
USA, KPC enzymes were reported from E. coli isolates from Israel (Navon-Venezia, 
Chmelnitsky et al. 2006), from S. marcescens, K. pneumoniae, and E. coli in China 
(Wei, Du et al. 2007; Cai, Zhou et al. 2008), and from K. pneumoniae in Europe 
(Naas, Nordmann et al. 2005; Woodford, Zhang et al. 2008; Fontana, Favaro et al. 
2010; Wendt, Schutt et al. 2010), and from K. pneumoniae and Pseudomonas spp. 
from Central and South America (Villegas, Lolans et al. 2006; Villegas, Lolans et al. 
2007). So far eleven variants are known (http://www.lahey.org/studies/), 
distinguished by one or two amino-acid substitutions. 
 
Enzymes of the GES type, also called IBC (integron-b rne cephalosporinase), is an 
infrequently encountered family that was first described in 2000 from K. pneumoniae 
from French Guiana (Poirel, Le Thomas et al. 2000) and from an E. cloacae isolate 
in Greece (Giakkoupi, Tzouvelekis et al. 2000). GES-1 presents activity against 
penicillins and extended-spectrum cephalosporins. This enzyme does not hydrolyse 
aztreonam, cephamycins and carbapenems and inhibited y β-lactamase inhibitors 
(Naas, Poirel et al. 2008). The GES-2 variant was reported from a clinical solate of  
P. aeruginosa isolated in 2000 in South Africa from blood cultures. GES-2 had a 
single amino acid substitution Gly170→Asn inside the omega loop of the catalytic 
site resulting in slow carbapenem hydrolysis, and is less inhibited by clavulanic 
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(Poirel, Weldhagen et al. 2001). Just like GES-2, other variants GES-4, GES-5, and 
GES-6 and GES-8 have Gly170→Asn substitution associated with imipenem 
hydrolysis. GES enzymes have been reported worldwide from Greece, France, 
Portugal, South Africa, French Guiana, Brazil, Argentina, Korea, and Japan 
(Queenan and Bush 2007; Naas, Poirel et a . 2008). 
 
 
1.1.5.3. Class B Metallo β-lactamases 
 
The molecular class B enzymes ‘metallo-β-lactamases’ were first to distinguish from 
serine β-lactamases in 1980 by Ambler (1980). Metallo-β-lactamases (MBLs) 
required one or two zinc ions for their activity. They hydrolyse penicillin, 
cephalosporins and carbapenems but not monobactams. The metallo β-lactamases are 
EDTA-inhibited enzymes and they are resistant to β-lactamase inhibitors. The 
metallo β-lactamases are subdivided on the basis of sequence alignments into three 
subclasses B1, B2 and B3. Phylogenetic studies sugge t that B1 and B2 descend 
from a common ancestor and subclass B3 shares only structural similarities with 
these subclasses. B1 and B3 are able to bind one or two zinc ions, B2 are mono-Zn 
enzymes that have evolved specificity toward carbapenems. The families of acquired 
MBLs enzymes have been identified until now are, IMP (active on imipenem), VIM 
(Verona integron-encoded metallo β-lactamase), GIM (German imipenemase), SPM 
(São Paulo MBL), and SIM (Seoul imipenemase) (Garau, Garcia-Saez et al. 2004; 
Walsh 2005; Walsh, Toleman et al. 2005; Bebrone 2007; Queenan and Bush 2007). 
 
The IMP family comprises 27 types designated 1 to 27 
(http://www.lahey.org/studies/). IMP-1, the first MBL conferring carbapenem 
resistance, was first discovered in 1988 in a Pseudomonas aeruginosa strain in Japan 
(Watanabe, Iyobe et al. 1991). IMP-1 constitutes the most common metallo-β-
lactamase in Japan, in both enteric Gram-negative organisms and in Pseudomonas 
and Acinetobacter species (Rasmussen and Bush 1997). The emergence of IMP-type 
enzymes have been described, mostly in Japan, China, Taiwan, Australia, USA, 
Canada, Brazil and Europe (Walsh, Toleman et al. 2005). The first member of the 
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IMP family found in Europe, IMP-2, was reported in an A. baumannii isolate from 
Italy in 1997 (Cornaglia, Riccio et al. 1999). 
 
VIM family, a second growing family of carbapenemases, was first discovered in P.
aeruginosa in Verona, Italy in 1997. As found for blaIMP
 genes, the blaVIM-1 gene was 
integrated as a gene cassette into a class 1 integron (Lauretti, Riccio et al. 1999). 
Since then, a total of 24 VIM-type MBLs have been reported 
(http://www.lahey.org/studies/). Although the VIM-types were initially considered as 
the European counterpart of the IMP-type predominant in Southeast Asia, nowadays 
VIM-type MBLs have established endemicity not only in Europe but also in Asia, 
South and North America and Australia. VIM-types alo detected in Pseudomonas 
putida, Pseudomonas fluorescens, A. baumannii, K. pneumoniae, K. oxytoca, E. 
cloacae, Proteus mirabilis and E. coli (Walsh, Toleman et al. 2005; Maltezou 2009).  
 
SPM was first detected from the clinical P. aerugenosa strain in 1997 in São Paulo, 
Brazil and then designated blaSPM-1 (Toleman, Simm et al. 2002). Whereas GIM-1 
was isolated in Germany in 2002 from the P. aerugenosa strain (Castanheira, 
Toleman et al. 2004). The enzyme SIM was first detected in Korea from A. 
baumannii strains. SIM-1 exhibited (64 to 69%) amino acid identity to the IMP 
family (Lee, Yum et al. 2005). Since their initial discoveries, SPM, GIM, and SIM 
metallo β-lactamases have not spread beyond their countries of origin. 
 
1.1.5.4. Class C AmpC-type β-lactamases 
 
With continuing use of 7-α-methoxy-cephalosporins (cefoxitin and cefotetan) and β-
lactamase inhibitor combinations (clavulanate, sulbactam or tazobactam) with 
(amoxicillin, ticarcillin, ampicillin, or piperacillin) plasmids encoding class C β-
lactamases appeared (Philippon, Arlet et al. 2002). AmpC-type β-lactamases 
constitute molecular class C in Ambler’s classification scheme. AmpC β-lactamases 
mediate resistance to most penicillin, broad and extended-spectrum cephalosporins 
and β-lactamase inhibitor-β-lactam combinations (Hanson 2003; Jacoby 2009). 
 27 
Cefoxitin resistance used as indicator for AmpC-mediat  resistance but it can also 
be an indication of loss outer membrane permeability (Philippon, Arlet et al. 2002). 
 
AmpC is typically encoded on the chromosome of Gram-negative bacteria including; 
Citrobacter freundii, Enterobacter cloacae, Morganella morganii, Hafnia alvei and 
Serratia marcescens. The chromosomal ampC gene expression in these organisms is 
inducible by β-lactam antibiotics such as cefoxitin and imipenem but poorly induced 
by the third- or fourth-generation cephalosporins. I  E. coli and Shigella spp., AmpC 
is usually constitutive, minimal and poorly expressed, while in Klebsiella and 
Salmonella species the ampC gene is missing from the chromosome. Induction 
requires the DNA-binding protein AmpR, AmpD and AmpG (Livermore 1995; Jones 
1998; Philippon, Arlet et al. 2002; Hanson 2003; Schmidtke and Hanson 2006; 
Jacoby 2009). 
 
AmpC enzymes have been named according to the resistance produced to 
cephamycins (CMY, 53 variants), cefoxitin (FOX, 7 variants), moxalactam (MOX, 8 
variants) or latamoxef (LAT, variants), according to the type of enzyme, such as 
Ambler class C (ACC , 4 variants) or AmpC type (ACT, 8 variants), according to the 
site of discovery, such as the Miriam Hospital in Providence (MIR, 5 variants) or the 
Dhahran Hospital in Saudi Arabia (DHA, 4 variants) and according the patient name 
Bilal (BIL) (Philippon, Arlet et al. 2002).  
 
AmpC enzymes were considered as exclusively chromosal until 1989, when MIR-
1, the first plasmid-encoded AmpC enzyme, was discovered (Papanicolaou, 
Medeiros et al. 1990). A plasmid-encoded β-lactamase (CMY-1) conferring extended 
broad spectrum resistance including cephamycins was identified in a K. pneumoniae 
strain isolated from a patient's wound. The new cephamycinase (CMY-1) was more 
strongly inhibited by sulbactam in the majority of combinations than by clavulanic 
acid or tazobactam (Bauernfeind, Chong et al. 1989). Infections by plasmid-encoded 
AmpC producing enterobacterial isolates resistant to extended-spectrum 
cephalosporins or aztreonam have become a serious problem worldwide in 
multihospital (Winokur, Canton et al. 2001; Philippon, Arlet et al. 2002; Alvarez, 
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Tran et al. 2004; Song, Kim et al. 2005). CMY-2 enzyme is the most common 
plasmid-mediated AmpC β-lactamase worldwide (Jacoby 2009). The association of 
CMY-encoding genes with mobile elements, such as ISEcp1, ISCR1 or IS26, might 
be the reason involved in mobilization of AmpC enzymes worldwide (Hossain, 
Reisbig et al. 2004; Miriagou, Tzouvelekis et al. 2004; Hopkins, Deheer-Graham et 
al. 2006; Toleman, Bennett e al. 2006). 
 
Failure to detect these β-lactamases has contributed to their uncontrolled spread and 
occasional therapeutic failures. (Perez-Perez and Hanson 2002) developed a 
multiplex PCR assay that proved useful as a rapid screening tool for the detection of 
plasmid-encoded ampC genes. 
 
1.1.5.5. Class D OXA β-lactamases  
 
The OXA β-lactamases differ from the TEM and SHV enzymes and they belong to 
class D (2d) according to Ambler classification (Ambler, Coulson et al. 1991). The 
OXA group mainly occur in Acinetobacter and Pseudomonas species. The OXA β-
lactamases attack the oxyimino-cephalosporins and have a high hydrolytic activity 
against oxacillin, methicillin and cloxacillin more than benzylpenicillin, inhibited 
less efficiently by clavulanate and their activity is inhibited by NaCl (Heritier, Poirel 
et al. 2005; Poirel and Nordmann 2006; Walther-Rasmussen and Hoiby 2006). 
Currently, over than 180 different variants of OXA enzymes have been identified on 
the protein level (http://www.lahey.org/studies/).  
 
Whereas most of the genes encoding class D oxacillinases have commonly been 
found on plasmids incorporated as gene cassettes in integrons, several chromosomal 
encoded oxacillinases have been reported (Heritier, Poirel et al. 2005; Walther-
Rasmussen and Hoiby 2006).  
 
Most OXA-type β-lactamases are not regarded as ESBLs, because they do not 
hydrolyse the extended-spectrum cephalosporins. OXA-11 a variant of OXA-10 
(previously known as PSE-2) is the first extended-spectrum from P. aeruginosa 
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ABD in October 1991 from blood cultures of a burn patient in Turkey (Hall, 
Livermore et al. 1993). Substitutions of an asparagine for serine at position 73, or an 
aspartate for glycine at position 157 are probably required for the ESBL phenotype 
(Bradford 2001). Most OXA-type ESBLs derive from OXA-10 (OXA-11, OXA-13, 
OXA- 14, OXA-16, OXA-17 OXA-19 and OXA-28), or to alesser extent from 
OXA-2 (OXA-15 and OXA-32), or others unrelated to any recognised broad-
spectrum OXA enzymes (OXA-18 and OXA-45) (Naas, Poirel et al. 2008).  
 
The first OXA β-lactamase ARI-1 (for "Acinetobacter resistant o imipenem"), later 
identified as OXA-23, with carbapenemase activity was described by Paton et al. in 
1993. The strain was isolated in 1985 from a patient in the Royal Infirmary of 
Edinburgh, Scotland (Paton, Miles et al. 1993). The hydrolysis of carbapenems by 
the class D oxacillinase in A. baumannii was classified into four subgroups of eight 
clusters and they have been designated OXA-23-like; OXA-40-like; OXA-51-like 
and OXA-58-like (Brown and Amyes 2006), whereas Walther-Rasmussen and Hoiby 
(2006) subclassified carbapenem-hydrolysing OXA enzymes into eight distinct 
branches or subgroups including OXA-23, OXA-24, OXA-48, OXA-50, OXA-51, 
OXA-55, OXA-58 and OXA-60. Another subgroup carbapenem-hydrolyzing 
oxacillinase OXA-62 was identified in Pandoraea pnomenusa from cystic fibrosis 
patients (Schneider, Queenan et al. 2006). OXA-51-like enzymes is intrinsic and 
naturally found in all A. baumannii strains tested (Heritier, Poirel t al. 2005). 
 
1.1.6. Plasmid-mediated quinolone resistance; QnrA, QnrB and QnrS 
 
After introduction of fluroquinolones, resistance to these agents by 
Enterobacteriacae has become common and wide spread (Tran, Jacoby et al. 2005). 
Quinolones act by inhibiting the action of topoisomerases II (DNA gyrase) for Gram-
negative bacteria and topoisomerase IV in the Gram-positive bacteria. Quinolones 
act by binding to gyrase/topoisomerase IV–DNA and forming quinolone-
gyrase/topoisomerase IV-DNA complex which is responsible for the inhibition of 
DNA replication (Nordmann and Poirel 2005; Tran, Jacoby et al. 2005).  
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The quinolone resistance results from mutations in the chromosomally-encoded type 
II topoisomerases, and via the upregulation of efflux pumps, or porin-related genes 
(Drlica and Zhao 1997; Tran, Jacoby et al. 2005). Recent studies demonstrate that 
the plasmid-mediated qnr genes (qnrA, B and S) play an emerging role in the 
dissemination of fluoroquinolone resistance. qnr, the gene product, is a member of 
the pentapeptide repeat family of proteins and has to block the action of 
ciprofloxacin on purified DNA gyrase and topoisomerase IV (Tran, Jacoby et al. 
2005). Plasmid mediated resistance to quinolone was first reported in 1998 in a K. 
pneumoniae clinical strains isolated in 1994 in Birmingham, Alabama, USA 
(Martinez-Martinez, Pascual et al. 1998), and then in Canada, Asia, Australia, 
Turkey and Europe (Poirel, Leviandier et al. 2006). Another qnr gene, qnrS, has also 
been found in a plasmid from a strain of Shigella flexnri isolated in Japan (Hata, 
Suzuki et al. 2005). Recently, qnrB-like determinants were found in Citrobacter 
koseri, E. coli, Enterobacter cloacae, and K. pneumoniae from the United States and 
India (Jacoby, Walsh et al. 2006).  
 
Two other genes, qnrC and qnrD, were more recently reported from China. The 
qnrC was described in aclinical strain of Proteus mirabilis from Shanghai, China, 
coding for a 221-amino-acid protein. QnrC shared 64%, 41%, 59%, and 43% amino 
acid identities with QnrA1, QnrB1, QnrS1, and QnrD respectively (Wang, Guo et al. 
2009). The qnrD gene was described from four Salmonella enterica isolates obtained 
from humans in the Henan Province of China. QnrD encodes a 214-amino-acid 
pentapeptide repeat protein and showed 48% similarity to qnrA1, 61% similarity to 
qnrB1, and 32% similarity to qnrS1 (Cavaco, Hasman et al. 2009). 
 
The qnr genes have been detected in a series of enterobacterial species, but mostly 
from E. coli, Enterobacter spp., Klebsiella spp. and Salmonella spp. (Mammeri, Van 
De Loo et al. 2005; Nordmann and Poirel 2005; Rodriguez-Martinez, Poirel et al. 
2006; Poirel, Cattoir et al. 2008).  
 
The qnrA gene is thought to have originated in Shewanella algae, an environmental 
species from marine and fresh water (Poirel, Rodriguez-Martinez et al. 2005), Qnr-
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like proteins have been detected from water-borne Vibrionaceae bacterial isolates 
and also proposed to be a possible origin of the clinically more important QnrA, 
QnrS, and QnrB determinants (Cattoir, Poirel et al. 2007b).  
 
qnrA and qnrS determinants share 59% amino acid identity, whereas both 
determinants share 40% and 37% amino acid identity w h qnrB respectively 
(Jacoby, Walsh et al. 2006; Poirel, Leviandier et al. 2006). The presence of the qnr 
gene increased the MICs to nalidixic acid and fluoroquinolones by four- to eightfold 
(Martinez-Martinez, Pascual et al. 1998; Tran and Jacoby 2002; Wang, Sahm et al. 
2004; Mammeri, Van De Loo et al. 2005). 
 
qnrA genes has been identified in complex In4 family class 1 integrons, known as 
complex sul1-type integrons that may act as a recombinase for mobilization of CTX-
M, and ampC. These genetic structures possess one 5`-conserved segment (5`-CS) 
which contains intI1 gene encoding for the integrase enzyme and duplicated 3`- 
conserved segments (3`-CS) each of them contains q cE∆1 and sul1 genes. The two 
3`-CS surround a common region (CR) which contains the ISCR1 (orf513) and a 
unique region. Usually, a single copy of ISCR1 is found downstream from qnrA1, but 
in some cases is bracketed by two copies of ISCR1 (Mammeri, Van De Loo et al. 
2005; Nordmann and Poirel 2005; Robicsek, Jacoby et al. 2006; Toleman, Bennett e
al. 2006).  
 
The qnrB1 located in a multi resistance plasmid in an integron-like structure near 
orf513 (orf1005) gene (Jacoby, Walsh et al. 2006). Also, the qnrB2 and the qnrB6 
determinants were reported to be located in a complex sul1-type integrons. The 
genetic structure contained duplicate copies of ISCR1 surround the gene (Garnier, 
Raked et al. 2006).  
 
Unlike qnrA and qnrB, qnrS genes have been reported that it is not part of a sul1-type 
integron and not as a form of a gene cassette in a common class 1 integrons.  The 
qnrS1 has been found to associate with Tn3-like blaTEM-1-containing transposon. 
Other reports found a novel Ambler class A β-lactamase gene, now named blaLAP, 
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instead of the Tn3 element (Hata, Suzuki et al. 2005; Nordmann and Poirel 2005; 
Poirel, Leviandier et al. 2006; Robicsek, Jacoby et al. 2006; Lavilla, Gonzalez-Lopez 
et al. 2008). 
 
The co-presence of qnr genes and ESBL genes on same isolates has been regularly 
reported (Nordmann and Poirel 2005; Jacoby, Walsh et al. 2006; Robicsek, Jacoby et 
























1.2. The genus Klebsiella  
 
1.2.1. General characteristics  
 
The genus Klebsiella is non-motile, non-sporulating, lactose-fermenting, oxidase-
negative, and Gram-negative with a prominent polysacch ride capsule of 
considerable thickness which gives the colonies their glistening and mucoid 
appearance on agar plates. Klebsiella is rod shape 0.3-1 µm in diameter and 0.6-6 µm 
in length arranged singly, in pairs or in short chains. Klebsiella is facultative bacteria 
and the colonies appear large, mucoid, and red withdiffusing red pigment on 
MacConkey agar indicating fermentation of glucose and cid production. Klebsiella 
are normal inhabitant of the intestinal tract of human and animal, soil, water and 
botanical environment (Ørskov 1984; Podschun and Ullmann 1998; Brisse, Grimont 
et al. 2006; Brooks 2007). 
 
1.2.2. TAXONOMY  
 
Klebsiella pneumoniae is a member of the Enterobacteriaceae family, recognised 
over 100 years ago as a cause of community-acquired pn umonia. The organism was 
named to honour Edwin Klebs, a 19th century German microbiologist (Brisse, 
Grimont et al. 2006; Keynan and Rubinstein 2007). 
 
The genus Klebsiella was originally divided into 3 main species based on 
biochemical reactions and medical importance into three species corresponding to 
the diseases they caused: K. pneumoniae, K. ozaenae, and K. rhinoscleromatis. 
Based on DNA-DNA hybridization data K. ozaenae and K. rhinoscleromatis, 
taxonomically, are regarded as subspecies of K. pneumoniae (Podschun and Ullmann 
1998; Drancourt, Bollet et al. 2001; Hansen, Aucken et al. 2004).  
 
The K. oxytoca was originally isolated from old milk. It was further considered as a 
distinct group from K. pneumoniae (Jain, Radsak et al. 1974). Other four new 
species: K. planticola, K. terrigena, K. trevisanii, and K. ornithinolytica were 
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identified in 1980s by (Bagley, Seidler et al. 1981; Izard, Ferragut et al. 1981; 
Ferragut, Izard et al. 1983; Sakazaki, Tamura et al. 1989) respectively. The K. 
planticola and K. trevisanii were subsequently combined and consider as K. 
planticola on the basis of DNA-DNA hybridization (Gavini, Izard et al. 1986). 
Enterobacter aerogenes and Calymmatobacterium granulomatis, due to their close 
relationships to Klebsiella species, were regarded as an eighth and ninth member of 
the genus Klebsiella and named Klebsiella mobilis and Klebsiella granulomatis, 
respectively (Carter, Bowden et al. 1999; Drancourt, Bollet et al. 2001). The three 
species:  K. terrigena, K. planticola, and K. ornithinolytica have recently been 
transferred to the new genus Raoultella (Drancourt, Bollet et al. 2001). 
 
Clinical isolates of K. pneumoniae fall into four phylogenetic groups based on 
nucleotide variations of the gyrA, parC, and rpoB genes, named KpI, KpII-A, KpII-
B, and KpIII, with the newly described species K. variicola appearing to correspond 
to KpIII (Alves, Dias et al. 2006). There are five sequence clusters, KoI, KoII, KoIII, 
KoIV and KoVI were found within K. oxytoca (Fevre, Jbel et al. 2005). 
 
1.2.3. Pathogenesis and clinical importance 
 
K. pneumoniae is the most medically important species of the group. K oxytoca and 
K. rhinoscleromatis have also been demonstrated in human clinical specimens 
(Podschun and Ullmann 1998). In recent years, Klebsiellae have become important 
pathogens in nosocomial infections (Alves, Dias et al. 2006). K. pneumoniae is also a 
potential community-acquired pathogen (Ko, Paterson et al. 2002). 
 
Extended-spectrum β-lactamases resistant Gram-negative bacteria have be n 
associated with increased mortality, length of hospitalization and hospital costs 
(Schwaber, Navon-Venezia et al. 2006). In humans, Klebsiella species may colonize 
the skin, pharynx, or gastrointestinal tract. They may also colonize sterile wounds, 
urine and may be regarded as normal flora in many parts of the colon, intestinal and 
biliary tract (Podschun and Ullmann 1998; Brisse, Grimont et al. 2006). 
Transmission of Klebsiella from patient to patient results from contaminated medical 
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equipments and contaminated hands of medical personnel and blood products, 
whereas, the portals of Klebsiella infections are surgical wounds, peritoneum, 
catheter entrance sites, urinary, respiratory, and biliary tracts (Goetz, Rihs et al. 
1995; Podschun and Ullmann 1998). 
 
K. pneumoniae is an opportunistic and major hospital-acquired pathogen, causing 
urinary tract infections, nosocomial pneumonia, bacteraemia and septicemia (Ko, 
Paterson et al. 2002). Community-acquired pneumonia is a very severe fatal illness 
with a rapid onset, high fever, and haemoptysis (currant jelly sputum), bulging 
interlobar fissure and cavitary abscesses observed by chest radiographic. The 
observed mortality rates range from about 25 to 50% (Feldman, Ross et al. 1995). 
Mortality rates are as high as 50% and approach 100% in hospitalized, 
immunocompromised patient with underlying diseases uch as diabetes mellitus 
(Sahly and Podschun 1997; Ko, Paterson et al. 2002). 
 
The Klebsiellae species are second only to E. coli causing bacteraemia representing 
3-8% of all nosocomial bacterial infection (Podschun and Ullmann 1998). 
Community acquired bacteraemia usually caused by urinary tract infection, vascular 
catheter infection, and cholangitis (Ko, Paterson et al. 2002). In addition, the 
Klebsiellae species especially K. pneumoniae has been shown to cause intra-
abdominal infections mediated by heat stable and heat labile enterotoxins (Rennie, 
Anderson et al. 1990).  
 
Since 1981, a distinctive syndrome of community-acquired K. pneumoniae 
septicaemia with liver abscess has been reported in Ta wan. This syndrome is 
characterized by high mortality (10 to 40%), and some cases have been complicated 
by meningitis or endophthalmitis (Fang, Sandler et al. 2005). The disease has also 
been reported in North America and Europe (Keynan and Rubinstein 2007). The 
symptoms of the disease characterized by fatigue, anorexia, nausea, diffuse 
abdominal discomfort, pleuritic chest pain, jaundice and fever (Lederman and Crum 
2005). The K1 capsular serotype is the predominant serotype of K. pneumoniae 
strains causing liver abscess (Struve, Bojer et al. 2005). In both Taiwan and Korea, 
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K1 capsular serotype is accounted for about 60% of K. pneumoniae strains causing 
liver abscess in these countries ((Fung, Chang et al. 2002; Chung, Lee t al. 2007). 
The frequency of the rmpA gene (mucoviscosity-associated gene A) is associated 
with the hypermucoviscosity phenotype of K. pneumoniae strains that cause liver 
abscess in Taiwan (Fang, Chuang et al. 2004; Yu, Ko et al. 2006). Rahimian and his 
colleagues (Rahimian, Wilson et al. 2004) elucidated that the liver abscess usually 
occur in patients were of Asian ethnicity, indicating a possible genetic linkage to 
disease susceptibility. Lederman and Crum (2005) report d a case series of pyogenic 
liver abscess caused by Klebsiella, 67% of their patients were Filipinos compared 
with only 29% non Filipinos among those patients with l ver abscesses caused by 
different bacterial pathogens. The presence of variable underlying diseases or 
conditions such as diabetes mellitus, heavy alcohol drinking, biliary tract diseases, 
malignancy, liver cirrhosis, end-stage renal disease, intra-abdominal infections, 
history of abdominopelvic surgery, history of steroid use, and history of previous 
antibiotic use considered as risk factors for the K1 serotype K. pneumoniae liver 
abscess (Kim, Chung et al. 2009). 
 
K. pneumoniae has also become a common cause of community acquired bacterial 
meningitis in adults in Taiwan. The proportion of cases of bacterial meningitis due to 
K. pneumoniae in one Taiwanese hospital increased from 8% during 1981 through 
1986 to 18% during 1987 through 1995 (Tang, Chen et al. 1997). Outside Taiwan, 
cases of K. pneumoniae meningitis have occurred, predominantly in other parts of 
Asia (Yanagawa, Nakamura et al. 1989; Li, Shing et al. 2001; Ohmori, Shiraki et al. 
2002), Europe and North America (Holder and Halkias 1988; Giobbia, Scotton et al. 
2003; Bouadma, Schortgen t al. 2006; Braiteh and Golden 2007). The rarity of these 
cases outside Asia raises the possibility of ethnicity or country of origin predisposing 
individuals to invasive disease (Ko, Paterson et al. 2002).  
 
K. pneumoniae consider as the most common pathogen in bacterial ndogenous 
endophthalmitis associated with liver abscesses in Asia. About 13% of K. 
pneumoniae endogenous endophthalmitis are complication of liver abscesses with 
the predisposing factors of endogenous K. pneumoniae endophthalmitis complication 
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are diabetic, and impaired immune function in diabetic’s patients (Han 1995; Wong, 
Chan et al. 2000; Seale, Lee t al. 2007). The disease also has been reported in 
countries of non- Asian origin (Scott, Matharoo et al. 2004; Lederman and Crum 
2005). In addition, the K. pneumoniae genotype K1 is capable of causing 
catastrophic septic ocular or central nervous system as complications from pyogenic 
liver abscess especially in underlying patients (Fang, Lai et al. 2007). 
 
K. pneumoniae has been implicated in the development of ankylosing spondylitis 
because of the high incidence of Klebsiella in the bowel flora of patients whose 
disease is in an active state (Ogasawara, Kono et al. 1986; Sahly and Podschun 
1997). Schelenz, Bramham et al. (2007) reported two cases of acute septic arthritis 
due to extended-spectrum beta-lactamase (ESBL) producing K. pneumoniae in renal 
transplant adult patients following a hospital acquired bacteraemia. Also, K. 
pneumoniae was associated with chronic diarrhoea in HIV-infected persons (Nguyen 
Thi, Yassibanda et al. 2003).  
 
Klebsiella strains are responsible for severe infections in anm ls, including metritis 
in mares following transmission from an infected stud especially capsular serotype 
K1, K2, K5 and K7 (Platt, Atherton et al. 1976). As well, K. pneumoniae can cause 
bovine mastitis (Braman, Eberhart et al. 1973). Klebsiella strains causes serious 
infection in other animals including dogs, monkeys, guinea pigs, muskrats, birds and 
Fox (Brisse, Grimont et al. 2006). 
 
Moreover, K. oxytoca is among the top 4 pathogens that cause infection in patients in 
neonatal intensive care units. It is the second most frequent cause of Gram-negative 
neonatal bacteraemia (Podschun and Ullmann 1998). Klebsiella oxytoca considered 
as an opportunistic infections in laboratory rodents (Bleich, Kirsch et al. 2008).  
 
K. pneumoniae subsp. rhinoscleromatis is associated with rhinoscleroma which was 
first Klebsiella species ever described in 1882 by von Frisch and chara terized by a 
chronic inflammatory process of the nasopharynx. This infection is distributed 
around the world and become an endemic in certain areas in Eastern Europe, Latin 
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America, central Africa, and southern Asia (Sahly and Podschun 1997; Hart and Rao 
2000).  
 
Ozena, a chronic atrophic rhinitis caused by K. pneumoniae subsp. ozaenae 
characterized by necrosis of the mucosa and mucopurulent nasal discharge 
(Strampfer, Schoch et al. 1987). K. pneumoniae subsp. ozaenae may cause invasive 
infections, especially in immunosuppressed hosts such as bacteraemia with or 
without meningitis, otitis, mastoiditis, urinary tract infections, wound infections, 
corneal ulcers, pneumonia, or brain abscess (Brisse, Grimont et al. 2006). 
 
1.2.4. PATHOGENCITY FACTORS 
 
1.2.4.1. Capsular Antigens 
 
Capsule polysaccharide (CPS) is recognized as one of the most important virulence 
factors of Klebsiella spp. The capsular repeating subunits are consisting of four to six 
sugars (glucose, galactose, mannose, fucose, and rhmnose) and, very often, uronic 
acids (as negatively charged components) (Podschun and Ullmann 1998; Brisse, 
Grimont et al. 2006). The K. pneumoniae K2 capsular polysaccharide has been 
reported to contain glucose, mannose, and N-acetyl-glucuronic acid (Arakawa, Ohta 
et al. 1991). The capsular material forms thick bundles of fibrillous structures 
covering the bacterial surface in massive layers to pr tect the bacterium from 
phagocytosis by macrophage, and prevents killing of the bacteria by bactericidal 
serum factors (Simoons-Smit, Verweij-van Vught et al. 1986; Kabha, Nissimov et al. 
1995; Cortes, Borrell et al. 2002; Lin, Chang et al. 2004; Brisse, Grimont et al. 
2006).  
 
In vitro studies have shown that the presence of CPS inhibits the deposition of the 
complement component C3 onto the bacterium, and reduces adhesion and 
phagocytosis of the bacterium by 12 macrophages and epithelial cells (Oelschlaeger 
and Tall 1997; Alvarez, Merino et al. 2000; Cortes, Borrell et al. 2002). The CPS-
mediated virulence involves high resistance of K1 or K2 capsules to phagocytosis by 
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macrophage. In contrast, non-K1/K2 isolates are usually not resistant to phagocytosis 
and less virulent than K1/K2 strains (Simoons-Smit, Verweij-van Vught et al. 1986; 
Kabha, Nissimov et al. 1995; Cortes, Borrell et al. 2002; Lin, Chang et al. 2004). 
 
The macrophages can recognize bacterial surface with mannose content of the CPS 
(Keisari, Kabha et al. 1997). K. pneumoniae with loose, thin capsule is reported to be 
a virulent (Wacharotayankun, Arakawa et al. 1993). Rapidly cleared K21a strain was 
shown to be less virulent, and K2 strain that is viable in blood is highly virulent. The 
binding of K21a to macrophage is responsible for its clearance, and the binding is 
inhibited by yeast mannan (Kabha, Nissimov et al. 1995). Macrophages with the 
mannose-a-2/3-mannose-specific lectin or mannose rec ptor recognize, ingest, and 
subsequently kill Klebsiella serotypes containing the capsular types with low 
virulence, such as the K7 or K21a antigen, repeating sequences mannose-a-2/3-
mannose or L-rhamnose-a-2/3-L-rhamnose by process called lectinophagocytosis 
which defined as nonopsonic phagocytosis that is based on recognition between 
surface lectins on one cell and surface carbohydrates on the opposing cell. 
Lectinophagocytosis may be mediated either by bacteri l surface lectins such as 
fimbriae or by phagocyte lectins that act as receptors. In contrast, strains that lack 
these repeating sequences are not recognized by macroph ges and hence 
phagocytosis does not take place (Ofek, Goldhar et al. 1995; Keisari, Kabha et al. 
1997). Wu et al. (2008) concluded that the possession of fucose might contribute to 
Klebsiella virulence by avoiding phagocytosis because fucose on bacteria had been 
implicated in immune evasion.  
 
The study done by Arakawa, Wacharotayankun et al. (1995) determined the 24,329-
bp nucleotide sequence of the cps region that is responsible for capsular 
polysaccharide synthesis in a K2 K. pneumoniae strain. Nineteen possible open 
reading frames (ORFs) were identified in sequenced ar a. Nassif et al. demonstrated 
that the mucoid phenotype is determined by a gene, designated “rmpA” (regulator of 
mucoid phenotype) located on a 180-kb plasmid, which also carries the aerobactin 
gene. Hypothetically, rmpA is a regulatory gene which controls the production of a 
shield (of unknown composition) surrounding the bacteria and protecting them from 
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interaction with anticapsule-specific antibodies. The 50% lethal dose for mice was 
increased by 1000-fold after a mutation in rmpA, although the mutated strain still 
expresses its capsular specificity (Nassif, Fournier et al. 1989; Nassif, Honore t al. 
1989).  
 
Capsular serotypes K1 and K2 are considered to be the predominant virulent strains 
of K. pneumoniae. Capsular type K1 is most frequently associated with acute 
pneumonia, but K2, K3, K4, K5, and K6 can also be involved (Brisse, Grimont et al. 
2006). K1 has been further investigated as the most common serotype isolated from 
patients with K. pneumoniae liver abscess and endophthalmitis (Chuang, Fang et al.
2006). 
 
Many reports linked between virulence determinants of K. pneumoniae capsule with 
liver abscess formation and serotype-specific genes lik  the magA gene for the K1 
serotype and the k2A gene for the K2 serotype (Arakawa, Wacharotayankun et al. 
1995; Kabha, Nissimov et al. 1995; Cortes, Borrell et al. 2002; Fang, Chuang et al. 
2004; Lin, Chang et al. 2004; Struve, Bojer et al. 2005; Chuang, Fang et al. 2006; 
Yu, Ko et al. 2006). 
  
Moreover, K. pneumoniae surface bound CPS may act as a protective shield on the 
bacterial surface against antimicrobial peptides (APs). Sub-lethal concentrations of 
APs induce an increase in the transcription of the cps operon which correlates with 
an increase in the amount of surface-bound CPS (Campos, Vargas et al. 2004). In 
addition, Llobet, Tomas et al. (2008) demonstrated that the decoy action of CPSs 
contributes significantly to the resistance against APs for pathogens expressing 
anionic CPS. The protective action of CPS will also all w the pathogen to activate 
other countermeasures against APs such as alteration of surface charge, which is a 
time-consuming process. The released CPS traps APs thereby blocking their 
bactericidal activity through the concentrations of de ensins present in tissues which 
are close to the MIC for several bacteria. Recently, Moranta and his colleagues 
(Moranta, Regueiro et al. 2010) started to study whether K. pneumoniae expresses 
mechanisms of resistance against APs. Concentrations of APs present in infected 
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tissues, for example those found in the surface liquid lining the airway epithelium, 
could be rather high due to the increased production of APs after recognition of the 
pathogen. Finally, Evrard, Balestrino et al. (2010) suggested that K. pneumoniae 
CPS, by hampering bacterial binding and internalization, induces a defective 
immunological host response, including maturation of dendritic cells (DCs) and pro-
Th1 cytokine production, whereas the LPS O antigen s ems to be involved 




Adhesion to mucosal and epithelial cell surfaces is often the first step in the 
development of colonization and infection. Adhesins are often also haemagglutinins 
and may be located on fimbriae (pili) that protude on the surface of the bacterial 
cells. More than 80% of clinical isolates of K. pneumoniae, but few K. oxytoca 
strains, express type-1 fimbriae (Podschun and Sahly 1991). Strains of K. 
pneumoniae commonly express three types of pili known as types 1 (common pili), 3 
and 6.  Pili are nonflagellar, filamentous projections on the bacterial surface. These 
structures are up to 10 mm long and have a diameter of 1 to 11 nm; they consist of 
polymeric globular protein subunits (pilin) with a molecular mass of 15 to 26 kDa 
(Podschun and Ullmann 1998). 
 
Type 1 fimbriae are well characterized and found in the most of enterobacterial 
species. Type-1 fimbriae were expressed in more than 80% of clinical isolates of K. 
pneumoniae, but few K. oxytoca strains. They mediate adhesion to mannose-
containing structures present on host cells or in the extracellular matrix and cause 
agglutination of guinea pig erythrocytes. A number of studies have shown that type 1 
fimbriae are an important virulence factor in K. pneumoniae urinary tract infection 
(Podschun and Sahly 1991; Podschun and Ullmann 1998; Brisse, Grimont et al. 
2006; Struve, Bojer et al. 2008; Struve, Bojer et al. 2009). 
  
Type 3 fimbriae are characterized by their ability to agglutinate erythrocytes treated 
with tannic acid. It is called mannose-resistant, Klebsiella-like hemagglutination 
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(MR/K-HA) because it was thought this fimbrial type is synthesized only by 
Klebsiella. In addition to Klebsiella species, type 3 fimbriae become common in 
Enterobacter, Serratia, Proteus, and Providencia isolates (Struve, Bojer et al. 2009). 
Type 3 fimbriae are encoded by the mrk gene cluster which comprises the major 
fimbrial subunit mrkA gene and the mrkD fimbrial adhesin responsible for mannose 
resistant Klebsiella-like hemagglutination.  In vitro studies have revealed that type 3 
fimbriae mediate binding to different structures in human; human endothelial cells, 
epithelia of the respiratory tract, uroepithelial cells, and type V collagen structures 
(Allen, Gerlach et al. 1991; Brisse, Grimont et al. 2006; Struve, Bojer et al. 2009).  
 
Furthermore, type 3 fimbriae are also believed to contribute to the formation of 
extended extracellular structures known as biofilms. Biofilms serve as structural 
anchors, barriers to contact with host defences and as impediments to antibiotics 




The lipopolysaccharide (LPS) molecule is composed of three distinct sections; lipid 
A, a core polysaccharide and a side chain O-antigen (O-Ag) polysaccharide. Nine O-
antigen types are distinguished in K. pneumoniae, O1 being the most frequent. The 
most important role of the O-antigen is to protect K. pneumoniae from complement 
mediated killing (Podschun and Ullmann 1998; Hansen, Mestre et al. 1999; Brisse, 
Grimont et al. 2006). 
 
The lipid A anchors the LPS molecule into the outer membrane and is also an 
endotoxin, stimulating the immune system through agonism of Toll-like receptor 4 
(TLR4) which is present on macrophages, dendritic cells and other cell types 
inducing NF-kB mediated production of cytokines (Alexander and Rietschel 2001). 
The core polysaccharide links the O-Ag onto the lipid A molecule and usually is 
negatively charged due to phosphate substitutions. The O-Ag forms a polysaccharide 
layer that extends up to 30 nm into the surrounding media (Kastowsky, Gutberlet 
al. 1992).  
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1.2.4.4. Other Factors   
 
There are many other factors contributing in pathogenicity of Klebsiella spp. such as 
siderophores, cytotoxins, enterotoxins and haemolysin. 
 
Iron is essential for bacterial growth. Bacteria secur  their supply of iron in the host 
by secreting high-affinity, low-molecular-weight iron chelators, called siderophores 
that are capable of solubilizing and importing the required iron bound to host 
proteins. Two different groups of siderophores are mostly produced in the genus 
Klebsiella, phenolates (enterobactin) (also known as enterochlin) and hydroxamates 
(aerobactin). All strains were found to produce enterochelin, only a few could 
produce aerobactin. The Klebsiella spp. produced third siderophore called 
“yersiniabactin,” which is encoded by the Yersinia high-pathogenicity island, but 
without known role in prevalence and pathogenesis (Podschun and Ullmann 1998; 




The important of typing methods is to obtain information about endemic and 
epidemic nosocomial outbreaks of Klebsiella infections and to determine the 
clonality of the strains. There are two methods have been used in Klebsiella typing.  
 




Biotyping is based on biochemical reactions and enviro mental tolerance. It is 
suitable method of typing for smaller not optimally equipped laboratories. It is useful 
in assessing outbreaks of Klebsiella but it is considered to be of little use in 
epidemiological studies. Biotyping can be carried out by using API 20E system with 
supplementary tests. Klebsiella strains are often currently identified by using 
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automated instruments based on classical biochemical tests, such as the Vitek and 
API systems. Laboratories might use macrotube testsalone or by combining API 20E 
with additional macrotube tests (Podschun and Ullmann 1998). However, 
identification to the species level is often difficult, because some of the species share 
similar biochemical profiles (Monnet and Freney 1994; Wang, Cao et al. 2008).  
 
Hansen et al., (Hansen, Aucken et al. 2004) evaluated a test panel consisting of 18 
biochemical tests on 242 strains preliminarily identified as belonging to the genus 
Klebsiella comprising all Klebsiella species and subspecies from three countries. 
This panel was used to differentiate any Klebsiella species, except Klebsiella 
rhinoscleromatis, from its closest relative as shown in Table 1.2.  
 
Table 1.2: Differentiation of Klebsiella species modified from Hansen t al. (2004). 























Lysine decarboxylase + V - + + + + + - 
Ornithine decarboxylase - - - - - - + + - 
Indole - - - + - V + - - 
Methyl red V V + V + + + - + 
Voges-Proskauer + - - + + + V + + 
Growth at 10°C - - - V + + + V + 
Gas from lactose at 
44.5°C 
V - - - - - - - - 
Malonate + - + + + + + + + 
Fermentation of:          
D-Arabinose V V V + - V V - - 
_-Gentiobiose + + - + + + + + V 
D-Melizitose - - - V + - - - - 
2-Deoxy-D-ribose V - V V + + + V + 
L-Sorbose V V V + + + + - - 
D-Tagatose V - V + V - V - - 
Utilization of:          
m-Hydroxy-benzoate - - - + V - - V - 
Histamine - - - - + + + V - 
Hydroxy-L-proline V - V - V + + + - 
Degradation of pectate - - - + - - - - - 




Serotyping is a reaction of specific antiserum to surface-exposed antigen 
determinant. Serotyping is currently the most widely used technique for typing 
Klebsiella species. The immunodeterminant of Klebsiella is the capsule. Klebsiellae 
usually have well developed polysaccharide capsules, which give their colonies their 
characteristic mucoid appearance. There are 77 distinct capsular antigens of 82 
described recognized an internationally. Klebsiellae also possesses 12 different O-
antigen types, but they are difficult to classify because they are covered by the heat-
stable capsules (Ørskov 1984; Hansen, Skov et al. 2002; Brisse, Issenhuth-Jeanjean 
et al. 2004).  
 
The techniques used in Serotyping are, countercurrent imunoelectrophoresis and 
immnofluroescence. The Quellung test depends on the adsorption of capsular 
antibodies onto the CPS, which results in a change i  the refractive index. But 
disadvantages of serotyping are (i) the occurrence of large number of serological 
cross-reactions among the 77 capsule types, (ii) the weak reaction due to a weak 
antigen which affects interpretation, (iii) time consuming methodology, (iv) lack of 
commercially available anti-capsule antisera, and (v) occurrence of non-typable 
isolates (Podschun and Ullmann 1998; Brisse, Issenhuth-Jeanjean et al. 2004; 
Paterson and Bonomo 2005; Brisse, Grimont et al. 2006) 
 
To avoid these drawbacks, Brisse, Issenhuth-Jeanjean et l. (2004) developed a 
molecular method that would enable determination of the capsular serotypes of 
Klebsiella isolates without the use of antiserum. PCR amplification of the capsular 
antigen gene cluster (cps) was followed by digestion with the restriction enzyme 
HincII (cps PCR-RFLP analysis). 
 
1.2.5.1.3. Phage Typing 
  
Bacteriophage typing is based on the susceptibility of bacterial strains to a panel of 
bacteriophages. Phage typing of Klebsiella was first developed in the 1964 by Milch 
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and Deak (1964). Phage typing has never become widespread because it shows poor 
typing rate of 19 to 67%; the lack of standardization and inoculum concentration; the 
limited availability of bacteriophages; the stability of bacteriophages must be 
evaluated and maintained over time. For these reasons, bacteriophage typing is useful 
mainly as a secondary method in combination with serologic testing but not used as 
an alternative to capsule typing (Podschun and Ullmann 1998; Brisse, Grimont e al. 
2006). 
 
1.2.5.1.4. Bacteriocin Typing 
 
Bacteriocins are bactericidal substances, usually proteins, produced by bacteria to 
inhibit the growth of other bacteria through inhibition of protein and nucleic acid 
synthesis and uncouple electron transport from active transport of thiomethyl-β D-
galactoside and potassium. Bacteriocins usually inhib t the growth of other bacteria 
members of the same species. Bacteriocins technique has become the method of 
choice for typing of organisms belonging to Klebsiella genus because only 34% of 
all Klebsiella isolates produce bacteriocins (Podschun and Ullmann 1998; Brisse, 
Grimont et al. 2006). 
 
1.2.5.2. Molecular Typing Methods 
 
Molecular typing methods, as applied to the genus Klebsiella, have increasingly 
become an integral part of both clinical and research microbiology laboratories. 
Microbial genotyping techniques consider valuable tools to distinguish bacterial 
strains or clones. Genotyping methods are divided into two methods; protein based 












SDS-PAGE method has been used to subtype Klebsiella by (Costas, Holmes et al. 
1990). Who did compared it with capsular serotyping a d concluded that SDS-PAGE 
protein profiles could be used as an effective method.  
 
1.2.5.2.2. Nucleic acid based methods 
 
1.2.5.2.2.1. PCR amplification and sequencing 
 
Klebsiella oxytoca can be differentiated from other Klebsiella species by a specific 
PCR targeting the pehX gene involved in pectin degradation (Kovtunovych, 
Lytvynenko et al. 2003). 
 
1.2.5.2.2.2. Pulsed-field Gel Electrophoresis (PFGE ) 
 
PFGE may be used for genotyping or genetic fingerprinting. It is commonly 
considered a gold standard in epidemiological studies of pathogenic organisms. 
PFGE analysis is recommended to address fine-scale epidemiological studies and can 
detect chromosomal rearrangements which by mobile elements with rapid 
evolutionary rates (Hansen, Skov et al. 2002; Vimont, Mnif et al. 2008).  
 
1.2.5.2.2.3. Randomly amplified polymorphic DNA (RA PD) 
 
The first use of RAPD was in 1996. This technique utilizes low-stringency PCR 
amplification with single primers of arbitrary sequence to generate strain-specific 
arrays of anonymous DNA fragments. RAPD technique may be used to determine 
taxonomic identity, assess kinship relationships, analyze mixed genome samples, and 
create specific probes.  
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1.2.5.2.2.4. Restriction fragment length polymorphi sm (RFLP) 
 
Identification of the isolates were confirmed by g rA PCR-RFLP using restriction 
enzymes HincII, TaqI and HaeIII of the 441-bp fragment of the gyrA gene, and the 
940-bp fragment of the RNA polymerase beta subunit gene (rpoB) allowing for the 
identification of K. pneumoniae species and K. oxytoca genetic groups (Brisse and 
Verhoef 2001; Brisse, van Himbergen t al. 2004). 
 
1.2.5.2.2.5. Multilocus sequence typing (MLST) 
 
A MLST method was previously developed for K. pneumoniae. MLST is a 
nucleotide sequence-based method used for characterizing the genetic relationships 
among bacterial isolates. It provides computerized data that allow multi-user 
international databases available. MLST is more appropriate for strain phylogeny and 
large-scale epidemiology. Analysis of nosocomial isolates showed that MLST can 
discriminate among epidemiologically unrelated isolates (Diancourt, Passet et al. 
2005; Vimont, Mnif et al. 2008). 
 
1.2.5.2.2.6. Repetitive sequence-based PCR (rep-PCR )  
 
The rep-PCR is a rapid method for strain typing anddelineation of bacteria. It uses 
primers targeting noncoding repetitive elements interspersed throughout the bacterial 
genome. Standardized, commercially available kits containing primers and PCR 
master mix reagents are marketed as DiversiLab systems which automated the 
detection and analysis by using microfluidics for rapid detection in a single day, and 
digitized the corresponding information in a software package. The standardized, 
digitized gel images are stored for comparison betwe n runs and between 






Aims of this study: 
 
• To establish the prevalence, variants and mechanisms of ESBLs (TEM, SHV, 
CTX-M, OXY) among K. pneumoniae and K. oxytoca isolates from Scotland. 
 
• To investigate the mechanisms of emergence of CTX-M enzyme within 
hospital and community. 
 
• To investigate the prevalence of plasmid-mediated quinolone resistance, 





















































2.1. Bacterial strains 
 
A total of two hundred and twenty three clinical isolates consecutively collected at 
Royal Infirmary of Edinburgh, Scotland. From these, ven isolates K. pneumoniae 
were collected during March, 2006. A year later, another 216 isolates were isolated 
from August to October 2007. From the relevant information available, the majority 
of the isolates 181 (81.1%) were collected from urine samples, 16 (7.2%) strains 
were collected from blood samples. The remainder 26 (11.7%) of the total strains 
were from assorted samples, including sputum, tip dialysis line, nephrostomy swabs 
and arthritis swabs. 
 
2.2. The phenotypic identification method 
 
All isolates were inoculated onto MacConky agar (Oxoid) plates and incubated 
overnight at 37°C. An isolated colony was used for identification by the phenotypic 
API 20E method according to the manufacturer’s instructions (BioMerieux, Marcy 
L'Etoile, France). Also, isolates were routinely identified in hospital laboratory by 
Vitek2 system. 
 
2.3. The genotypic identification (AFLP) 
 
Identification of the isolates were confirmed by g rA PCR-RFLP using restriction 
enzymes HincII, TaqI and HaeIII of the 441-bp fragment of the gyrA gene, and the 
940-bp fragment of the RNA polymerase beta subunit gene rpoB allowing for the 
identification of K. pneumoniae species and K. oxytoca genetic groups as previously 
described (Brisse, van Himbergen et al. 2004; Brisse and Duijkeren 2005).  
 
2.4. Standard laboratory strains for susceptibility  test 
 
Three strains, Staphylococcus aureus NCTC 6571, Escherichia coli NCTC 10418 
and Pseudomonas aeruginosa NCTC 10662 were used as MIC controls. Isolates 
SHV-1, SHV-3, TEM-1 and TEM-2 from lab collections were used as IEF controls. 
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2.5. Storage of isolates 
 
Isolates were inoculated onto MacConky agar (Oxoid, Basingstoke) plates and 
incubated overnight at 37°C. A single colony was added to the Cryobank System 
beads (Mast Diagnostic, UK) to each vial for long-term storage according to the 
manufacturer's instructions at -70°C. 
 
2.6. Growth media 
 
All growth media were sterilized by autoclaving for15 minutes at 121ºC and cooled 
prior to bacterial inoculation. Normal saline was prepared with 0.85% NaCl and then 
sterilized before use. 
 
2.7. Chemicals, buffers and media 
 
All chemicals were purchased from Sigma-Aldrich Company (Poole, UK) Ltd unless 
otherwise stated. All media were purchased in powder from Oxoid (Basingstoke, 
UK) and then prepared with distilled water before st rilization according to 
manufacturer’s instructions.  
 
2.8. Preparation of electrocompetent bacteria  
 
A single clone of E. coli DH10B or DH5α from lab collections was grown overnight 
in 50 ml of LB broth at 37°C. 10 ml of the overnight culture were inoculated into 1 L 
of LB broth and incubated at 37°C until it reaches 0.5 at an OD600nm. The culture 
was rapidly chilled on ice for 30 minutes. The bacteria were transferred into 
centrifugation containers and centrifuged for 10 minutes at 6000 g (600 rotor 
centrifuge) at 4°C. The supernatants were discarded and the bacteria pellets were 
resuspended in equal volume of sterilised 10% glycerol. The bacteria were 
centrifuged for 10 minutes at 6000 g. The pellets were resuspended in 250 ml of 10% 
glycerol followed by a centrifugation at 6000 g for 10 minutes. Then, the 
supernatants were discarded and the pellets resuspended in 125 ml of 10% glycerol 
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and centrifuged at 6000 g for 10 minutes. Finally, the cells were resuspended in 10% 
glycerol to give a final volume of 2-5 ml and were aliquoted to 100 µl into 1.5ml 
Eppendorff tubes. The cells were frozen and stored at -70°C until used. 
 
2.9. Antimicrobial susceptibility testing  
 
2.9.1. Antimicrobial agents 
 
Antimicrobial agents used in this study were: Imipenem (Merck Sharpe Dohme, 
Rahway, NJ, USA), meropenem (ASTRA Zeneca, Loughborough, UK), potassium 
clavulanate (Sigma), cefotaxime (Sigma), ceftazidime (Sigma), ceftriaxone (Sigma), 
aztreonam (Sigma), cefepime (Sigma), ampicillin (Sigma), co-amoxiclav 
(Augmentin) (Sigma), nalidixic acid (Sigma), ciprofloxacin (Bayer AG, Germany), 
gentamicin (Sigma) and amikacin (Sigma), rifampicin (Sigma).  
 
2.9.2. Minimum inhibitory concentrations (MICs) 
 
Minimum inhibitory concentrations (MICs) are considered the `gold standard’ for 
determining the antimicrobials susceptibility of organisms. Isolates were tested for 
antimicrobial susceptibility by agar double dilution method (MIC) following the 
BSAC guidelines (BSAC 2006). Minimum inhibitory concentrations were performed 
on IsoSensitest (IST) agar containing the appropriate concentrations of antimicrobial 
agents. The bacterial inocula were adjusted to be at 0.5 McFarland standards. 
Bacterial cultures were diluted to 104 cfu in physiological saline before use. The 
inoculation was done using a multipoint inoculator (Denley; Surrey, UK) to deliver 1 
µl of suspension (104 cfu/spot) on to the surface of the agar. Inoculated plates were 
incubated overnight at 37º C. Standard strains Staphylococcus aureus NCTC 6571, 
Escherichia coli NCTC 10418 and Pseudomonas aeruginosa NCTC 10662 were 
used to validate the experiment.  
 
Isolates found resistant to cefotaxime, ceftriaxone r ceftazidime, were considered as 
potential ESBL producers and were subsequently subjected to confirmatory tests.   
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2.9.3. Confirmation of ESBLs production 
 
2.9.3.1. Disc diffusion method 
 
The antimicrobial susceptibility of isolates was teted by the disc diffusion test. 
Briefly, an overnight culture in IST broth was diluted in sterile 0.85% saline; spread 
the inoculum over the entire surface of the plate by three dimensional ways. A 
selective of discs has been applied to the surface of the agar within 15 minutes of 
inoculation. 
 
2.9.3.2. Double disc synergy method 
 
Synergy between cefotaxime and clavulanate was detected by placing a disc of 
Augmentin (20 µg of amoxicillin plus 10 µg of clavulanate) and a disc of cefotaxime 
30 mm apart (centre to centre). A clear-cut extension of the edge of the cefotaxime 
inhibition zone toward the disc containing clavulanate (as shown in figure 1) was 
interpreted as synergy. The double-disc synergy test wa  considered positive when 
decreased susceptibility to cefotaxime was combined with synergy between 
cefotaxime and Augmentin (Jarlier, Nicolas et al. 1988). 
 
2.10. Analytic isoelectrical focusing (IEF) 
 
This experiment was performed with polyacrylamide gels containing ampholines 
with a pH range of 3.5 to 10.0 as previously described (Mathew, Harris et al. 1975). 
The pI values of the β-lactamases were determined by comparison with the pI values 
of known β-lactamases, TEM-1 (pI 5.4), TEM-2 (pI 5.6), SHV-1 (pI 7.6) and SHV-3 
(pI 7.0). 
 
2.10.1. Preparation of β-lactamases 
 
The bacterial strains were grown in 5 ml of sterile nutrient broth overnight at 37°C 
with shaking (200osc/min). Cells were harvested by centrifugation at 3000 g 
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(H1000B rotor, Sorvall RT 6000D, Du pont) for 15 minutes at 4°C. The pellet was 
resuspended in 2 ml of 50mM sodium phosphate buffer, pH7.0 and the cell 
suspensions were transferred into bijou bottles. Cells were subjected to 
ultrasonication (MSE Soniprep 150, MSE instruments, Crawley) for 3 x 30 seconds 
at amplitude of 8 microns with 1 minute cooling period between each sonication. The 
cell lysate was cleared by centrifugation at 16000 g for 10 minutes at 4°C. The β-
lactamase extracts were stored at -20°C until requid.  
 
2.10.2. Detection of β-lactamase activity by nitrocephin spot assay 
 
A 30 µl volume of β-lactamase preparation was added to 100 µl of nitrocephin (50 
mg/L) in a microtitre plate. The β-lactamase activity was equal to the time in seconds 
for the colour change of the solution from yellow to red, and the time in seconds for 
this change to take place was recorded.  
 
2.10.3. Gel casting 
 
The casting chamber was formed from two glass plates separated by rubber tubing 
placed along their perimeters and clamped together into which the gel solution was 
poured prior to assembly.  One of the glass plates was coated with a binding solution 
(0.55 w/v gelatine, 0.5% w/v chromium potassium sulphate dodecahydrate), and 
dried at 55 C to promote adhesion of the gel to the glass. The other plate was 
siliconised to permit easy separation of the polymerized gel. The gel solution has 
been poured between the glass plates and was left to polymerise for at least 4 hours. 
The components of the gel in the order they were added shown in Table 2.1.  
 
2.10.4. Loading IEF gel 
 
The volume (µl) of β-lactamase preparation that was equivalent to its nitrocephin 
spot test time was applied to the gel surface close t  the anode. A maximum of 15 µl 
of preparation was added per lane. β-lactamase preparations of known isoelectrical 
points were also applied to the gel in order to quantify the gradient.  
 56 
Table 2.1: composition of an IEF gel 
 
Material Volume added Final concentration 
Distilled water 25 - 
40% (w/v) ampholines pH 
3.5-10 
2.0 2% (w/v) 
100 g acrylamide plus 2.7 
g methylene bisacrylamide 
(BDH) in 300 ml distilled 
water 
9.0 
Acrylamide 75 g/L 
Bisacrylamide 2 g/L 
Riboflavin (20mg/L) 4.0 2 mg/L 
5% (v/v) TEMED* 0.2 0.005% (v/v) 
 
2.10.5. Running conditions  
 
Isoelectric focusing was performed at 500 V (limiting), 1 W (constant) and 20 mA 
(limiting) for 18 hours at 4ºC. 
 
2.10.6. Visualisation of β-lactamases after electrophoresis  
 
The β-lactamase activity was detected by soaking a piece of filter paper (Whatman 
No. 1, Whatman International Ltd, Maidstone) in nitrocephin solution (50 mg/L) and 
overlaying the surface of the gel. The focused β-lactamases appeared as red bands on 
a yellow background. Stained gels were photographed with a Polaroid camera using 
a Tiffen green filter.  
 
2.10.7. Inhibitor overlays  
 
The β-lactamase inhibition was detected by soaking a filter paper in the required 
concentrations of antimicrobial inhibitor solutions and laid over the gel surface for 
10 minutes at 37°C. The filter paper was removed an the gel was stained with 
nitrocephin as described in section (2.10.6).  
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2.11. Conjugation studies by broth mating method 
 
Broth mating experiment was performed with E. coli J62-2 (RifR). Cultures of each 
donor and the recipient strain were grown in LB broth (Sigma) and then mixed in the 
ratio of 1:9 and incubated overnight at 37°C. The mating mixture was serially diluted 
in 0.9% saline. A 100 µl aliquot of each dilution was spread onto MacConkey agar 
plates containing (50 mg/L amoxicillin) or (2 mg/L cefotaxime) or (8 mg/L naladixic 
acid) and (150 mg/L rifampicin). Controls of each strain were prepared by 
inoculating equal volumes of each broth onto separate agar plates containing the 
same antibiotic concentrations. Both control plates and conjugated plates were 




For transformation, plasmid DNA was transferred by electroporation into E. coli 
DH5α cells. Transformants were plated on LB agar supplemented with appropriate 




The DNA was mixed with the electrocompetent E. coli bacteria in 2 mm gap cuvette. 
The cuvette containing the sample was placed on the shocking chamber of the gene 
pulser (Electroporation 32 System) and the mixture was electroporated at 2.5 volt. 
Cells were recovered by adding 500 µl LB medium and incubating at 37°C for 1hour 
whilst shaking.  
 
2.14. Preparation of DNA 
 
2.14.1. Extraction of DNA from the bacterial isolat es 
 
Bacterial culture was grown in 5 ml IST broth and then 1.5 ml of the culture was 
centrifuged at 16000 g for 1 minute. The pellet was resuspended in 100 µl of distilled 
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water by repeated pipetting and boiling for 10 minutes followed by centrifuge at 
10000 g for 1 minute. The supernatant was transferred to another tube and kept at - 
20ºC until used. 1 µl was used as DNA template.  
 
Genomic DNA was extracted using the Puregene DNA isolation Kit (Qiagen, UK) 
according to the manufacturer’s instructions.  
 
2.14.2. PCR reagents 
 
All PCR reagent were performed with Promega reagents (Promega, Southampton, 
UK), Go Taq Flexi DNA Polymerase (5u/µl) in 5x green or colourless buffer, MgCl2 
solution (25mM) and deoxynucleoside triphosphates (dNTP) / PCR nucleotide mix 
(10mM each). Sterilized distilled water was used as the diluents. 
 
2.14.3. PCR reaction 
 
All PCR reactions unless otherwise indicated were performed in 50µl volumes in 
PCR tubes. The reaction mixture consisted of 2.5mM MgCl2, 0.1mM dNTPs, 5X 
reaction buffers, 0.05mM each primer, 0.2 units of Taq, 1µl extracted DNA template 
and the volume of the reaction mixture was completed to 50µl using sterilized 
distilled water. The thermal cycler was adjusted according to the type of the reaction. 
All amplification experiments included a negative control blank which contained all 
reagents with the exception of target DNA. 
 
2.14.4. Primers used 
 
Primers were designed either with perlprimer v1.1 software 
(http://perlprimer.sourceforge.net/), or the sequences were taken from previously 
published work. Table 2.2 shows primers used for PCR amplifications in this study. 




Table 2.2: Oligonucleotides used for PCR amplification and Sequencing 






































AGA GGA TTT CTC ACG CCA GG 
TGC CAG GCA CAG ATC TTG AC 
GGM ATH GAA ATT CGC CAC TG 
TTT GCY GYY CGC CAG TCG AA 
GCA AGT TCA TTG AAC AGG GT 
TCT AAA CCG TCG AGT TCG GCG 
GGG TAT GGA TAT TAT TGA TAA AG 
CTA ATC CGG CAG CAC TAT TA 
AGT GAT CTC ACC TTC ACC GC 
CAG GCT GCA ATT TTG ATA CC 
TGG AAA CCT ACA ATC ATA CAT ATC G 
TTA GTC AGG ATA AAC AAC AAT ACC C 
ACC TGA GCG GCA CTG AAT TTA T 
TCG CAA TGT GTG AAG TTT GC 
GAT GAC TCT GGC GTT AGT TGG 
CCA TGA CAG CGA TAC CAA GA 
TTT GCG ATG TGC AGT ACC AGT AA 
CGA TAT CGT TGG TGG TGC CAT A 
CTT CCA GAA TAA GGA ATC 
CCG TTT CCG CTA TTA CAA 
GCA GGT CTT TTT CTG CTC C  
TTT CCG CAG CAC CGT TTG C  
TGC TCT GTG GAT AAC TTG C 
GCG GTA AAT CGT GGA GTG AT 
ATT CGG CAA GTT TTT GCT GT 
CCC CTA TTT GTT TAT TTT TC 
GAC AGT TAC CAA TGC TTA ATC A 
GGG CAA GAG CAA CTC GG 
CAG CAA TGG CAA CAA CGT TG 
CAA CGT TGT TGC CAT TGC TGC AG 
ACC GAG TTG CTC TTG CCC 
GCC GGG TTA TTC TTA TTT GTC GC 
TCT TTC CGA TGC CGC CGC CAG TCA 
GGA CTA CTC GCC GGT CAG C 
GCT GAC CGG CGA GTA GTC C 
GAT TGT CGC CCT GCT TTG G 
CCA AGC AGG GCG ACA ATC 










(Hopkins, Wootton et al. 2007)  
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(Edelstein, Pimkin et al. 2003)  
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(Dutour, Bonnet et al.  2002) 
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(Poirel, Decousser et al. 2003)  
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(Woodford, Ward et al. 2004)  
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(Mabilat and Goussard 1993)  
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CAT TTC AAA AAC TCT GCT TAC 
TAC ACA GGC GAA TAT AAC GC 
GAT CGA GCA CTG GCA ACG 
TGA TTC CAA TAG AAC GAC ATC 
TCC CGC ACT CGC GAT AC 
ATG ATA AAA AGT TCG TGG C  
TTA AAG CCC TTC GGT CAC 
GAA CAT AGC GGC TCC TTA T 
GGT TAC AAC TTC GAA GAC TC 
GGC GAA ATG GCW GAG AAC CA 
CGC GTA CTA TAC GCC ATG AAC GTA 
ACC GTT GAT CAC TTC GGT CAG G 
GGG GAC AAG TTT GTA CAA AAA AGC AGG 
CTC CGC CGG AAT TCC ATC ATC AAT A 
GGG GAC AAG TTT GTA CAA AAA AGC AGG 
CTC CGC CAT GAT AAA AAG TTC GTG G 
GGG GAC CAC TTT GTA CAA GAA AGC TGG 
GTT TAA AGC CCT TCG GTC AC 
CCT TCG AAT GCT GTA ACC GC            
ACG CCC TTG AGC GGA AGT ATC 
GAG GGC TTT ACT AAG CTT GC            
ATA CCT ACA AAG CCC CAC GC 
TCA GAC GTC GTG GAT GTC G  
CGA AGA ACC GCA CAA TCT CG 
CAC GGA TAT GCG ACA AAA AGG T 
GTA GCA AAC GAG TGA CGA AAT G 
CCA TGC TGG TTC TAG AGA AGG TG 
GTA TAT CCT TAC TGG CTT CCG CAG 
GGA GTT CTG ACA CAC GAT TTT CTG 
CTC CCG TCG CTT CAG GGC ATT 
GAG AAC CAA AGA CAA AGA CCT GGA 
ACG ACA AAC CTG AAT TGC CTC CTT 
GTC TAA CGA GCT TAC CGA AG 
GTT TCA ACT CTG CCA AGT TC 
CTG TCG TAA GCT GAT GGC 
CTC TGC CAC AAA CTT CAG C 
GGA TGA AAA CTA TCA GCA TCT GAA G 
CTG CAG GGG CGA TTC TTT AGG 
CGA AAG CCG GAC GGC AGA A 
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(Brisse and Duijkeren 2005 ) 
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(Brisse and Verhoef 2001)  
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(Machado, Canton et al. 2005)  
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TCG TCG TTC CGC CAA GTT CGT 
GTG AAC TGG CAG ATG AGG AAG G 
TTC TCC TCG TCG CCA AAC TAG AT  
GGC ATC CAA GCA CAA GC 








2.14.5. Screening of PCR products 
 
Agarose (1gm) was added to 100 ml TAE buffer (40mM Tris acetate, 20mM Acetic 
acid, 1mM EDTA, pH7.6). The agarose was solubilized by heating in a microwave 
oven for 10 minutes and then left to cool to room te perature. Five µl of each of the 
PCR product samples were applied to the gel along with 5 µl molecular weight 
marker after mixing each with 1 µl loading buffer on a piece of parafilm. Each 
mixture was applied to a slot using 10 µl micropipette. The electrophoresis cell was 
covered and the power supply was switched on and adjuste  at 10 Volt/cm. The gel 
was immersed in ethidium bromide solution (0.5 mg/L) for between 10-30 minutes 
depending on the concentration of DNA being analysed. The gel was taken out from 
the cell and examined under gel documentation. 
 
2.14.6. Purification of PCR product 
 
PCR products were purified either directly or by separation of the DNA fragment 
from 1% TAE agarose gel electrophoresis. The DNA band of the correct size was cut 
out from the gel. The purification of DNA from the direct PCR and gel purification 
were done using (Qiagen purification kit) according to the manufacturer’s 
instructions. 
 
2.14.7. Determination of DNA concentration 
 
The concentration and purity of the purified DNA was determined by measuring the 
UV absorbance at 260 and 280 nm. The DNA concentration was calculated with the 
OD260nm (1 OD260nm = 50 µg/ml dsDNA or 33 µg/ml ssDNA). The purity was 
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estimated with the OD260nm/OD280nm ratio, with a ratio of ca. 1.8 indicating a low 
degree of protein contamination. 
 
2.14.8. Sequencing of the genes 
 
The resulting PCR products were sequenced by the Sanger method using an ABI 
373A DNA sequencer (PE Applied Biosystems, Warringto , UK). The BLAST and 
FASTA programs of the National Centre for Biotechnology Information 
(http://www.ncbi.nlm.nhi.gov) were used to search databases for similar nucleotide 
and amino acid sequences. The amino acid sequences were translated using the 
EXPASY translate website (http:www.expasy.ch/tools/dna.html). Multi-alignment of 
DNA or amino acid sequences was performed with the online website Multalin 
(http://www.toulouse.inra.fr/multalin.html) or Clustal W tools 
(http://www.ebi.ac.uk/Tools/clustalw2/). 
 
The sequencing of the blaOXY-2 genes was done commercially by GATC Biotech 
(Konstanz, Germany), using pDONR207 vector forward an reverse primers. 
 
2.14.9. Restriction endonuclease digestion 
 
Restriction endonuclease reactions were performed according to the manufacturer’s 
recommendations. In general, 1.5 µg DNA was digested for 2 hours at the 
appropriate temperature with 10-20U enzyme. Efficacy of the cleavage reaction was 
determined by 0.7% agarose gel electrophoresis stained with ethidium bromide. 
 
2.15. Pulsed Field Gel Electrophorasis (PFGE) 
 
2.15.1. Preparation and digestion of DNA in plugs 
 
PFGE was applied to assess the clonality of bacteril isolates. Without shaking 
overnight cultures from 5ml of Brain Heart Infusion (BHI) were collected by 
centrifuged at 4000 g for 20 minutes. The supernatant was removed and the pellets 
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were re-suspended in 2ml of PIV buffer (1.0 M Tris base, 1.0 M NaCl, pH 7.6) and 
allowed to equilibrate to 50ºC for an hour. An equal volume of 1.6% low-melting-
point agarose (Boehringer Mannheim, Indianapolis, USA) prepared in PIV buffer 
was added to each suspended cell and the mixture pipetted into Bio-Rad (Richmond, 
California, USA) plug moulds and refrigerated at 4ºC for 30 minutes.  
 
The protocol then followed that described by (Mirand , Kelly et al. 1996). The cells 
embedded in agarose plugs were incubated in 5ml of lysis buffer (1.0 M Tris, 1.0 M 
NaCl, 100 mM EDTA, 0.5% Brij 58, 0.2% deoxycholate, 0.5% Na lauroyl sarcosine) 
supplemented with 50mg/ml RNase and 1mg/ml lysozyme overnight at 37ºC. The 
lysis buffer was replaced by ESP buffer (0.4 M EDTA, 1% sodium lauroyl sarcosine, 
0.5mg/ml proteinase K, pH 9.0) and incubated at 50ºC for 24 hours prior to washing 
once with 1X TE at 37ºC (5 mM Tris HCl, 5 mM EDTA, pH7.5) containing 1mM 
phenylmethylsulfonyl fluoride and three times wash with 0.1X TE for at least 30 
minutes each wash. Plugs could be stored at this stage at 4ºC in 0.1X TE buffer. 
 
For PFGE digestion, a slice of plug was equilibrated in 200µl of the 1X restriction 
endonuclease buffer for 2 hours at room temperature. After this, the slice was 
incubated with 30 U of  Xba1 restriction endonuclease (Promega, UK) in a fresh 100 
µl 1 X reaction buffer containing 1µl BSA in water bath at 37ºC for 12 hours. The 
reaction was stopped by adding 300 µl of 0.5X TBE buffer (0.089M Tris base, 0.089 
Boric acid, 2.5 mM disodium EDTA) (ICN Biomedical, Aurora, Ohio, USA). Plug 
slices were then loaded into wells of 1% PFGE agarose gel preapared in 0.5 TBE 
buffer. Electrophoresis was performed in a CHEF-DRII system (Bio-Rad 
Laboratories, Ltd). The gel was run for 24 hours at 200V (6v/cm) at 14ºC with 5-45 
initial and final pulse times. Lambda ladder PFGE marker (New England, Biolabs) 
was used as the size standard marker. Gels were stained for 30 min in ethidium 
bromide (0.5mg/ml), destained twice in distilled water for 30 minutes and visualized 





2.15.2. Interpretation of PFGE 
 
All isolates were analysed using BioNumerics software, version 4. Isolates which 
clustered together with a similarity of >85% were considered to belong to the same 
PFGE type. Results were obtained in phylogenetic trees.  
 
2.16. Southern Blotting Protocol 
 
2.16.1. Transferring of DNA 
 
DNA quantities were assessed by running 1µl of DNA with 9µl of gel loading buffer 
on a 1.2% gel for 45 minutes, 38mv, and 70V. The DNA was digested with an 
appropriate restriction endonuclease for 2 hours at optimal temperature and subjected 
to electrophoresis on a 1% agarose gel. The gel was stained for 15 mins in ethidium 
bromide (125 µl in 250 ml dH2O). The top right hand corner of the gel was cut for 
orientation. Transfer of restricted DNA was carried out by soaking the gel for 15 
minutes in 750 ml acid wash. Then the gel was soaked in 750 ml alkaline wash for 
60 minutes. Finally, the gel was soaked twice for 20 minutes in 750 ml neutral wash. 
The gel was rinsed briefly in distilled water between each wash. The neutral wash 
was poured off, and the gel was flipped over and placed on the centre (uncovered) 
part of a wick of 3 sheets of blotting paper sandwiched together. The dated nylon 
membrane was soaked in the 10 X SSC and then placed on top of the gel. 
Individually three pieces of blotting paper was soaked in 10 X SSC and lied carefully 
over the membrane. The stack of paper towels, a glass plate, and a bottle of around 
500 g were placed on top of this. Each time air bubbles were removed. The station 
was left for 8-24 hours to allow capillary transfer to occur. 
 
2.16.2. Preparation of DIG labelled probe 
 
The PCR reaction for amplification of labelled probe was carried out using PCR DIG 
probe synthesis kit (Roche) as described below: 
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 DIG labelled probe Unlabelled control  
dH2O 33.25 30.25 
PCR buffer + MgCl2 (Vial 3) 5.0 5.0 
PCR DIG labelling mix (Vial 
2) 
2.5 - 
dNTP stock (Vial 4) 2.5 5.0 
Primer A 2.0 2.0 
Primer B 2.0 2.0 
Enzyme Mix (Vial 1) 0.75 0.75 
DNA template 2.0 5.0 
 
The PCR programme was as follow: 2 minutes at 95°C, 30 cycles of 30 sec at 95°C, 
30 sec at 50°C, and 30 sec at 72°C, and final extension of 7 min at 72°C. To confirm 
the probe has been produced, 5µl PCR product mixed with 5µl loading dye was run 
against the unlabelled control PCR on 1.2% Gel at 70 V for 45 minutes. 
 
2.16.3. Hybridisation procedure 
 
Hybridisations with labelled probes were performed using DIG easy-hybridisation kit 
(Roche, Germany). The nylon membrane was placed on a piece of saran wrap/cling 
film and U.V. cross-linked for two minutes on both sides. The hybridisation 
incubator (Techne Hybridiser, Cambridge) was adjusted to 50°C. The membrane was 
pre-hybridised in the hybridisation oven with 20 mlDIG easy hyb for 30 minutes. 
The labelled probe was boiled for 5 minutes and rapidly cold on ice. For 
hybridisation, appropriate concentration (5-20 µl) of the labelled probe was added to 
20 ml DIG easy hyb., and incubated overnight at the appropriate temperature for the 
probe. 
 
2.16.4. Post-hybridisation washes  
 
2 X 5 minutes in Wash 1 at room temperature. 
2X 15 minutes in Wash 2 at 68°C. 
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2.16.5. Immunological detection 
 
All steps were done at room temperature with agitation  
-1-5 minutes in 100 ml 1 X washing Buffer. 
- 30 minutes in 100 ml 1 X blocking solution. 
- 30 minutes in antibody solution (10 µl antibody in 200 ml 1 x blocking solution). 
- 2 X 15 minutes in 100 ml 1 X washing Buffer. 
-3 minutes in 20 ml 1 X detection buffer. 
- 20-25 drops CDP* ready-to-use was added to the DNA side of the membrane in a 
hybridisation bag or saran wrap and was incubated for 5 minutes at 37ºC. 
Autoradiography film (HyperfilmTM, Amersham Life Science) was exposed initially 
for 30 minutes and extended up to 5 hours depending on the strength of the signal 
after the initial period.  
 
2.16.6. Stripping and reprobing of DNA blots 
 
Membranes were saturated in 2X SSC and stored at -20ºC in a hybridisation 
bag/saran wrap. Reprobing the membrane was carried out by rinsing the membrane 
briefly in distilled water followed by rinsing the membrane in the stripping solution 
(0.1% (w/v) SDS) which had been brought to the boilat 5ml/cm2 membrane for 15 
minutes at 37ºC to remove the DIG labelled probe. This step was repeated again and 
the membrane was rinsed thoroughly in 2 x SSC (5-6 rinses) and pre-hybridised and 
hybridised with second probe. If reprobing was not to be carried immediately, the 









Table 2.3: Solutions used in southern blot hybridisation 
Solution Working concn. 
Store 
concn. 




2 X SSC 





Room temp. / can be 
made in advance 
Wash 2 






Room temp. / can be 
made in advance 
*Washing Buffer 1X 10X 10 ml in 90 ml dH2O Room temp. 
*Maleic acid Buffer 1X 10X 10 ml in 90 ml dH2O Room temp. 
*Blocking Solution 1X 10X 
10ml/90ml 1X maleic 
acid 
Prepare fresh 
*Detection Buffer 1X 10X 10 ml in 90 ml dH2O Room temp. pH9.5 
Pre-hybridisation 
solution 
5 X SSC 
0.1% N-laurylsarcosine (w/v) 
0.02% SDS (w/v) 











Acid wash 0.25 M HCl 35-38% 




1.5 M NaCl 





Room temp./can be 
made in advance 
Neutral wash 
0.5 M Tris HCl (pH8.0) 
1.5 M NaCl 







Room temp./can be 
made in advance 
20 X SSC 
3M NaCl 
0.3 M NaCitrate 
Solid 
Solid 
175.3 g/1000 ml 
88.0 g/1000 ml 
Room temp./can be 
made in advance  
pH7.0 
* These reagents are part of the DIG wash and block buffer set 
 
2.17. Plasmid analysis 
 
2.17.1. Extraction of plasmid DNA 
 
Several different plasmid extraction protocols were us d in this study. The extraction 
methods employed included the mini and midi kit (Qiagen), and miniprep rapid 
alkaline lysis method described by (Birnboim and Doly 1979) with some 
modifications. Briefly, a single bacterial colony was selected from the LB plates and 
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was transferred to 5 ml of LB broth and incubated overnight at 37°C with constant 
shaking. The cells were harvested by centrifugation at 3000 g for 10 minutes at 4°C. 
The supernatant was discarded and the bacterial pellet was washed in 250 µl of TE 
(10mM Tris, 1mM EDTA, pH8). The bacterial pellet was resuspended in 300 µl of 
ice-cold solution I. For the alkaline lysis of the bacteria, 300 µl of solution II were 
added and mixed properly and left on ice for 10 minutes. Three hundred µl of ice-
cold solution III were added and were stored again on ice for 10 minutes. The 
mixture was centrifuged at 16000 g for 10 minutes. The protein and genomic DNA 
was removed from the supernatant with phenol: chloroform: isoamyl alcohol 
(25:24:1) mixture followed by centrifugation at 16000 g for 10 minutes. 
Subsequently, the plasmid DNA was precipitated by double volume of absolute 
ethanol and washed with 0.5 ml 70% ethanol followed by a centrifugation at 13000 
rpm for 10 minutes in each step. Finally, the DNA was dissolved in 50 µl of 
nuclease-free water. 
 
Solutions for the small scale preparation of the pl asmid DNA extraction 
 
Solution I: 50 mM glucose 
25 mM Tris Cl pH 8.0 
10 mM EDTA pH 8.0 
Solution II: 0.2 N NaOH 
1% SDS 
Solution III: 3 M potassium acetate adjusted to pH5 with glacial acetic acid and 
then adjusted to the final volume with distilled water. 
 
2.17.2. Determination of plasmid profile by Nucleas e S1  
 
This procedure converts the circular plasmid DNA to the linear form to determine the 
accurate molecular sizes of plasmids. The closed circular supercoiled form moves 
very slowly, the naked plasmids remain trapped in the sample wells. The protocol 
was modified from (Barton, Harding et al. 1995), briefly the plugs of PFGE 
containing DNA was equilibrated into 200 µl S1 buffer (Promega) for 20 minutes at 
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room temperature. The buffer was replaced with 100 µl of fresh buffer with 8 U of 
nuclease S1 (160 U/ µl) (Promega) and incubated for 45 minutes at 37ºC. The 
reaction was stopped by adding 0.5M EDTA (pH8). Then the gel was running as for 
Xba1 PFGE electrophoresis. The size of plasmids was determined by comparison to 
Lambda ladder PFGE markers (New England Biolabs).  
 
2.18. DNA cloning of OXY-2 beta-lactamase 
 
2.18.1. Primers design and PCR amplification 
 
The cloning of OXY-2 beta-lactamases was done with Gateway® Technology with 
Clonase™ (Invitrogen, UK) as described by manufacturer’s instructions. Primers 
were designed using perlprimer v1.1 software (http://perlprimer.sourceforge.net/) 
and adjusted the annealing temperature to be approximately 55ºC. Two primer pairs 
were designed for nested PCR. The first primer-pair consisted of gene specific 
primers containing the internal parts of the attB1 and attB2 recombination sites. The 
second pair of primers contains the external parts of the attB1 and attB2 
recombination site in addition to a 12 nucleotide ov rlap with the internal forward 
and reverse primers (Table 2.4). 
 
Table 2.4: Primer construction for nested polymeras chain reaction (PCR) 
 
1 attB1 internal for AAAAAGCAGGCTCCGCC ATGXXXXXXXXXXXXX 
2 attB1 internal rev AGAAAGCTGGGT XXXXXXXXXXXXXXXXXXXXX 
3 attB2 external for GGGGACAAGTTTGTACAAAAAAGCAGGCT 
4 attB2 external rev GGGGACCACTTTGTACAAGAAAGCTGGGT 
Bold letters: attB1/attB2 sequence, underlined letters: Kozak sequence, italic letters: 
forward and reverse sequence of blaOXY-2 gene. 
 
The two PCR reactions were performed with Expand Long Template PCR System 
(Roche) according to the descriptions below, with 10 µl of the first reaction being 




10x buffer I 5 µl 
Internal Forward Primer 10 pmol/µl 2 µl 
Internal Reversed Primer 10 pmol/µl 2 µl 
Template 10ng/µl 2 µl 
dNTP Mix 10mM 1 µl 
Polymerase 1.5U 0.3 µl 
Distilled water to final volume 50 µl 
                                                 
2nd PCR: 
10x buffer I 5 µl 
External Forward Primer 10 pmol/µl 1 µl 
External Reversed Primer 10 pmol/µl 1 µl 
Template (1st PCR Reaction) 10 µl 
dNTP Mix 10mM 1 µl 
Polymerase 1.5U 0.3 µl 
Distilled water to final volume 50 µl 
 
PCR conditions for both PCRs were as follows: 2 minutes at 94°C, 15 cycles of 10 
sec at 94°C, 30 sec at 55°C, and 2 minutes at 68°C, and final extension of 7 min at 
68°C. The PCR products were used in cloning vectors pDONR207, pGBKT7 and 
pGADT7 which were isolated by midiprep alkaline lyses according to manufacturer’s 
instructions (Qiagen, UK) in reactions described below. 
 
2.18.2. The BP reaction 
 
PCR product 2-7 µl 
pDONR 207(150 ng/ µl) 1 µl 
BP Reaction buffer (5x) 1.5 µl 
BP Clonase    1 µl 
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The reaction was incubated at 37°C overnight. After incubation, 1 µl of proteinase K 
was added and incubated for 10 minutes at 37°C. 1 µl of the reaction was 
transformed into 50 µl of electrocompetent DH10B bacteria. Cells were recovered by 
adding 500 µl LB medium and incubating at 37°C for 1h whilst shaking. The whole 
volume of transformation reaction was spread on LB plates containing 15 µg/ml 
gentamicin and incubated overnight. Plasmid DNA wasisolated from single colony 
by mini prep alkaline lyses (Qiagen Kit). The plasmids were digested with the 
restriction endonuclease BanII to determine the corre t size of the inserted fragment 
and sent to sequencing to assure no presence of frame shift. This plasmid was used in 
LR reaction.  
 
2.18.3. The LR reaction 
 
Purified Entry Clone (150 ng/µl) 1 µl 
pGBKT7 1 µl 
pGADT7  1 µl 
Distilled water 1 µl 
LR Clonase 1 µl 
 
Two µl of the reaction mixture were transformed into 50 µl of electrocompetent 
DH10B bacteria. Cells were recovered by adding 500 µl LB medium and incubating 
at 37°C for 1h whilst shaking. The transformation reaction was divided in two parts. 
One was spread on LB plates containing 50 µg/ml kanamycin for pGBKT7 (bait 
vector), the other on ampicillin plates (50 µg/ml) for pGADT7 (prey vector). The 
plasmids were digested with the restriction endonucleases EcoRI and BamHI to 








2.19. Ribonucleic acid analysis 
 
2.19.1. RNA extraction 
 
Total RNA was extracted from bacterial cultures grown to an optical density of 0.6-
1.0 at OD600 with RiboPure
TM-Bacteria Kit (Ambion, UK). Sterilization of 
contaminating RNAases from the benches and equipments was done by RNAZAP 
(Ambion, UK). RNA was electrophoresed on denaturing (1% formaldehyde) agarose 
gel electrophoresis. The resulting RNA was treated with DNase 1 at 37°C for 30 
minutes for removal of the trace amounts of genomic DNA from the eluted RNA. 
 
2.19.2. Reverse transcription 
 
RNA was reverse transcribed to cDNA and PCR amplification of a specific target 
RNA from total RNA using one-tube, two enzyme system (Access RT-PCR System 
Kit, Promega). The reverse transcription was done according to the manufacturer’s 
instructions. The PCR products were analysed by agarose gel electrophoresis and 
stained with ethidium bromide. The image was examined using UV Gel 
Transillumination.   
 
 
2.20. Determination of outer membrane proteins by S odium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PA GE) 
 
2.20.1. Protein extraction 
 
The outer membrane protein was extracted according to the method described by 
(Bossi and Figueroa-Bossi 2007). Briefly, bacterial cells were grown in 5 ml of LB 
to OD600 of 0.35 and collected by centrifugation at 3000 g (Sorvall RT 6000D) for 15 
minutes at 4°C. The pellet was re-suspended in 1 mlof 10 mM Tris pH 8.0 and 
sonicated with cooling, using three pulses of 20 s with 30 s resting intervals (MSE 
Soniprep 150, MSE instruments, Crawley). Lysate was centrifuged at 7000 g for 
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5 minutes. Then the supernatant recovered and centrifuged at 13 000 rpm for 
45 minutes at 20°C. The pellet was re-suspended in 0.5 ml of freshly made 10 mM 
Tris-HCl pH 8.0, 10 mM MgCl2, 2% (v/v) Triton X-100. Furthermore, the 
suspension was incubated at 37°C for 30 minutes, then centrifuged at 16000 g for 
45 minutes at 20°C. Finally, the pellet was re-suspended in 50–100 µl of 100 mM 
Tris-HCl pH 8.0, 2% SDS. The suspension was kept at −20°C until use.  
 
2.20.2. Polyacrylamide gel electrophoresis 
 
The separating and stacking gels were calculated from the website 
(http://www.changbioscience.com/calculator/sdspc.htm) as shown below. 
Ammonium persulfate was the last components to be add d just before pouring and 
mixed gently to avoid the addition of air which affects the gel matrix. The separating 
solution was poured into the preassembled gel appartus. Two ml ethanol was added 
on the surface of separating gel to get even surface and the gel was left to polymerise 
for approximately 30 minutes. The stacking gel was poured followed by insertion of 
a 10 well comb and left to polymerise for at least 45 minutes.   
 
Stacking gel 4% 
 
 Separating gel 15%  
Distilled water (mL) 3.65 Distilled water (mL) 3.55 
40% Polyacrylamide (mL) 0.625 40% Polyacrylamide (mL) 3.75 
1M Tris(pH6.8)(mL 0.625 1.5M Tris(pH8.8)(mL) 2.5 
10% SDS (mL) 0.05 10% SDS (mL) 0.1 
10% Ammonium persulfate (µL) 12 10% Ammonium persulfate 
(µL) 
22 
TEMED (µL) 12 TEMED (µL) 22 
Total volume (mL) 5 Total volume (mL) 10 
 
Samples were mixed with an equal volume of SDS-PAGE loading dye (950 µl, 50 µl 
β-mercaptoethanol), heated at 100ºC for 5 minutes and kept on ice until required for 
gel loading. About 20 µl volume of each sample was loaded into the wells. 
Molecular weight markers (Bio Rad) were added to a well to accurate size. The gel 
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was inserted into a gel electrophoresis apparatus (Protean II, Bio Rad). The 
electrophoresis was run at 200 V for approximately 60 minutes or until the dye had 
reached the end of the gel.  
 
2.20.3. Protein detection 
 
The membrane was stained in (0.1% w/v Coomassie blue R-250, 50% v/v methanol, 
1% v/v acetic acid in distilled water) for 30 minutes. Destaining of the membrane 
was carried out in destaining solution (50% v/v methanol, 1% v/v acetic acid in 


























































CHAPTER - 3:   
 
 






























3.1. ABSTRACT  
 
Objectives: This study was planned to investigate the prevalence of ESBL-producing 
Klebsiella spp. from Scotland. 
Results: From 223 isolates collected from Royal Infirmary of Edinburgh during 2006 
and 2007, 219 K. pneuminae, 2 K. oxytoca, 1 E. cloacae, and one isolate Salmonella. 
enterica were identified by API 20E. Out of 223 isolates teted by MICs, 34 (15.2%) 
of these strains were resistant to cefotaxime, 36 (16.1%) to ceftazidime, 35 (15.7%) 
to ceftriaxone, 45 (20.2%) to nalidixic acid, 30 (13.5%) to ciprofloxacin, 55 (24.7%) 
to cefoxitin and 0 (0%) to meropenem. The overall frequency of ESBL producers 
observed in this study was 35/223 (15.7%), most of them 32/35 (91.4%) were from 
K. pneumoniae. SHV β-lactamases were detected in 32 (91.4%), TEM and CTX-M 
were detected in 24 (68.6%) and 16 (45.7%) respectively of ESBLs-positive isolates, 
two OXY-2 enzyme were detected in K. oxytoca isolates. Qnr genes were expressed 
from 18 K. pneumoniae isolates.  
Conclusion: This work reports phenotypic, genotypic analysis and antimicrobial 
susceptibility profiles of clinical isolates of K. pneumoniae of both community and 





Klebsiella spp. are opportunistic human pathogens that can be isolated from various 
animal and human clinical specimens. Klebsiella spp. are responsible for 1% to 5% 
of all cases of community-acquired pneumonia and betwe n 0% to 23% of those 
acquired in the hospital and its frequency is greater in alcoholic patients (Podschun 
and Ullmann 1998). K. pneumoniae is a Gram-negative bacterium, which causes 
hospital and community acquired infections such as pneumonia, urinary tract 
infection, septicaemia, soft tissue infections. K. pneumoniae is responsible for 75–
80% of Klebsiella infections, particularly which associated with ESBLs (Sarno, 
McGillivary et al. 2002; Brisse, van Himbergen et al. 2004). Since 1981 a distinctive 
syndrome of community-acquired Klebsiella bacteraemia with primary liver abscess 
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has been observed (Ko, Paterson et al. 2002; Fang, Sandler et al. 2005). K. 
pneumoniae has also become a common cause of community acquired bacterial 
meningitis in adults in Taiwan (Lederman and Crum 2005).  
 
Extended-spectrum β-lactamases producing Enterobacteriacae are emerging as one 
of the major public health threats. The wide use, and in some cases, misuse of 
antibiotics over the past several decades has been cited as a responsible factor in the 
development of drug resistance in all bacterial species (Arpin, Dubois et al. 2003). 
Recently, the isolation of multidrug-resistant strains of ESBL-producing K. 
pneumoniae has become increasingly common, especially in intensiv  care units and 
other high-risk hospital areas (Tumbarello, Spanu et al. 2006). 
 
The identification of Klebsiella to the species or DNA group level phenotypically is a 
difficult problem due to significant phenotypic overlapping between strains which 
are genotypically closely related (Monnet and Freney 1994; Wang, Cao et al. 2008).  
Laboratories might use macrotube tests alone or by combining API 20E with 
additional macrotube tests (Podschun and Ullmann 1998). The API 20E system is a 
useful 1st stage for the identification of Gram-negative bacteria. 
 
A simple and rapid genotypic method for the identification of Klebsiella using gyrA 
PCR-RFLP profiles using restriction enzymes HincII, TaqI and HaeIII has been 




3.3. RESULTS  
 
3.3.1. Phenotypic identification 
 
Results of phenotypic identification using Vitek2 system and API 20E revealed that 
219 isolates were identified as K. pneumoniae, 2 isolates K. oxytoca, 1 isolates 
Enterobacter cloacae, and one isolate Salmonella enterica.  
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3.3.2. Genotypic identification 
 
Restriction analysis of the gyrA gene (gyrA PCR-RFLP) using primers gyrA-A and 
gyrA-C (annealing temperature 50º C) as described by Brisse and Verhoef (2001) 
was used to assign the 38 (34 ESBLs-positive and 4 ESBLs-negative) isolates to 
Klebsiella species and phylogenetic groups. The isolates were identified as K. 
pneumoniae phylogenetic type KpI (29 isolates), K. pneumoniae KpIII (7 isolates), 
K. oxytoca (two isolates). None of the K. pneumoniae KpII, K. planticola and K. 
terrigena was identified in this study. 
 
Because gyrA PCR-RFLP does not distinguish between the two phylogenetic groups 
of K. oxytoca, the rpoB gene sequence was determined for the two K. oxytoca 
isolates. The sequence of a 940 bp portion of the rpoB gene was determined using 
primers VIC-2 (GGT TAC AAC TTC GAA GAC TC) and VIC-3 (GGC GAA ATG 
GCW GAG AAC CA) for PCR and sequencing. The PCR anne li g temperature was 
50° C. Sequencing was performed using ABI Big Dye Terminator. Both isolates 
were shown to belong to K. oxytoca group II (KoII).  
 
As described by (Brisse, van Himbergen t al. 2004; Brisse and Duijkeren 2005), 
HincII enzyme did not cut the gyrA PCR products from K. planticola and K. 
terrigena, whereas it generated profile HincII-B (298 bp and 143 bp) for all K. 
pneumoniae isolates and profile C (196 bp, 168 bp and 77 bp) for all isolates of K. 
oxytoca. In addition, the use of TaqI and HaeIII separately would distinguish 
between KpI (profiles TaqI-B, HaeIII-C), KpII ( TaqI-E, HaeIII-C or HaeIII-D) and 
KpIII ( TaqI-B and HaeIII-B). Profile TaqI-B consists of the expected 197-bp, 142-
bp, 93-bp and 9-bp fragments, and profile TaqI-E of the expected 197-bp, 151-bp 
and 93-bp fragments. Profile HaeIII-B consists of the expected 175-bp, 174-bp and 
92-bp fragments, profile HaeIII-C of the expected 175-bp, 129-bp, 92-bp and 45-bp 

















Fig 3.1: Gel electrophoresis of HincII, HaeIII and TaqI restriction endonuclease for 
some Klebsiella isolates. Picture A; lanes 1, 6, 13: K. oxytoca isolate MU946294N 
and. Lanes 2, 7, 14: K. oxytoca isolate MB193997E. Lanes 3, 8, 11: isolate 106; 
Lanes 4, 9, 12: isolate 135. Picture B; isolates numbers 187, 195, 206, 172, 214, and 
MU946294N. Picture C: isolates numbers MB, 32, 175, 197, 215, and MU946294N 




3.3.3. Antimicrobial susceptibility 
 
The MIC values of a range of antibiotics tested against these isolates are shown in 
Table 3.1. Out of 223 isolates tested by MICs, the highest percentage of resistance 
24.7% (n= 55) was found to cefoxitin, followed by nalidixic acid 20.2% (n = 45). In 
addition, 34 (15.2%) of these strains were resistant o cefotaxime, 36 (16.1%) to 
ceftazidime, 35 (15.7%) to ceftriaxone, 30 (13.5%) to ciprofloxacin. Meropenem was 
the most effective antibiotic tested, with none of is lates resistant.  
 
As shown in Table 3.1 and Fig 3.2, there was a wide range of MICs between the 
lower and higher level of resistance and also betwen the MIC50 and MIC90. The 
results of MIC50 indicated that more than half of collected isolates were sensitive for 
all antibiotics used. None of the isolates tested was resistant to meropenem making 
the meropenem the drug of choice in treatment of ESBL-producing K. pneumoniae 





































































Nalidixic acid 2 - >128 8 >128 19.6 16 
Ciprofloxacin 0.008 - >128 0.03 4 13.2 1 
Ceftriaxone 0.008 - >128 0.06 16 14.6 1 
Cefotaxime 0.008 - >128 0.03 16 14.6 1 
Ceftazidime 0.06 - >128 0.25 64 15.5 2 
Cefoxitin 1 - >128 4 16 24.2 8 
Meropenem 0.015 - 2 0.03 0.03 0.0 4 
(*) Breakpoints as listed in BSAC guidline 2006. 
 
3.3.4. Confirmation of ESBLs production 
 
All isolates that expressed antimicrobial resistance to cefotaxime, ceftazidime or 
ceftriaxone were subjected to confirmatory methods by double and combination disc 
diffusion methods as described before in section 2.9.3.1 and 2.9.3.2 (Materials and 
Methods) and shown in Figs 3.3 and 3.4. The K. pneumoniae isolate Mu930798E 
was found to be ESBLs-negative by confirmatory tests. However, it was resistant to 
ceftazidime (MIC= 2 mg/L).  
 
Surprisingly, 12 (5.4%) isolates were found to be resistant to meropenem by disc 




          
 
Fig 3.3: Combination disc method 
showing synergy between 
cefotaxime, ceftazidime and 
amoxicillin-clavulanate 
(amoxiclav).  The right disc is 
cefotaxime, the left is 
ceftazidime. Amoxiclav disc is 
in middle.  
Fig 3.4: Confirmation of ESBLs 
production by double disc 
diffusion method. The plate 
shows that the inhibition zone 
around cefotaxime-
clavulanate (left disc) is more 
than 5 mm of cefotaxime 
(right disc).  
        
3.3.5. Prevalence and types of ESBLs 
 
The presence of ESBL-producing isolates was inferred by double and combination 
disc diffusion methods. The overall frequency of ESBL producers observed in this 
study was 35/223 (15.7%) and distributed as follows, 
 
The production of ESBL-producing K. pneumoniae isolates was 32 /219 (14.61 %) 
isolates. The types of ESBLs were determined by PCR. SHV β-lactamases were 
detected in 32 (100 %), whereas TEM and CTX-M were detected in 24 (75 %) and 
16 (50 %) respectively of ESBLs-positive isolates. The SHV primer also amplified 
negative-ESBLs isolates that could explain the presence of high prevalence of SHV 
β-lactamases that may or may not be ESBLs. 
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ESBL-producing K. oxytoca isolates were 2/2 (100%) and constitute 0.9% of total 
isolates. These two isolates, MU946294N and MB193997E, were obtained from 
urine and blood samples obtained respectively from two hospitalized patients during 
September, 2007. These two isolates were found to be K1 (blaOXY-2) after amplifying 
and sequencing using specific primers. None of the o r ESBL genes tested in this 
study such as those encoding TEM, SHV and CTX-M β-lactamases were identified 
by PCR in these two isolates. Additionally, both isolates were found negative by 
PCR for qnr genes. These results were confirmed by IEF analysis as well.  
 
The Enterobacter cloacae isolate was recovered from urine of hospitalized patient 
and tested for ESBL-production. Results show that tis isolate expressed ESBL 
phenotype by MIC but none of blaTEM, blaSHV, blaCTX-Mand qnr genes were identified 
by PCR.  
 
The S. enterica isolate was tested with MICs for antimicrobial susceptibility. It was 
found negative for all antibiotic used in this study.  
 
For these reasons, E. cloacae and S. enterica were excluded from this study. 
 
3.3.6. The source of ESBL-producing isolates 
 
As indicated in Table 3.2, the number of ESBLs-positive isolates recovered from 
urine was 24 (68.6%) of total ESBLs-positive isolates. Moreover, ESBLs isolates 
collected from blood and assorted samples were 6 (17.1%) and 5 (14.3%) 
respectively.  
 
From the relevant information available, the majority 24/35 (68.6%) of isolates that 
expressed ESBL phenotypes were recovered from hospitalized patients. Eleven 
(31.4%) isolates, all of them from K. pneumoniae, were collected from community-




Table 3.2: Source and community versus hospitalized of ESBL-producing isolates included in this study 
 























    
Micro-
organisms 
No. % No. % No. % No. No. No. No. % No. % No. % 
K. pneumoniae 178 79.8 15 6.7 26 11.7 22 5 5 32 14.35 11 34.4 21 65.6 
K. oxytoca 1 0.45 1 0.45 0 0 1 1 0 2 0.9 0 0 2 100 
E. cloacae 1 0.45 0 0 0 0 1 0 0 1 0.45 0 0 1 100 
S. enterica 1 0.45 0 0 0 0 0 0 0 0 0 - - - - 




3.3.7. Detection of AmpC  
 
Cefoxitin resistance was found in 55 (24.7%) of total isolates included in this study. 
Cefoxitin considered as presumptive indication for AmpC production. Confirmation 
of AmpC β-lactamases production was confirmed with inhibitor-based methods as 
described by (Coudron 2005). Briefly, 120 mg of phenylboronic acid 
(benzeneboronic acid (Sigma-Aldrich, UK) was dissolved in 3 ml of dimethyl 
sulfoxide and another 3 ml of distilled water was added to this solution. Twenty 
microliters of the stock solution was dispensed onto discs containing 30 µg of 
cefotetan or blank discs and left to dry for 30 min. Two discs, one disc containing 30 
µg of cefotetan and another disc containing 30 µg of cefotetan and 400 µg of boronic 
acid, were placed on the IST agar similar to the standard disc diffusion method. 
Inoculated plates were incubated overnight at 35°C. An organism that demonstrated 
a zone diameter around the disc containing cefotetan and boronic acid that was 5 mm 
or greater than the zone diameter around the disc containing cefotetan was 
considered an AmpC producer. 
 
I tried to identify types of blaAmpC genes with multiplex PCR with primers targeting 
FOX, DHA, BIL, CIT, MOX, ACC and EBC as described by (Perez-Perez and 
Hanson 2002), but I failed to identify any of these g nes even with several PCR 
condition modifications.  
 





3.4.1. Phenotypic identification  
 
K. pneumoniae strains are found worldwide associated to pneumonia a d urinary 
tract infections in nosocomial and community environments. Klebsiella spp. consider 
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the second important Enterobacteriaceae in bloodstream infections causing 4.7% to 
6.0% of bacteraemia (Ko, Paterson et al. 2002; Livermore, Hope t al. 2008).   
 
Biotyping is useful in assessing outbreaks of Klebsiella but it considered of little use 
in epidemiological studies (Podschun and Ullmann 1998). Identification Klebsiella to 
the species level is often difficult, because some of the species share similar 
biochemical profiles (Monnet and Freney 1994; Wang, Cao et al. 2008). API 20 E 
was used as a presumptive identification of the genomic species. 219 isolates were 
identified K. pneumoniae, 2 isolates K. oxytoca, 1 isolates E. cloacae, and one isolate 
S. enterica were identified by this method.  
 
There was a problem in differentiation between K. pneumoniae and K. oxytoca by 
API 20E because the two K. oxytoca isolates were diagnosed by API 20E to be K. 
pneumoniae, whereas these isolates were identified K. oxytoca by Vitek 2 system and 
results were confirmed using yrA PCR-RFLP method. These results were in 
agreement with previous finding that the Vitek 2 system is able to identify the 
Klebsiella spp more accurately than API 20E system. That is because biochemical 
tests like API 20E may fail to differentiate between K. pneumoniae and K. oxytoca 
(Kovtunovych, Lytvynenko et al. 2003). 
 
3.4.2. Genotypic identification 
 
The gyrA PCR-RFLP method was developed recently as a rapid method to identify 
Klebsiella species and phylogenetic groups (Brisse, van Himbergen et al. 2004). The 
present results agree with others which confirm that is method is reliable, faster 
and cheaper than gene sequencing (Brisse and Duijkeren 2005).  
 
In this study I used restriction analysis of the gyrA gene with gyrA PCR-RFLP 
method in assigning the 38 isolates to Klebsiella species. The K. pneumoniae 
phylogenetic group 1, KpI, was dominant (29 isolates), followed by K. pneumoniae 




My finding is similar to previous investigations inwhich the majority of isolates 
belonged to KpI group. Analysis of 420 clinical isolates from 26 hospitals showed 
that KpI comprised 80.3% of 305 isolates from blood and 82.2-97.2% of isolates 
from other clinical sources. KpIII was never found among isolates from urinary tract 
infections (Brisse, van Himbergen et al. 2004). In another study, analysis of 
phylogenetic groups of representative isolates showed that most of them belonged to 
KpI-type (74.6%), less to the KpIII-type (20.9%), and only 3% belonged to KpII-
type (Valverde, Coque t al. 2008). Further report indicated that KpI (78 isolates), 
KpII (five isolates), KpIII (eight isolates), K. oxytoca (three isolates), K. planticola 
(four isolates) and K. terrigena (two isolates) were identified from 100 isolates with 
gyrA PCR-RFLP profile (Brisse and Duijkeren 2005). 
 
The rpoB gene sequence distinguished the two K. oxytoca isolates to belong to 
phylogenetic group KoII. The both isolates were found to carry blaOXY-2 by PCR and 
DNA sequencing. The previous findings indicated that e chromosomal blaOXY gene 
of K. oxytoca is able, like housekeeping genes, to classify the K. oxytoca 
phylogenetic groups. Also, strains harbouring blaOXY-2 gene fall into a clearly distinct 
phylogenetic group (Granier, Leflon-Guibout et al. 2003; Fevre, Jbel et al. 2005).  
 
3.4.3. Antimicrobial susceptibility  
 
The natural, semisynthetic and synthetic β-lactam antibiotics can be subdivided into 
6 different structural subtypes: 
(i) penams (e.g. benzylpenicillin, ampicillin) 
(ii) cephems which include 2nd and 3rd generation cephalosporins, (e.g. cefuroxime, 
cefotaxime, ceftazidime) 
(iii) cephamycins as 7-α methoxy cephalosporins (e.g. cefoxitin) 
(iv) monobactams as monocyclic molecules (e.g. aztreonam) 
(v) penems with a 2,3-double bond in the fused thiazol ne ring (e.g. faropenem) 




The resistance to 3rd generation cephalosporins among K. pneumoniae varies 
between different geographic locations and in several countries the resistance to 3rd 
generation cephalosporins has increased since the 1990s (Potz, Hope et al. 2006; 
Livermore, Canton et al. 2007). In UK, emergence of this resistance mechanism 
compared with other European countries may result from differences in 
cephalosporin usage, methods of detecting ESBL producers, prevalence of resistant 
serovars, or the import of resistant strains through travel (Yates and Amyes 2005).  
 
In this study, antimicrobial susceptibility showed a moderate-level of resistance in all 
isolates against cefoxitin and nalidixic acid with 24.7% (n= 55) and 20.2% (n = 45) 
respectively. The low-level of resistance 34 (15.2%), 36 (16.1%), 35 (15.7%) and 30 
(13.5%) of these strains was found toward cefotaxime, ceftazidime, ceftriaxone and 
ciprofloxacin respectively. Compared with other antimicrobial agents tested, none of 
the isolates were found resistant to meropenem keeping these the drug of choice in 
treatment of multi-resistant isolates. 
 
Interestingly, 12 isolates were found border-line resistance to meropenem by disc 
diffusion method but not with MICs. The most likely explanation is these isolates 
might produce either class A carbapenemases (KPC, GES) or MBLs (IMP, VIM) 
with low-level of resistance. Further work is needed to investigate the exact 
mechanism(s) of resistance. 
 
These results concatenated with other findings that carbapenems were active against 
all ESBL-positive enterobacteria in different studies from Italy (Luzzaro, Mezzatesta 
et al. 2006; Mugnaioli, Luzzaro et al. 2006). Other reports confirmed that 
meropenem and imipenem had greatest activity against ESBL-producing E. coli and 
Klebsiella spp. in both Europe (96.9–100.0%) and the United States (100.0%) 
(Goossens and Grabein 2005). Furthermore, imipenem remained >99% active against 
K. pneumoniae isolates collected from Latin America, Asia/Pacific Rim, Europe, and 
North America (Reinert, Low et al. 2007). So, this study agrees with the conclusion 
drawn that the continued efficacy of carbapenems such as meropenem confirms that 
these remain first-line agents for treatment of nosoc mial infections caused by 
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Enterobacteriaceae-producing ESBL or AmpC β-lactamases (Goossens and Grabein 
2005).  
 
 Production of extended-spectrum β-lactamases (ESBLs) in particularly by E. coli 
and Klebsiella spp. is the most important means of resistant to third and fourth 
generation cephalosporins such as ceftazidime and cefepime and occurrence of 
antimicrobial resistance in the hospital setting (Goossens and Grabein 2005). The 
prevalence and genotype of ESBLs from clinical isolates vary between countries and 
even from different hospitals and locations at which they are isolated from (Bradford 
2001).  
 
In this study, ESBL production was detected in 35/223 (15.7%) of the strains by 
MICs and confirmed by combination and synergy double disc methods. 
 
This result is quite similar to the survey in Portugal, whereas (14%) of isolates 
reported to be ESBLs (Mendonca, Ferreira et al. 2009). Moreover, in the Asia-
Western Pacific region the ESBL rate of Klebsiella spp. was (17.8%) (Turnidge, Bell 
et al. 2002). 
 
But results presented here show a lower prevalence when it compared with the higher 
prevalence reported in other literatures in which ESBL was reported in 1999 in 
paediatrics centres in France to be (32%) (Raymond, Nordmann et al. 2007). 
Additionally, in South America, rates of up to 45% are reported for K. pneumoniae 
strains, with a comparable rate of 8% in Europe (Winokur, Canton et al. 2001). In a 
survey of intensive care units in Europe undertaken in 1994, it was shown that 24% 
of third-generation resistant isolates of Klebsiella in France carried the ESBL 
phenotype, and in Turkey 59% and in Portugal 49%. This is in marked contrast to the 
findings in the UK and Spain, where 0 and 1% isolates carried the ESBL phenotype 
(Livermore and Yuan 1996). In Italy it was (20%) (Luzzaro, Mezzatesta et al. 2006). 
In a recent study based on the Tigecycline Evaluation and Surveillance Trial (TEST) 
global surveillance database, the rate of ESBL production was highest among the K. 
pneumoniae isolates collected in Latin America, followed by Asia/Pacific Rim, 
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Europe, and North America with 44.0%, 22.4%, 13.3% and 7.5%, respectively 
(Reinert, Low et al. 2007).  
  
On the other hand, the lower prevalence were found in previous reports show that 
0.1% of E. coli and 0.3% of K. pneumoniae isolates clinical isolates recovered from 
196 medical institutions during January 1997 to January 1998 in Japan were ESBLs 
(Yagi, Kurokawa et al. 2000). Moreover, ESBLs are prevalent in 3.9% and 7.7% of 
E. coli species and 8.6% and 28.3% of Klebsiella samples from North America and 
the rest of the world, respectively (Sader, Hsiung et al. 2007). In another report, 
Klebsiella spp. strains with ESBL phenotype were detected in an overall frequency 
of 4% in the United States and 12% in Europe in the last 6 to 8 years (Goossens and 
Grabein 2005). Whereas in Austria an overall frequency of 1% of Klebsiella spp. 
were found to carry ESBL phenotype (Eisner, Fagan et al. 2006).  
 
Concurrent with these findings, Mulvey, Bryce et al. (2004) demonstrated that the 
most prevalent enzymes in Canada were SHV derived, an  that TEM-type ESBLs 
were rarely found. In another study, SHV-type ESBL was the most common ESBL, 
occurring in 67.1% (49 of 73) of isolates. In addition, TEM-type ESBL was found i 
just 16.4% (12 of 73) of isolates. CTX-M-type ESBLs (blaCTX-M-2 type and blaCTX-M-3 
type) were found in 23.3% (17 of 73) of isolates (Paterson, Hujer et al. 2003). 
 
Of the strains tested, 16/223 (7%) expressed CTX-M enzymes. This confirms the 
emergence of this family of β-lactamases in K. pneumoniae in Scotland as in other 
countries. A recent dramatic increase in ESBL-producing organisms is being 
observed both in hospitals and in the community, mainly caused by the CTX-M-15 
enzyme (Canton and Coque 2006; Livermore, Canton et al. 2007). CTX-M-15 first 
reported in the UK in 2003, co-existed with CTX-M-9, CTX-M-14, SHV-12 and to a 
lesser extent with TEM derivatives both in the hospital and in the community. It has 
now become the most prevalent enzyme in both settings (Yates, Brown et al. 2004; 
Livermore, Canton et al. 2007). In Italy, in 2003, only 12% of K. pneumoniae strains 
presented CTX-M enzymes (Mugnaioli, Luzzaro et al. 2006), and between 1998 and 
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2003, the SENTRY program in the Asia-Pacific region, reported that 25% of strains 
possessed CTX-M enzymes (Bell, Chitsaz et al. 2007).  
 
Overall, of the 223 strains studied, 24 possessed non-ESBL-TEM-1b genes. TEM β-
lactamase is one of the most widely distributed β-lactamases, which hydrolyse the 
ampicillin and related antimicrobials such as piperacillin, carbenacillin. The survey 
of E. coli collected from faeces of patients presenting for elective surgery in West 
London in 1968, was found 17% carried plasmid-mediat  ampicillin resistance 
(Datta 1969). Additionally, from all isolates tested only 18 (8%) of the strains 
presented resistance to fluoroquinolones. A multi-continental study reported similar 
resistance to fluoroquinolones (8%) (Deshpande, Jones et al. 2006). The association 
of beta-lactamase production and transferable quinolone resistance genes, qnr, was 
reported (6.7%) in Enterobacteriaceae strains (Castanheira, Mendes et al. 2008). 
 
In this study, 24 of total 35 ESBL-producing strains (68.6%) of our isolates from 
patients with urinary tract infections were ESBL-producing strains, whereas the 
ESBLs isolates collected from blood were 6 (17.1%) isolates.  
 
Consistent with this study, many reports indicated the high proportions of ESBLs –
producing Enterobacteriaceae especially E. coli and Klebsiella spp. isolated from 
urinary tract infection patients (Rodriguez-Bano, Navarro et al. 2004). The 
corresponding Figures are 27%, 2% for Latin America and United States respectively 
(Turnidge, Bell et al. 2002). Furthermore, most (63%) of CTX-M producers were 
recovered from patients with urinary tract infections from Austria (Eisner, Fagan et 
al. 2006). A Canadian study showed that total of 146 patients (93%) had ESBL-
producing E. coli identified from urine cultures (Pitout, Hanson et al. 2004). 
Additionally, ESBL strains were isolated from 45 urine cultures and from 6 blood 
cultures (2 strains were isolated from cultures of b th urine and blood) of 49 





On the other hand, these results were in contrast to findings reported by Tumbarello, 
Spanu et al. (2006), when he found about 30% of ESBL-producing K. pneumoniae 
isolates that examined were isolated from blood.  
 
The ESBL-producing Enterobacteriaceae have increased among community-
acquired strains (Rodriguez-Bano, Navarro et al. 2004; Woodford, Ward et al. 2004; 
Pitout, Nordmann et al. 2005). This study illustrated that the majority 24/35 (68.6%) 
of isolates expressed ESBLs phenotypes were recovered from hospitalized patients. 
Eleven (31.4%), all of them from K. pneumoniae, isolates were collected from 
community-acquired infection. But this information has some limitations. We do not 
have enough information about how long patients been in hospital, the ambulatory 
patients who visited hospitals regularly. Also, theinformation concerning previous 
hospital admissions, underlying diseases (diabetes m llitus, recurrent UTI), and 
antibiotics use was not available.  
 
As reviewed by (Pitout, Nordmann et al. 2005), the first community-acquired ESBL 
strain was found in Ireland in 1998. A population-based surveillance CTX-M-
producing E. coli study in Canada showed that ESBL-producing E. coli is 
predominantly a community-onset pathogen. Of 157 patients, 111 (71%) had 
community-onset infections and 46 (29%) had nosocomial infections (Pitout, Hanson 
et al. 2004). In another Canadian study, 177 (72%) of patients were community 
acquired, whereas 70 (28%) were healthcare associated (Laupland, Church et al. 
2008). A French study demonstrated that the ESBL-producing Enterobacteriaceae 
(including E. coli, K. pneumoniae and Proteus mirabilis) was identified in 39 isolates 
(1.5%) that produced various types of ESBLs (TEM-3, -19, SHV-4 and CTX-M-1). 
ESBL producers were isolated from 38 patients, including 33 residents of 11 clinics 
or nursing homes (acquired infections) and 5 from nosocomial acquisitions (Arpin, 
Dubois et al. 2003). Another Spanish study cited by (Rodriguez-Bano, Navarro et al. 
2004) showed that 93% of ESBL-producing K. pneumoniae strains were isolated 
from inpatients, 51% of ESBL-producing E. coli strains were isolated from 
outpatients. Additionally, more than 70% of all ESBL-producing isolates of 
community origin screened for the presence of CTX-M enzymes were found to be 
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positive, compared with 21% of all ESBL producers of hospital origin (Eisner, Fagan 
et al. 2006). In the UK, investigators reported that Of 291 CTX-M-producing E. coli 
isolates studied from 42 UK centres, 70 (24%) were r portedly from community 
patients, many of whom had only limited recent hospital contact (Woodford, Ward et 
al. 2004). 
 
The increase in community-acquired ESBL infections in the United Kingdom has not 
yet been explained. A Canadian study was published confirmed that advancing age; 
female gender and the presence of other sever medical conditions increase the risk 
for community-acquired ESBLs (Laupland, Church et al. 2008). Also, the human 
immigrants play a major role in transferring the community-acquired ESBLs (Pitout, 
Nordmann et al. 2005; Livermore, Canton et al. 2007; Laupland, Church et al. 2008). 
Another review stated that antibiotic overuse in humans and animals, hospital cross-
infection, the food chain, trade and human migration seem to have contributed to the 
recent dissemination of ESBLs outside hospitals, although the role of these factors is 






These findings report on distribution of ESBLs among the clinical isolates collected 
from Edinburgh district, Scotland. The β-lactamases found in this study represented a 
low percentage of resistance than other previous findings worldwide. This is first to 
report in emergence of blaCTX-M from Edinburgh district with CTX-M-15 is the only 
CTX-M-type described in this study. However, the dissemination of TEM- and SHV-
type ESBLs in this study is more predominate than CTX-M-15. Finally, the 
community-acquired ESBLs infections still lower than the hospitalized infections 
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Objectives: This study was carried out to investigate the prevalence and genetic 
characteristics of transferable blaCTX-M-15 from hospital and community-acquired 
Klebsiella pneumoniae isolates in Scotland.  
Methods: A total of 219 clinical isolates of K. pneumoniae was collected in 2006 and 
2007 at Royal Infirmary of Edinburgh, Scotland. The isolates were tested for 
antimicrobial susceptibility by the agar double dilution method. PCR and sequencing 
were used to detect blaCTX-M, blaTEM, blaSHV and qnr
 genes. The genetic environment 
was analysed using various set of PCR primers. Clonality of the isolates was 
assessed by PFGE.   
Results: Sixteen (7.3%) isolates were found to be producers of CTX-M-15 ESBLs, 
of which two isolates (12.5%) were reported to be from community-acquired 
infections. The insertion sequence ISEcp1 was detected by sequencing 48 
nucleotides upstream of blaCTX-M-15 in all isolates except one. One to two plasmids, 
ranging in size from approximately 40 to 210 kb, were observed per strain. By PCR-
based replicon typing method, the plasmids carrying the blaCTX-M-15 were assigned to 
IncFII or with IncN types. Sequencing and PCR analysis revealed the presence of 
complex Class 1 integrons in all isolates except one. Two isolates positive for class 1 
integrons were positive for class 2 integrons as well. Five different clones of CTX-
M-15-producing isolates were identified by PFGE.  
Conclusions: This work reports the emergence of hospital and community-acquired 




The CTX-M β-lactamases constitute one of the most rapidly growing ESBL families. 
Outbreaks of CTX-M enzyme have been described in bacteri  from numerous 
countries of Africa, Europe, South America and Asia (B raniak, Fiett et al. 2002; 
Livermore and Woodford 2006; Livermore, Canton et al. 2007). The CTX-M family 
is subclassified into 5 groups: CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and 
CTX-M-25 in which the members of each group share 94% identity (Bonnet 2004). 
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CTX-M types evolved through the escape of chromosomal genes from Kluyvera 
ascorbata and Kluyvera Georgiana (Humeniuk, Arlet et al. 2002; Poirel, Kampfer et 
al. 2002; Rodriguez, Power et al. 2004; Olson, Silverman et al. 2005). The ability of 
insertion sequences ISEcp1, ISCR1, phage-related elements and plasmids to mobilize 
and to promote the expression of β-lactamase genes may explain the current spread 
of CTX-M-type enzymes worldwide (Poirel, Decousser et al. 2003; Bonnet 2004; 
Oliver, Coque et al. 2005; Canton and Coque 2006). 
 
The CTX-M-15 β-lactamase was first detected in isolates from India (Karim, Poirel 
et al. 2001). It is derived from CTX-M-3 by an Asp240→Gly substitution, which 
increased catalytic activity to ceftazidime (Poirel, Gniadkowski et al. 2002). Since 
2003, E. coli isolates with the CTX-M-15 ESBL have become widely distributed 
throughout the UK. Five major related E. coli strains, A to E, were identified by 
PFGE. They all belong to sequence type ST131 and serotyp  O25:H4. Strain A is the 
most distributed lineage in the UK (Woodford, Ward et al. 2004; Lau, Kaufmann et 
al. 2008).  
 
Little is known about the population structure of CTX-M-15-producing K. 
pneumoniae causing outbreaks in UK when compared to far better id ntified CTX-




4.3.1. Characterization of β-lactamases 
 
The overall frequency of ESBL-producing K. pneumoniae observed in this study was 
32/219 (14.61 %). The presence of CTX-M genes was screened by PCR, initially 
with universal primers, CTX-M_F and CTX-M_R, which were able to detect the 
CTX-M genes belonging to different groups (Edelstein, Pimkin et al. 2003), and then 
with primers specific for blaCTX-M-1
 group (Dutour, Bonnet et al. 2002). PCR 
conditions were as follows: 5 min at 94°C, 35 cycles of 30 seconds at 95°C, 1 min at 
52°C, and 1 min at 72°C, and final extension of 7 min at 72°C. The resulting PCR 
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products were sent for sequencing. Results revealed that CTX-M genes were 
detected in 16 (7.3%) isolates of K. pneumoniae representing 16/32 (50%) of all 
ESBL K. pneumoniae producing isolates. All isolates were identified as CTX-M-15 
by results of sequence analysis of the deduced amino acid sequences. 
 
4.3.2. The β-lactam susceptibility profile 
 
The pattern of resistance to antimicrobial agents i all 16 cefotaxime-resistant K. 
pneumoniae strains is shown in Table 4.1. The antimicrobial susceptibility patterns 
showed that all strains (100%) harboured CTX-M-15 ESBLs were characterized by 
high resistance to all cephalosporins tested including cefotaxime, ceftazidime, 
ceftriaxone, cefuroxime and cephalexin. In addition, all isolates were found resistant 
to aztreonam (a monobactam). Among the CTX-M-15 producing isolates, 93.8% (n 
= 15) were resistant to fluoroquinolones (ciprofloxacin) and nalidixic acid. 
Resistance to cefoxitin was observed in 81.3% (n = 13) of the isolates. Overall, none 
of the isolates tested was resistant to meropenem.  
 
CTX-M-15 ESBLs confer high-level resistance to ceftazidime and cefotaxime with 
(MIC range: 64- >128 mg/L). Sequence analysis of all 16 isolates revealed there was 
glycine at position 240. This substitution has already been reported in CTX-M-15, 
CTX-M-16, CTX-M-32 and CTX-M-27 and is known to confer high-level resistance 
to ceftazidime.   
 
4.3.3. Association of blaCTX-M-15 with resistance genes 
 
The association between blaCTX-M-15 and the genes coding blaTEM, blaSHV, qnrA, qnrB 
and qnrS was identified by amplification by PCR from genomic DNA using 
oligonucleotide primers as described before (Mabilat and Goussard 1993; Cattoir, 
Poirel et al. 2007). As shown in Table 4.2, all isolates harbouring the CTX-M 
enzyme were found to carry either SHV-1 or SHV-11 or SHV-12 or SHV-5 or SHV-
80 β-lactamases by PCR. Moreover, all isolates but one was found to express TEM-
1b. Additionally, in this study, ten of qnrB1 genes were associated with CTX-M-15.   
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32 Mu 932 491 P >256 64 >128 16 >128 >128 64 64 >128 >128 0.03 8 
33 Mu 932 330 >256 >256 >128 16 >128 >128 >128 64 >128 >128 0.03 >128 
69 Mu 936 327 N >256 >256 >128 >128 >128 128 64 128 >128 >128 0.03 8 
73 Mu 936 619 A >256 >256 >128 >128 >128 128 64 128 >128 >128 0.03 8 
91 Mu 939 312 V >256 >256 >128 16 >128 >128 64 128 >128 >128 0.03 4 
113 Mu 940 148 Z >256 >256 >128 16 >128 >128 64 128 >128 >128 0.03 4 
115 Mu 940 460 H >256 >256 >128 32 >128 >128 64 128 >128 >128 0.03 8 
175 Mg 768 689 P >256 >256 >128 >128 >128 128 128 128 >128 >128 0.03 16 
187 Mu 949847 W >256 >256 >128 >128 >128 >128 128 128 >128 >128 2 64 
195 Mr 148167 R >256 >256 8 0.25 >128 >128 128 128 >128 >128 0.06 4 
197 Mu 950618 L >256 >256 >128 >128 >128 >128 128 128 >128 >128 0.06 64 
213 Mu 960 478 >256 >256 >128 >128 >128 128 64 128 >128 >128 0.06 8 
215 Mu 966 491 T >256 >256 >128 >128 >128 >128 128 128 >128 >128 0.25 64 
MB Mb141078 >256 >256 >128 >128 64 64 >128 128 >128 >128 0.06 16 
B79 B143279 >256 >256 >128 >128 128 64 128 128 >128 >128 0.06 16 
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69 Mu 936 327 N + + + + + +  1 + 1 1 210 + -11 B1 
73 Mu 936 619 A + + + + + + + 1 + 1 1 210 + -11 B1 
175 Mg 768 689 P + + + + + +  1 + 1 1 210 + -12 B1 
187 Mu 949847 W + + + + + +  1 + 1 1 210 + -12 B1 
197 Mu 950618 L + + + + + +  1 + 1 1 210 + -5 B1 
213 Mu 960 478 + + + + + +  1 + 1 2 195 + -11 B1 
215 Mu 966 491 T + + + + + +  1 + 1 2 195 + -11 B1 
MB Mb141078 + + + + + +  1 + 2 3 135, 180 + -11 B1 
B79 B143279 + + + + + +  1 + 2 3 135, 180 + ND B1 
BV B14124V + + + + + +  1 + 2 3 135, 180 + -11 B1 
32 Mu 932 491 P - + + + - +  2 + 3 4 60, 120 + - - 
33 Mu 932 330 - + + + - +  2 + 3 4 60, 120 + - - 
91 Mu 939 312 V - + + + - +  2 + 3 4 60, 120 + -11 - 
113 Mu 940 148 Z - + + + - +  2 + 3 4 60, 120 + ND - 
115 Mu 940 460 H + + - - + -  - + 4 5 40, 60 - -11 - 
195 Mr 148167 R + + + + + + + 1 + 5 6 75 + -11 - 
(+) positive result,  (-) negative result, (ND) not determined, (CS) conserved sequence of class 1 integrons, (kp) kilo base pair.  
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32 Mu 932 491 P Urine 9/8/07 RIE  
33 Mu 932 330 Urine 8/8/07 RIE 
69 Mu 936 327 N Urine 17/8/07 
Milton practice (Mount castle) 
(G.P) 
73 Mu 936 619 A Urine 17/8/07 RIE, Immediate care centre 
91 Mu 939 312 V Urine 13/8/07 RIE, renal transplant 
113 Mu 940 148 Z Urine 27/8/07 RIE, renal transplant 
115 Mu 940 460 H Urine 27/8/07 
Charles Bell Pavilion 2 
(Morningside hospital) 
175 Mg 768 689 P N. swab 12/9/07 WGH 
187 Mu 949847 W Urine 18/9/07 Liberton hospital 
195 Mr 148167 R Sputum 18/9/07 RIE 
197 Mu 950618 L Urine 19/9/07 
Linlithgow group medical 
practice (G.P) 
213 Mu 960 478 Urine 10/10/07 WGH 
215 Mu 966 491 T Urine 23/10/07 WGH 
 Mb141078 Blood 13/3/06 WGH 
 B143279 Blood 13/3/06 WGH 
 B14124V Blood 13/3/06 WGH 
 
RIE: Royal Infirmary of Edinburgh, WGH: Western General Hospital, N. swab: 








4.3.4. Phylogenetic type  
 
Identification of the phylogenetic types of strains u ing gyrA PCR-RFLP, all 16 
isolates producing CTX-M-15 were assigned to be K. pneumoniae phylogenetic 
group I (KpI). 
 
4.3.5. Hospital versus community specimen 
 
As listed in Table 4.3, among the 16 CTX-15-producing isolates for which relevant 
information was available, two isolates (12.5%) were reported to be derived from 
community-acquired infections. This was a significantly lower proportion of the 
community-acquired CTX-M-producing K. pneumoniae than had been found in the 
hospital isolates. The two isolates were collected from urine specimens, the 
remaining isolates collected from hospitalized patients. The majority of the CTX-M-
producing isolates were associated with urinary tract infections (11 strains) 
representing (69%) of all isolates. Three (19%), 1 (6%), and 1 (6%) were isolated 
from blood, sputum, and nephrostomy swab respectively. As expected, most (82%) 
of the urine samples were from patients categorised as having hospital-acquired 
infections. 
 
4.3.6. Plasmid and replicon type determination 
 
S1-nuclease plasmid profiles were obtained for all CTX-M-producing isolates after 
plasmid DNA PFGE electrophoresis was performed in 1% agarose. A total of one to 
two plasmids ranging in size from approximately 40 to 210 kb were observed per 
strain as shown in Table 4.2 and Figs 4.1, 4.2. A total of 8 isolates produced a single 
plasmid, two plasmids were identified from 8 isolates as well. The putative high-
molecular-weight plasmids of approximately 210 kb were obtained and confirmed 
after several gel electrophoresis runs.  
 
Fingerprint analysis of extracted blaCTX-M-15-carrying plasmids revealed 6 different 




Plasmids were classified according to their incompatibility group with the PCR-based 
replicon-typing. The primer pairs targeting FIA, FIB, FIC, I2, I1, L/M, N, A/C, and 
FII replicons were used in separate PCR reactions. The primers were used as 
described before (Carattoli, Bertini et al. 2005) and stated in Table 2.2 (Materials and 
Methods). PCR conditions were as follows: 5 min at 94°C, 30 cycles of 30 seconds 
at 95°C, 1 min at 60°C, and 1 min at 72°C, and final extension of 7 min at 72°C 
except for FII primers, the annealing temperature was 52°C. Results indicated that 
the IncN plasmid was identified from all isolates, the IncFII plasmid was obtained 
from 12 isolates only.  
 
In this study the IncN plasmid by PCR is always present when the blaCTX-M-15 gene 
was identified even in the absence of IncFII. As the IncN plasmid is the only type 
present, these results are the first to indicate the role of IncN replicon types in the 
dissemination of the blaCTX-M-15 genes. 




Fig 4.1: Pulsed field gel electrophoresis of S1-nuclease plasmid profiles for all CTX-
M-producing isolates. Lane 1: isolate no 215. Lane 2: isolate no 195. Lane 3: isolate 
no 197. Lane 4: isolate no 187. Lane 5: isolate no 115. Lane 6: isolate no 113. Lane 
7: isolate no 91. Lane 8: Lambda ladder PFGE marker standard size. Lane 9: isolate 
no 69. Lane 10: isolate no 73. Lane 11: isolate no 33. Lane 12: isolate no 32. Lane 
13: isolate no MB. Lane 14: isolate no BV. Lane 15: isolate no. B79. 
 
 104 




Fig 4.2: Pulsed field gel electrophoresis of S1-nuclease plasmid profiles for CTX-M-
producing isolates. Lanes 1 to 15: isolates numbers 213, 215, 197, 187, 175, 73, 69, 
Lambda ladder PFGE marker, 195, 115, 113, 33, 32, BV, MB respectively.  
 
4.3.7. Identification of plasmids by probe hybridiz ation 
 
PCR amplification of blaCTX-M-15 from template DNA with universal primers, CTX-
M_F and CTX-M_R, to amplify 550 bp fragment within the gene. The PCR product 
was analysed by gel electrophoresis to confirm the correct size of the product. The 
plasmid DNA from the strains was restricted with Apa1 endonuclease which does not 
cut within CTX-M gene and transferred to a piece of nylon membrane. The 
hybridization study did not give accurate information about the plasmids carrying 
CTX-M-15. As shown in Fig 4.3, the intra-genic gene probe was hybridized strongly 
with isolates 113 and 195, a weak signal was obtained from isolate 115. However, 
the probe was hybridized with the chromosomal DNA from these strains and the 
signals were very strong. In addition, attempts to pr be the CTX-M genes from S1 







Fig 4.3: Probe hybridization of CTX-M-15. Lane 1: Lambda DNA/Hind111 
molecular marker. Lane 2: isolate no. 113. Lane 3: isolate no. 115. Lane 4: isolate no. 
195. Lane 5: hybridized isolate no. 195. Lane 6: hybridized isolate no. 115. Lane 7: 
hybridized isolate no. 113.   
 
 
4.3.8. Exploration of the regions surrounding blaCTX-M-15 genes   
 
The genetic organization of the blaCTX-M genes was investigated by PCR and 
sequencing of the regions surrounding these genes. D tection of upstream ISEcp1 
insertion sequence was investigated using CTX-M1_R reverse and Prom+ primers 
(Poirel, Decousser et al. 2003). The internal IS26 was determined using primers (ISF 
and ISR) as described before (Woodford, Ward et al. 2004). The annealing 
temperatures were 55ºC and 52ºC for ISEcp1 and IS26 insertion sequences 
respectively.  PCR identified the insertion sequence ISEcp1 upstream of the blaCTX-
M-15 gene in all strains (Table 4.2) except one strain (strain 115). ISEcp1 was detected 




IS26 insertion sequence was identified upstream in all iso ates and found about 
200 bp integrated in ISEcp1 insertion sequence.  
 
4.3.9. Incidence of class 1 and class 2 integrons 
 
To characterize the presence of inserted gene cassettes within the variable region, the 
primer pair 5_ CS and 3_ CS for class 1 integrons wa used (Zhao, White t al. 
2001). The results identified class 1 integrons in all but one of the CTX-M-producing 
K. pneumoniae isolates (Table 4.2). PCR identified two different sizes of class 1 
integrons, the largest one was ~ 2 kb and the second was ~1.0 kb in size. After 
sequencing of representative samples the three diffrent gene cassette arrangements 
were as follows dfrA12 + aadA2, aadA1, aadA2. 
 
K. pneumoniae isolates were screened for the presence of Intl1, Sul1, and qacE∆1 
which represent class 1 integrons, and for intI2 integrase encoded on class 2 
integrons (Machado, Canton et al. 2005). The 15 integrons-positive isolates did 
contain the conserved qacE∆1-sul1 region. All isolates were tested for the presence 
of class 2 integrons using Intl2 primers. Only two isolates were positive for class 2 
integrons. These two isolates were positive for class 1 integrons as well.  
 
Four of these isolates were negative for integrase (intI1) gene. Interestingly, the 
isolates which was negative for 3′-conserved segments, gave a band with integrase 




Fig 4.4: Gel electrophoresis of intI1, qacE∆1, and sulI1 multiplex PCR for 13 CTX-
M-producing isolates. Lane 1: molecular marker of 100 bp. Lane 2: isolate no MB. 
Lane 3: isolate no BV. Lane 4: isolate no 69. Lane 5: isolate no 73. Lane 6: isolate no 
32. Lane 7: isolate no 33. Lane 8: isolate no 175. Lane 9: isolate no 187. Lane 10: 
isolate no 91. Lane 11: isolate no 113. Lane 12: isolate no 115. Lane 13: isolate no 
195. Lane 14: isolate no 215.  
 
4.3.10. Transfer of resistance 
 
Cefotaxime resistance transferred by transconjugation and transformation was 
obtained for all CTX-M-producing K. pneumoniae isolates.   
 
4.3.11. Epidemiological analysis 
 
PFGE analysis was used to analyze the molecular epidemiology of the 16 CTX-M-
15-producing clinical isolates. As indicated from the result of PFGE in Figs 4.5 and 
4.6, there were 5 different clusters of CTX-M-15-producing isolates. The first large 
cluster comprised seven strains which appeared to have near identical patterns 
(Figure 4.5; Lane 8, 9, 10, 11 and 12). Four strains also appear to have the same 
pattern (Figure 4.5; Lanes 3, 4, 5 and 6) and constitute the second cluster. Similarly a 









third clone comprising three further strains (Figure 4.5 Lanes 13 and 14 respectively) 
appear to have the same patterns. The two remaining clusters each comprised only 
one strain, strain 195 (Figure 4.5 Lanes 1) and strain 115 (Figure 4.5 Lane 2) 
respectively.    
 
Fig 4.5: PFGE patterns of CTX-M-producing K. pneumoniae isolates. Lane 1: isolate 
no 195. Lane 2: isolate no 115. Lane 3: isolate no 32. Lane 4: isolate no 33. Lane 5: 
isolate no 91. Lane 6: isolate no 113. Lane M: Lambda ladder PFG marker standard 
size. Lane 7: isolate no 215. Lane 8: isolate no 69. Lane 9: isolate no 73. Lane 10: 
isolate no 175. Lane 11: isolate no 187. Lane 12: isolate no MB. Lane 13: isolate no 





Fig 4.6: PFGE dendogram analysis of CTX-M-producing K. pneumoniae isolates. 
Dendrogram showing the relationship between isolates of K. pneumoniae obtained 
after Xba1-digested the chromosomal DNA of 16 clinical isolates. 







































































CTX-M first detected in Japan in 1986 from a cefotaxime-resistant E. coli (the 
enzyme was named FEC-1) (Matsumoto, Ikeda et al. 1988). A few years later in 
1989, a similar cefotaxime-resistant clinical E. coli strain from Germany was 
reported to produce β-lactamase nzyme designated CTX-M-1 (Bauernfeind, Grimm 
et al. 1990). CTX-M β-lactamases constitute a novel and rapidly growing family of 
plasmid-mediated ESBLs (Baraniak, Fiett  al. 2002). The rise in cephalosporin 
resistance may be attributable to the spread of extended-spectrum β-lactamases, 
particularly CTX-M types (Livermore, Canton et al. 2007). Outbreaks of CTX-M-
15-producing K. pneumoniae isolates have been recently described in some European 
countries (Lytsy, Sandegren et al. 2008; Mesko Meglic, Koren et al. 2009). 
 
The overall frequency of K. pneumoniae ESBL producers observed in this study was 
32 /219 (14.61 %). By PCR CTX-M genes were detected in 16 (7.3%) isolates of K. 
pneumoniae. CTX-M-15 was the only CTX-M enzyme identified by sequence 
analysis of the deduced amino acid sequences. The expr ssion of pI (8.6) band by 
IEF was the confirmation of presence of CTX-M-15 β-lactamase.  
 
In this study, I identified CTX-M-15 enzymes, which is the most common CTX-M 
type in UK. The first CTX-M ESBL in the UK was found in 2000, in one isolate of 
K. oxytoca (Alobwede, M'Zali et al. 2003). During June 2001, the first hospital 
outbreak, 36 K. pneumoniae isolates from 33 patients from 15 different wards and 
departments around Birmingham described as CTX-M-25-like (Brenwald, Jevons et 
al. 2003). In 2001, a survey examined over 900 E. coli from 28 hospitals in the UK 
and Ireland and recorded 4 isolates with CTX-M-15 enzyme (Mushtaq, Woodford et 
al. 2003). In 2004, Woodford, Ward et al. (2004) identified an epidemic clone of E. 
coli producing CTX-M-15 that had become widely distributed throughout the UK. 
 
In Scotland, CTX-M was reported in two clinical salmonellae isolates harbouring 





CTX-M-15 β-lactamase was previously reported among isolates of K. pneumoniae in 
European countries. In a multi-centric study from Russia, CTX-M gene was reported 
in 35.9 % of E. coli and 34.9% of K. pneumoniae ESBL strains (Edelstein, Pimkin et
al. 2003). In a nationwide survey in Italy, CTX-M producing strains were reported 
by 10 of the 11 participating centres, with remarkably variable rates among the 
centres (1.2 to 49.5% of the ESBL producers) (Mugnaioli, Luzzaro et al. 2006). In 
Another study, Among 149 ESBL-producing Enterobacteriaceae isolates collected 
from patients in Austria from 1998 to 2004, 49 (38 E. coli and 11 Klebsiella spp.) 
isolates were CTX-M producers. The majority of CTX-M producers (38/49; 78%) 
had CTX-M-15 enzymes; the remainder had group 9 enzymes (Eisner, Fagan et al. 
2006). Additionally, blaCTX-M-15 enzymes were detected by sequencing in 60/177 
(34%) of ESBL-producing K. pneumoniae isolates collected from eight Slovenian 
hospitals during 2005 and 2006 (Mesko Meglic, Koren et al. 2009). As reviewed, the 
spread of a K. pneumoniae clone with CTX-M-15 has recently been reported in 
Hungary (Livermore, Canton et al. 2007). The high prevalence (100%) was found in 
Spain where all 162 isolates were identified as ESBL-producers, and the blaCTX-M-15 
gene was detected in all isolates (Oteo, Cuevas t al. 2009). Furthermore, the first 
major ESBL outbreak in Scandinavia was caused by a clonal spread of 64 
multiresistant K. pneumoniae producing CTX-M-15 (Lytsy, Sandegren t al. 2008). 
 
Worldwide, CTX-M types especially the most widely distributed CTX-M-15 have 
replaced TEM and SHV mutants as the predominant ESBLs in numerous countries 
of Africa, Europe, South America and Asia (Baraniak, Fiett et al. 2002; Saladin, Cao 
et al. 2002; Livermore and Woodford 2006; Livermore, Canton et al. 2007). CTX-
M-15 was first detected in E. coli isolated from India during 2001 and considered as 
the most successful and widespread CTX-M among others (Karim, Poirel et al. 
2001). In Canada, CTX-M-15 was identified from E. coli and K. pneumoniae (Boyd, 
Tyler et al. 2004; Mulvey, Bryce et al. 2004; Pitout, Church et al. 2007). Also, CTX-




As shown in Table 4.2, all isolates harbouring the CTX-M enzyme were found to 
carry either SHV-1 or SHV-11 or SHV-12 or SHV-5 β-lactamases by PCR. 
Moreover, all isolates but one were found to express TEM-1. This association is 
frequent and has already been described (Boyd, Tyler et al. 2004; Eckert, Gautier et 
al. 2004). In this study, ten of qnrB1 genes were associated with CTX-M-15. The co-
presence of qnrB and ESBL genes on same plasmids has been regularly reported 
(Jacoby, Walsh et al. 2006).  
 
The pattern of resistance to antimicrobial agents i all 16 cefotaxime-resistant K. 
pneumoniae strains showed that the strains harboured CTX-M-15 ESBLs 
characterized by high resistance to all cephalosporins tested in this study. Resistance 
of CTX-M-producing isolates to cefotaxime, ceftazidime, ceftriaxone, cefuroxime, 
cephalexin, nalidixic acid, ciprofloxacin, cefoxitin and meropenem was found to be 
100, 100, 100, 100, 100, 93.8, 93.8, 81.3 and 0% respectively. This high resistance to 
most antibiotics is explained by the finding that the blaCTX-M genes are commonly 
found on plasmids often carrying genes that confer resistance to multiple antibiotics, 
including aminoglycosides, chloramphenicol, sulfonamide, trimethoprim, and 
tetracycline (Bonnet 2004).  
 
The CTX-M enzymes confer higher level resistance to cef taxime, cefotriaxone and 
aztreonam than to ceftazidime (Dutour, Bonnet et al. 2002; Saladin, Cao et al. 2002). 
CTXM-15 was derived from CTX-M-3 by (Asp240Gly) substitution, which 
increased catalytic activity to ceftazidime (Poirel, Gniadkowski et al. 2002). These 
findings indicated that CTX-M-15 ESBLs confer high-level resistance to ceftazidime 
(MIC range: 64- to >128 mg/L). Sequence analysis revealed an Asp240→Gly 
substitution. This substitution has already been report d in CTX-M-15, CTX-M-16, 
CTX-M-32 and CTX-M-27 and is known to confer high-level resistance to 
ceftazidime (Cartelle, del Mar Tomas et al. 2004; Doublet, Granier et al. 2009; 
Poirel, Gniadkowski et al. 2002) 
 
Another substitution responsible for higher levels of resistance to ceftazidime, as 
compared to cefotaxime, is the Pro167Ser mutation, which differentiates CTX-M-19 
 
 113 
from CTX-M-14 (Poirel, Naas et al. 2001). But this substitution not found in these 
results. 
 
Concerning “non β-lactam” susceptibility of CTX-M producers, all strains but one 
were resistant to ciprofloxacin. High rates of ciprofloxacin resistance in CTX-M 
producing isolates have also been reported in previous findings (Pitout, Nordmann et 
al. 2005; Eisner, Fagan et al. 2006).   
 
Identification of the phylogenetic types of CTX-M-15-producing strains using yrA 
PCR-RFLP, all isolates were assigned to be K. pneumoniae phylogenetic group I 
(KpI). In contrast to these findings, there was a clear relationship between the KpIII 
group and production of CTX-M-10 enzymes (44.5% of CTX-M isolates) (Valverde, 
Coque et al. 2008).  
 
The majority of the CTX-M-producing isolates were associated with urinary tract 
infections (11 strains) representing (69%) of all isolates. Three (19%), 1 (6%), and 1 
(6%) were isolated from blood, sputum, and nerphrostomy swab respectively. As 
expected, most (82%) of the urine samples were frompatients categorised as having 
hospital-acquired infections. Among the 16 CTX-15-producing isolates for which 
relevant information was available, two isolates (12.5%) were reported to be from 
community-acquired infections collected from urine specimens, the remaining 
isolates collected from hospitalized patients. These findings show a significantly 
lower proportion of the community-acquired CTX-M-producing K. pneumoniae if it 
compared with other studies in UK, where 70 (24%) of 291 CTX-M-producing E. 
coli isolates studied from 42 UK centres were reported from community patients, 
many of whom had only limited recent hospital contact (Woodford, Ward et al. 
2004). In another study, 22 ESBL-producing Enterobacteriaceae (9 E. coli, 7 E. 
cloacae, 4 C. freundii, 1 Klebsiella spp. and 1 Salmonella spp.) were detected among 
565 faecal specimens from York. The authors identifi d eight ESBL-producing E. 
coli and one ESBL-producing Salmonella spp. were from community patients, the 
remaining 13 isolates were collected from hospital p tients. The β-lactamases 
identified were 5 blaCTX-M-15, 3 blaCTX-M-14 and 9 blaCTX-M-9 (Munday, Whitehead et 
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al. 2004). Moreover, Most (63%) CTX-M producers were recovered from patients 
with urinary tract infections. In total, more than 70% of all ESBL-producing isolates 
of community origin screened for the presence of CTX-M  enzymes were found to be 
positive, compared with 21% of all ESBL producers of hospital origin (Eisner, Fagan 
et al. 2006). 
 
For all CTX-M-producing isolates, a total of one to two plasmids ranging in size 
from approximately 40 to 210 kb were observed per strain with S1-nuclease plasmid 
profiles as shown in Table 4.2. Similar to these results, blaCTX-M-32 and blaCTX-M-1 
(CTX-M group-1) were carried in a single 40-kb IncN plasmid or with an IncL/M 
plasmid of 50 kb from different E. coli strains in Spain since 2000 (Novais, Canton et 
al. 2007). In another study, blaCTX-M-15 alone or with aac(6′)-Ib and/or aac(6′)-Ib-cr  
co-localised on IncR, IncFII, IncFIIk replicons on different plasmids size of ca. 
30 kb, 60 kb, 75 kb, 80 kb, 85 kb, 90 kb, 190 kb, 290-kb and 340-kb (Coelho, 
Gonzalez-Lopez et al. 2010). In a Spanish study, all CTX-M-15 clones studied were 
harboured the same plasmid (pRYCE34) of 180 kb isolated from 2002 to 2004 
(Valverde, Coque et al. 2008). Hybridization studies showed that blaCTX-M-15
 was 
located on ~150-kb plasmids K. pneumoniae strains from Slovenia (Mesko Meglic, 
Koren et al. 2009). 
 
In this study the IncN plasmid determined by PCR is always present when blaCTX-M-
15 gene was identified even in the absence of IncFII. As the IncN plasmid is the only 
type present, these results are the first to indicate the role of IncN replicon types in 
the dissemination of the blaCTX-M-15 genes in K. pneumoniae, although IncN plasmid 
has been found on one occasion to carry the CTX-M-15 gene in E. coli (Marcadé, 
Deschamps et al. 2009). It was confirmed that mobilization and spread of CTX-M-15 
seems to be related to IncFII plasmids (Coque, Novais et al. 2008; Carattoli 2009). 
The blaCTX-M-15 was also detected in IncFI or IncL/M types (Lavollay, Mamlouk et 
al. 2006; Oteo, Cuevas et al. 2009). Additionally, blaCTX-M-32 and blaCTX-M-1 (CTX-M 
group-1) were located in a single 40-kb IncN plasmid or with an IncL/M plasmid of 
50 kb from different E. coli strains in Spain since 2000 (Novais, Canton et al. 2007). 
Additionally, plasmids encoding CTX-M-15 carried three distinct replicons, IncFII, 
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IncR and IncFIIk, were reported among 37 K. pneumoniae strains isolated in the 
Barcelona metropolitan area (Coelho, Gonzalez-Lopez et al. 2010). 
 
There should be great concern about  the dissemination of the gene on broad-host-
range IncN plasmids, because it maximises  the further spread of CTX-M-1-like 
enzymes among other members of Enterobacteriaceae (Novais, Canton et al. 2007). 
 
PCR identified the insertion sequence ISEcp1 upstream of the blaCTX-M-15 gene in all 
strains (Table 4.2) except one strain (strain 115). ISEcp1 was detected by sequencing 
48 nucleotides upstream of blaCTX-M-15. This result was consistent with other studies, 
a 48bp sequence, previously described for blaCTX-M-15 from India and previously 
named as the W sequence (Karim, Poirel et al. 2001; Poirel, Decousser t al. 2003; 
Eckert, Gautier et al. 2006). The insertion sequences ISEcp1 or ISEcp1-like were 
repeatedly identified upstream of many blaCTX-M genes, and played an important role 
in the mobilization and expression of these genes (Cao, Lambert et al. 2002; Saladin, 
Cao et al. 2002; Poirel, Decousser et al. 2003; Eckert, Gautier et al. 2006), 
suggesting a similar origin and organisation from those already described previously. 
 
The presence of IS26 was found upstream of the blaCTX-M-15 gene in all strains tested 
by PCR. The insertion sequence IS26 was described by Saladin et al. (Saladin, Cao et 
al. 2002) to be upstream of a blaCTX-M-1 gene. The presence of IS26 in all isolates 
probably due to the presence of this insertion sequence on known plasmids, such as 
IncFII, IncN, and IncL/M (Novais, Canton et al. 2007). 
 
Class 1 integrons are widespread genetic elements that allow promoterless bacteria to 
capture and express gene cassettes. These integrons contribute to the dissemination 
of antibiotic resistance genes between bacteria of the same or of different species 
(Jove, Da Re et al. 2010). Results identified class 1 integrons in all but one of CTX-
M-producing K. pneumoniae isolates (Table 4.2). PCR identified two different sizes 
of class 1 integrons, the largest one was ~ 2 kb and the second was ~1.0 kb in size. 
After sequencing of representative samples the three different gene cassette 
arrangements were dfrA12 + aadA2, aadA1, aadA2. Similar to my study, class 1 
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integrons including dfr and aadA gene cassettes have been the most prevalent type of 
integrons (Vinue, Saenz et al. 2008).  
 
The conserved qacE∆1-sul1 region was identified by PCR from all the 15 integrons-
positive isolates. These results were in agreement with findings that the 3′-conserved 
segments of the class 1 integrons usually contain the genetic determinants qacE∆1 
and sul1 (Carattoli 2001). 
 
In this study I identified four isolates beard class 1 integrons were negative for 
integrase (intI1) gene. (Jove, Da Re et al. 2010) reported that there are currently 13 
Pc variants corresponding to 10 variants of the class 1 integrase Intl1. The Pc 
promoter in class 1 integrons is located within theintI1 coding sequence. The Pc 
polymorphism affects the amino acid sequence of IntI1 and the effect of this feature 
on the integrase recombination activity. 
 
Cefotaxime resistance transferred by transconjugation and transformation was 
obtained for all CTX-M-producing K. pneumoniae isolates. These results indicating 
the highly transconjugated IncN plasmid carry CTX-M-15. The corresponding 
Figures indicated that 60 isolates comprised plasmid  encoding CTX-M-15 enzyme 
were highly transmissible as well (Mesko Meglic, Koren et al. 2009). 
 
PFGE analysis was used to analyze the molecular epidemiology of the 16 CTX-M-
15-producing clinical isolates. As indicated from the result of PFGE, there were 5 
different clones of CTX-M-15-producing isolates. In Spain, one epidemic clone 
characterized by PFGE from a single institution in Madrid (Valverde, Coque t al. 
2008). In another study, (Oteo, Cuevas et al. 2009) identified seven PFGE clusters 
corresponded to seven different K. pneumoniae STs collected from five Spanish 
hospitals. Mesko Meglic, Koren et al. (2009) identified 11 pulsed-field gel 
electrophoresis-defined strains, with several clusters of closely related isolates 







Despite the prevalence of CTX-M-15 in UK, less work has been done on Klebsiella 
spp. with CTX-M enzymes. This work confirms the emergence of hospital and 
community-acquired CTX-M-type enzymes and their spread in the Edinburgh area, 
Scotland. Additionally, this study showed some alarmingly high rates (50%) of CTX-
M-15 among ESBL-producing K. pneumoniae isolates. By PCR all isolates were 
associated with IncFII and/or with the broad host range IncN plasmid, in future 
would accelerate the spread of these genes. I identified five PFGE clusters of K. 






































Prevalence of blaSHV genes from K. pneumoniae clinical 

































All 219 K. pneumoniae strains isolated during 2006 and 2007 were collected from 
the Royal Infirmary of Edinburgh. The total number of amplified blaSHV genes from 
60 (32 ESBLs-positive and 28 “non-ESBL” producing) isolates was 54 (90%) 
isolates. From the ESBL-producing isolates, molecular methods identified ten strains 
possessing ESBL-SHV genes (1 strain blaSHV-5, 1 strain blaSHV-80 and 8 strains blaSHV-
12) and 19 isolates producing narrow-spectrum SHV β-lactamases (17 strain carry 
blaSHV-11 and 2 isolates with blaSHV-1). Conjugation methods demonstrated that 29/32 
isolates harbour transferable blaSHV. All blaSHV-12 but one, blaSHV-80 and blaSHV-5 were 
successfully transconjugated. The large SHV transposon-borne promoter (IS26-lacY-
recF-SHV) was amplified from only one isolate harbouring non-transferable blaSHV-
11, 15 isolates were produced the small SHV transposon-borne promoters (IS26-
SHV). The genetic relatedness of the isolates was studied by PFGE analysis. The 
strains were diverse, and 17 clusters were defined, the largest including 7 strains 





SHV enzymes are classified in groups 2b and 2be of the Bush-Jacoby-Medeiros 
classification scheme and in Ambler class A (Ambler, Coulson et al. 1991; Bush, 
Jacoby et al. 1995). SHV-1 was first described in 1972 and called Pit-2 from the 
author’s name Pitton (Pitton 1972). The chromosomal SHV-1 confers resistance to 
ampicillin, amoxicillin, carbenicillin and ticarcillin and considered to be ubiquitous 
amongst the great majority of K. pneumoniae strains (Livermore 1995; Babini and 
Livermore 2000). SHV enzymes were also detected in other Enterobacteriaceae s 
plasmid-mediated β-lactamases (Matthew 1979; Sabate, Miro et al. 2002). IS26 
insertion sequence mediates mobilization of plasmid- e iated blaSHV genes from 
genome to plasmid and increases promoter strength through the introduction of a 
different –35 region (Podbielski, Schonling et al. 1991a). The majority of SHV 
variants possess an ESBL phenotype characterized by the substitution of a glycine 
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for serine at position 238 and/or glutamic acid for lysine at position 240 (Huletsky, 





5.3.1. Prevalence of SHV ESBLs 
 
SHV β-lactamases were detected in 32/32 (100%) of ESBLs-positive isolates (all 
from K. pneumoniae) using primers (Kp-SHV_for and Kp-SHV_rev) as described 
earlier and shown in Table 2.2 (Materials and Methods). PCR conditions were as 
follows: 5 min at 94°C, 35 cycles of 40 seconds at 95°C, 1 min at 65°C, and 1 min at 
72°C, and final extension of 7 min at 72°C. The blaSHV-11 was detected after 
sequencing in 21 ESBLs-positive strains (17 isolates lone and 4 isolates associated 
with blaSHV-12 and blaSHV-80). Other previously described narrow-spectrum β-
lactamases genes detected here were blaSHV-1 (2 strains, 1 with blaTEM-1, and 1 
together with blaCTX-M-15). The extended-spectrum SHV β-lactamases genes detected 
were; blaSHV-12 (8 strains, 1 alone, 1 together with qnrA1, 3 together with blaCTX-M-15 
and blaTEM-1 genes and 3 together with blaTEM-1), blaSHV-80 (1 strain co-expressed 
blaCTX-M-15 and blaTEM-1) and blaSHV-5 (1 strain together with blaCTX-M-15, blaTEM-1 and 
qnrB1). In addition, 3 strains carry an unidentified blaSHV (Table 5.1).  
 
The isolate 33 that carries blaSHV-80 showed an unusual resistance phenotype toward 
meropenem antibiotic. It showed once increase in MIC (8 mg/L) and then back to 
(0.03 mg/L). 
 
5.3.2. Prevalence of blaSHV from “non-ESBL-producing” isolates 
 
Amplification of blaSHV from 28 “non-ESBL-producing” strains revealed that 22 
isolates were positive for blaSHV, 6 isolates were negative. The blaSHV-11 was detected 
from one representative isolate with sequencing. This isolate was found to carry 




The total number of amplified blaSHV genes from 60 (32 ESBL-positive and 28 
ESBL-negative) K. pneumoniae isolates was 54 (90%), whereas 6 (10%) isolates 
were negative for blaSHV gene.   
 
5.3.3. Presence of more than one copy of blaSHV genes  in the same 
isolate 
 
Four isolates (numbers 32, 84, 208 and 33) all were identified as SHV-11 with DNA 
sequencing. But after the sequencing repeated each isolate was found to express 
another SHV enzyme. The new enzymes were identified as blaSHV-12 from strains 
(32, 84, 208), the strain number 33 was found to harbour blaSHV-80. 
 
5.3.4. Association of blaSHV with resistance genes 
 
The blaTEM was detected in 24 strains associated with blaSHV; no TEM-derived 
ESBLs were found by representative sequenced samples, 16 isolates co-expressed 
blaCTX-M-15. 18 isolates were found to be positive by PCR for the qnr genes. Of these 
qnr-positive isolates, 16 isolates were ESBL-positive (11 qnrB1 gene and 5 qnrA1 
gene) and 2 isolates were ESBLs-negative, both of tem harboured the qnrB6 gene 
(Table 5.1).  
 
5.3.5. Phylogenetic groups  
 
Analysis of phylogenetic groups of 32 ESBLs SHV-producing isolates tested showed 
that most of them, 26 isolates (81.25%), were belonged to KpI-type. In addition, 6 
isolates were belonged to the KpIII-type (18.75%). All isolates containing CTX-M-
15 belonged to the KpI group. Interestingly, there was a clear relationship between 
the KpIII group and production of qnrA genes in which 4 of 5 isolates were found to 
harbour the qnrA1 gene (Table 5.1).  
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  class 1 
bp 
32 Mu 932 491 P SHV-11/12 + 1500 - + - + +  + - + I 2k 
33 Mu 932 330 SHV-11/80 + 1500 - + - + +  + - + I 2k 
69 Mu 936 327 N SHV-11 + 1500 + + + + +  + B1 + I 1k 
73 Mu 936 619 A SHV-11 + 1500 + + + + + + + B1 + I 1k 
84 Mu 939 776 Z SHV-11/12 + 800 ND ND + + +  + - - III 1.5- 2k 
85 Mu 939 772 SHV-1* + - - - - - -  + - - I - 
91 Mu 939 312 V SHV-11 + 1500 - + - + +  + - + I 2k 
106 Mu 939 649 W SHV-11 + - + + + + +  + A1 - III 1.5- 2k 
113 Mu 940 148 Z SHV-11 + 1500 - + - + +  + - + I 2k 
114 Mu 940 595 G SHV-12 + 800 + + + + +  - - - I ND 
115 Mu 940 460 H SHV-1 * + 800 + + + - -  - - + I - 
125 Mu 941 508 P ND + - + - - - -  - - - III 1.5- 2k 
135 Mu 943 702 T SHV-11 + 800 + + + + +  + A1 - III 1.5-2k 
175 Mg 768 689 P SHV-12 + 800 + + + + +  + B1 + I 1k 
187 Mu 949847 W SHV-12 + 800 + + + + +  + B1 + I 1k 
195 Mr 148167 R SHV-11 - 3kb + + + + + + + - + I 1k 
197 Mu 950618 L SHV-5 + - + + + + +  + B1 + I 1k 
CS: Conserved sequence of class 1 integrons 
(-): Negative 
(+): Positive 



















































  class 1 
bp 
203 Mg 769750 ND - 800 - + + + +  - - - I 2k 
204 Mu 953545 C SHV-11 + 800 + + + + +  + A1 - III 1.5-2k 
205 Mu 953096 R SHV-11 + 800 - + + + +  - - - I 2k 
206 Mu 956107 Q SHV-11 + 800 - + + + +  + A1 - III 1.5-2k 
208 Mg 771610 V SHV-11/12 - 800 + + + + +  + - - I 2k 
210 Mu 956764 R SHV-11 + 800 - - + + +  + B1 - I 2k 
213 Mu 960 478 SHV-11 + 1500 + + + + +  + B1 + I 1k 
214 Mb 195 491 Y SHV-12 + 800 - + + + + + - A1 - I ND 
215 Mu 966 491 T SHV-11 + 1500 + + + + +  + B1 + I 1k 
MB Mb141078 SHV-11 + 1500 + + + + +  + B1 + I 1k 
B79 B143279 SHV-11 + 1500 + + + + +  + B1 + I 1k 
B31 Mb143231 SHV-11 + - - - - - -  - - - I ND 
U54 Mu724454 SHV-12 + 800 ND ND + + +  + - - I 2k    
BV B14124V SHV-11 + 1500 + - + + +  + B1 + I 1k 
MR Mr112663 ND + 800 - - - - -  - - - I ND 





Conjugation and genotyping of 32 K. pneumoniae isolates producing SHV-type 
ESBLs demonstrated that 29 isolates harbour transferable blaSHV. From these 
transferable blaSHV isolates: 50% (n=16) carry blaSHV-11, 21.9% (n=7) carry blaSHV-12, 
6.25% (n=2) carry blaSHV-1, 6.25% (n=2) carry unidentified SHV genes, 3.1% (n=1) 
carry blaSHV-5, and 3.1% (n=1) carry blaSHV-80. Additionally, 3 (9.4%) isolates 
harbour non-transferable blaSHV: one isolate produce chromosomal blaSHV-11, one 
isolate harboured blaSHV-12, and one isolate not sequenced.  
 
Attempts to transfer ampicillin resistance TEM from the study strains to E. coli by 
conjugation showed that about 80% isolates harbouring blaTEM failed to donate their 
plasmids to the recipient strain. Moreover all CTX-M strains were successfully 
transconjugated.  
 
5.3.7. Genetic environment 
 
Results shown in Table 5.1 indicated that the large SHV transposon-borne promoters 
(IS26-lacY-recF-SHV) were amplified from only one large SHV transposon-
containing isolate harboured non-transferable blaSHV-11 using primers IS26-FCJ and 
SHV-12-F-1 as in Table 2.2 (Materials and Methods). The amplified PCR product 
was sequenced from both ends, which enabled sequencing of the region in both 
directions. The sequence was quite similar to accession number AJ245670 
[GeneBank]. The sequence product had about 500 bp which is corresponding to 
kdpC gene and was missing in the AJ245670 GeneBank.  
 
The promoter sequence from large SHV transposon-containi g isolate was 
(AAAAAT) instead of (ACAAAT) in the -10 region. This promoter has (CA) 
mutation at second nucleotide in the -10 region.  
 
A total of 15 isolates produced a PCR product of about 800bp. DNA sequencing of 
representative samples were found to harbour the small SHV transposon-borne 
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promoter (IS26-SHV). The representative DNA samples were sequenced and 
compared with GenBank EF370423 [GenBank]) sequence. The results revealed that 
IS26 was found 73 bp upstream of the blaSHV genes as shown in Fig 5.1. 
 
Eleven isolates produced a band of ~1.5 Kbp but it proved impossible to sequence 
these isolates. The remaining isolates were negative by PCR for IS26.  
 
The last two groups, negative group and ~1.5 kbp producing group, were produced a 
PCR product of about 800bp after several repeats of he PCR reactions. The most 
likely explanation is these isolates each harbour two or more different blaSHV genes.  
 
In addition, the RecF protein and DEOR transcriptional regulator were identified by 
PCR upstream and downstream from all isolates using primers SHV-12-F-1, SHV-
12-R-1, DEOR-R and RECF-F as in Table 2.2 (Materials nd Methods). The 
sequencing of representative samples revealed that the putative DEOR transcriptional 
regulator was identified 21 bp downstream of all blaSHV strains tested by PCR when 
the genes was compared with GenBank EF370423 [GenBank] sequence as shown in 

















Fig 5.1: Alignment of IS26-blaSHV from strain 84 and the GeneBank EF370423  
 
84              TCGGTGTTCAACGTCAGACGGGCACCGGCCTTCGC GTTTGAGCAGAGCAAGCGCGCGACC 240 
EF370423                           GGCACCGGCCTTCGCGTTTGAGCAG AGCAAGCGCGCGACC 40 
                                    *************** ************************* 
84              ATAGGCGGGCGCTTTATCCGTGTTGATGAATCGCG GGATCTGCCACTTCTTCACGTTGTT 300 
EF370423        ATAGGCGGGCGCTTTATCCGTGTTGATGAATCGCGGGATCTGCCA TTCTTCACGTTGTT 100 
                *********************************** ************************* 
84              GAGGATTTTACCCAGAAACCGGTATGCAGCTTTGC TGTTACGACGGGAGGAGAGATAAAA 360 
EF370423        GAGGATTTTACCCAGAAACCGGTATGCAGCTTTGCTGTTACGACGGGAGGAGAGATAAAA 160 
                *********************************** ************************* 
84              ATCGACAGTGCGGCCCCGGCTGTCGACGGCCCGGT ACAGATACGCCCAGCGGCCATTGAC 420 
EF370423        ATCGACAGTGCGGCCCCGGCTGTCGACGGCCCGGTACAGATACGCC AGCGGCCATTGAC 220 
                *********************************** ************************* 
84              CTTCACGTAGGTTTCATCCATGTGCCACGGGCAAA GATCGGAAGGGTTACGCCAGTACCA 480 
EF370423        CTTCACGTAGGTTTCATCCATGTGCCACGGGCAAAGATCGGAAGGGTTACGCCAGTACCA 280 
                *********************************** ************************* 
84              GCGCAGCCGTTTTTCCATTTCAGGCGCATAACGCT GAACCCAGCGGTAAATCGTGGAGTG 540 
EF370423        GCGCAGCCGTTTTTCCATTTCAGGCGCATAACGCTGAACCCAGCG TAAATCGTGGAGTG 340 
                *********************************** ************************* 
84              ATCGACATTCACTCCGCGTTCAGCCAGCATCTCCT GCAGCTCACGGTAACTGATGCCGTA 600 
EF370423        ATCGACATTCACTCCGCGTTCAGCCAGCATCTCCTGCAGCTCACGGTAACTGATGCCGTA 400 
                *********************************** ************************* 
84              TTTGCAGTACCAGCGTACGGCCCACAGAATGATGT CACGCTGAAAATGCCGGCCTTTGAA 660 
EF370423        TTTGCAGTACCAGCGTACGGCCCACAGAATGATGTCACGCTGAAA TGCCGGCCTTTGAA 460 
                *********************************** ************************* 
                                                                          -- 
84              TGGGTTCATGTGCAGCTCCATCAGCAAAAGGGGAT GATAAGTTTATCACCACCGACTATt 720 
EF370423        TGGGTTCATGTGCAGCTCCATCAGCAAAAGGGGATGATAAGTTTA CACCACCGACTATt 520 
                *********************************** ************************* 
                ------------ 
84              tgcaACAGTGCCAACGCCGGGTtattctTATTTGTCGCTTCTTTACTCGCCTTTATCGGC 780 
EF370423        tgcaACAGTGCCAACGCCGGGTtattctTATTTGTCGCTTCTTTACTCGCCTTTATCGGC 580 
                *********************************** ************************* 
                                          
84              CTTCACTCAAGGATGTATTGTGGTT ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTT 840 
EF370423        CTTCACTCAAGGATGTATTGTGGTT ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTT 640 
                *********************************** ************************* 
84              AGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGC AGCCGCTTGAG               886 
EF370423        AGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAG 700 
                *********************************** ***********               
(Bold ATG ) Start codon for blaSHV (positon 606) 
(Small case) Promoter of SHV at position 520-525 (-3  signal), 543-548 (-10 signal) 
(-) Iverted repeat sequence of IS26 (position 519-532) 
(*) Indicate identity 
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Fig 5.2: Alignment of DEOR transcriptional regulator gene from isolate 84 with the 
GeneBank EF370423  
 
84                                              AAT CAGCAAATCGCCGGGATCGGCGCGG 28 
EF370423        TGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGG 1440 
                                                *** ************************* 
                                                               --- 
84              CGCTGATCGAGCACTGGCAACGC taaGCCGGCGGTGGCCGCGCGCGTTATCCGGCCCGCA 88 
EF370423        CGCTGATCGAGCACTGGCAACGCtaaGCCGGCGGTGGCCGCGCGCGTTATCCGGCCCGCA 1500 
                *********************************** ************************* 
84              GCACCTTGCAGGCGTGCCGGGCGATATGACTGGCG GCGGCATCGGAAAGATGCCGGTCGG 148 
EF370423        GCACCTCGCAGGCGTGCCGGGCGATATGACTGGCGGCGGCATCGGAAAGATGCCGGTCGG 1560 
                ****** **************************** ************************* 
84              TAATGATAGTGGTGAACCGGGTCAAAGGTAACGCC ATAAACGTGGCCACCTGATTGTATT 208 
EF370423       TAATGATGGTGGTGAACCGGGTCAAAGGTAACGCCATAAACGTGGCCACCTGATTGTATT 1620 
                ******* *************************** ************************* 
84              TCGAACTGTCGCACAGCAGGATGCTTCTCGCGCTG ACCTGGCTGACGGTCTCCTTGACGG 268 
EF370423        TCGAACTGTCGCACAGCAGGATGCTTCTCGCGCTGACCTGGCTGAC GTCTCCTTGACGG 1680 
                *********************************** ************************* 
84              TAACCTTGTTCTCATCAGGGGTGAATATCCCGTGA CTGTCCCAGCCGCTGGCGGAGATAA 328 
EF370423        TAACCTTGTTCTCATCAGGGGTGAATATCCCGCGACTGTCCCAGCCGCTGGCGGAGATAA 1740 
                ******************************** ** ************************* 
84              AGGCCGTATCGATAGCCAGGTGGCGTAACGTACGC GCCGCCGATTCGCCCACGCAGGAGC 388 
EF370423        AGGCCGTATCGATAGCCAGGTGGCGTAACGTACGCGCCGCCGATTCGCCCACGCAGGAGC 1800 
                *********************************** ************************* 
84              GGTTCTCCCGGCACAGAGTGCCGCCGGTGTGGATC ACGCCGCACTGGCTGGCATCGATCA 448 
EF370423        GGTTCTCCCGGCACAGAGTGCCGCCGGTGTGGATCACGCCGCACTGG TGGCATCGATCA 1860 
                *********************************** ************************* 
84              GCAGCTGGGTTATCTCAAAATCATTGGTGACCACC TGGAGATCGTTCCGGTCGAGGATCG 508 
EF370423        GCAGCTGGGTTATCTCAAAATCATTGGTGACCACCTGGAGATCGTCCGGTCGAGGATCG 1920 
                *********************************** ************************* 
84              CCCGCGCCAGCGCCAGGGTGGTAGTCCCGGCATCC AGATAGATGCAACTGTTTTTAGCGA 568 
EF370423        CCCGCGCCAGCGCCAGGGTGGTAGTCCCGGCATCCAGATAGATGC ACTGTTTTTAGCGA 1980 
                *********************************** ************************* 
84              TATGACTCGCCGCCAGCGCGCCGATCGCCTGTTTC TCCTCACTCTGCAGCGTGCTTTTCA 628 
EF370423        TATGACTCGCCGCCAGCGCGCCGATCGCCTGTTTCTCCTCACTCTG AGCGTGCTTTTCA 2040 
                *********************************** ************************* 
84              CCAGATGACTGGGTT                                              687 
EF370423        CCAGATGACTGGGTTCCGCGGCCAGCCGGCTGACGGCGCGTACGCCGCCCGAGACGCTGA 2100 
                ***************    
(Small case): taa, stop codon of blaSHV 





5.3.8. Genetic environment of blaSHV-12 and  blaSHV-5 
 
The environment of blaSHV-12 genes identified in this study confirmed that IS26 was 
found 73 bp upstream of the blaSHV-12
 gene in all cases but one which produced a 
band of 1.5 kbp but it could not be sequenced. Furthermore, in all SHV-12-producing 
strains, the putative DEOR transcriptional regulator (GenBank EF370423 
[GenBank]) was identified 21 bp downstream of the blaSHV-12 gene. 
 
The environment of blaSHV-5 gene was surrounded by a gene encoding a putative 
RecF protein (GenBank AY532647 [GenBank] ) upstream and the gene coding the 
putative DEOR transcriptional regulator downstream (Figure 5.3). The upstream 
IS26 of blaSHV-5 was negative by PCR.  
 











Isolate 84: small SHV transposon
Isolate 215: Small SHV transposon
K transport ATPase, kdpc
Un-sequenced region
 
Fig 5.3: Large and small SHV transposons. The large SHV transposon map is based 
upon the sequence of Escherichia coli plasmid p1658/97 and the small transposon 
map is based upon the sequence of Enterobacter cloacae plasmid pEC-IMPQ. The 
large SHV transposon typically harbours non-transferabl  a blaSHV encoding the non-
ESBL SHV-11. The small SHV transposon typically harbours a blaSHV encoding the 




5.3.9. Reverse transcriptase PCR  Results 
 
blaSHV mRNA levels were measured using reverse transcriptase
 PCR, and the 
difference in the cycle number between the wo amplification reactions (or ∆Ct 
values) which provides a measure of relative gene dosages of each allele were 
calculated as follows: ∆Ct = Ct (blaSHV
 cDNA) – Ct (16S cDNA). Three isolates 
carry different transposon (Large, Small, and un-sequenced) were analysed (Table 
5.2) and (Fig. 5.4, 5.5, 5.6). The ∆Ct for the large SHV transposon-containing 
isolates was 110.1 cycles, which is significantly more than the value for the small 
SHV transposon isolates (63.3 cycles). Thus, the presence of the large SHV 
transposon increases blaSHV
 mRNA by ~2x. This confirms that the mutated promoter 
has enhanced the activity.  
 









187, small transposon 71.2 7.9 63.3 
195, large transposon 123 12.9 110.1 










Fig 5.4: Gel electrophoresis of reverse transcriptase mplification of SHV enzyme. 
Lane 1: 1Kbp molecular marker. Lane 2: isolate no. 187. Lane 3: isolate no. 195. 





Fig 5.5: Gel electrophoresis showing amplification of 16s ribosomal RNA. Lane 1: 
1Kbp molecular marker. Lane 2: isolate no. 187. Lane 3: isolate no. 195. Lane 5: 






Fig 5.6: Gel electrophoresis showing extraction of mRNA. Lane 1: 100 bp molecular 
marker. Lane 2: isolate no. 197 (excluded due to degraded mRNA). Lane 3: isolate 
no. B31 (excluded due to degraded mRNA). Lane 4: isolate no. 187. Lane 5: isolate 
no. 195. Lane 7: isolate no. 215.   
 
5.3.10. Incidence of class 1 and class 2 integrons 
 
Results of class 1 integrons tested from 32 ESBLs-positive strains by PCR revealed 
that 9 isolates produce (~2kbp band), 11 isolates produce a 1kbp band and 6 isolates 
produce 2 bands (1.5kbp and 2kbp), 2 isolates were n gative. Four isolates did not 
run by PCR. The sequencing of representative samples from each group show that 
the first group (~ 2 kb in size) were found to harbour two gene cassettes; 
dihydrofolate reductase and aminoglycoside adenyltransferase genes, dfrA12 and 
aadA2, which confers resistance to trimethoprim and, streptomycin/spectinomycin; 
the second group (1.0 kb in size) was identified either with the aadA2 or aadA1 gene 
cassette; the third group (1.5kbp and 2.1 kbp in size) found to be dihydrofolate 
reductase gene, dfrA12 and erythromycin esterase ereA2 genes.  
 
Class II integrons were identified in three isolates. These isolates were positive for 




The intl1, sul1, and qacE∆1 genes representing the class1 integrons were identif ed 
by PCR as shown in Table 5.1. Five isolates were negative for all of these genes, 4 
isolates lacked intl1 and harboured sul1, and qacE∆1 genes. One isolate carried intl1 
only while it was negative for class1 integrons primer (5-CS and 3-CS).  
 
5.3.11. Isoelectric focusing (IEF) analysis 
 
IEF of crude extracts from isolates revealed β-lactamases with pIs of 8.2 (SHV-12 
and SHV-5) and 7.6 (SHV-1, SHV-11 and SHV-80). Twenty-four isolates produced 
enzymes with a pI of 5.4, which matched the TEM-1 β lactamase. In addition, 16 
isolates were found to express pI of 8.6 matching the CTX-M-15 β-lactamase. Some 
isolates produced other pIs bands.  
 
5.3.12. Plasmid analysis  
 
The plasmids analysis from ESBL K. pneumoniae strains carrying blaSHV genes were 
assigned to be IncN and/or IncFII replicons. The IncN type was identified by PCR 
from 24 isolates, the IncFII type was amplified from 18 isolates from which 16 
isolates were found to carry both IncFII and IncN replicons. Two isolates did not 
determine. In addition, 4 isolates were negative for any replicons type identified 
using the primers pairs targeting FIA, FIB, FIC, I2, I1, L/M, N, A/C, and FII 
replicons.  
 
Both IncFII and IncN replicons types were identified by PCR from all strains 
carrying blaSHV-12 and blaSHV-5 genes except one isolate producing blaSHV-12 was 
assigned to be IncN plasmids only. Additionally, the strain carrying blaSHV-80 was 



















































































































Fig 5.7: PFGE dendrogram showing the relationship between SHV-producing K. 
pneumoniae isolates obtained after Xba1-digested the chromosomal DNA. A band 
position tolerance of 2.0% was used in PFGE pattern analysis with the Dice band-
based similarity coefficient. Strain numbers and source are shown on the right. 




5.3.13. PFGE  
 
PFGE analysis was used to assess the clonality of 33 f the K. pneumoniae strains 
producing SHV and LEN β-lactamases. Results of PFGE revealed that 17 PFGE (> 
85 similarity) profile types were identified. Five profile types, defined clusters I to V, 
included two or more isolates that were genetically related (with >85% similarity) 
(Fig 5.7). The largest cluster IV consisted of 7 strains producing mainly SHV 
associated with CTX-M-15, TEM and qnrB1. The second largest cluster II consisted 
of five strains, all expressed SHV, TEM and most (n = 4) co-expressed qnrA1 genes. 
Clusters I and III contained 4 and 3 isolates obtained from urine and blood 
respectively, all of them characterized by production of CT-M-15 co-expressed with 
SHV. On the other hand, the isolate number 172 which carries blaLEN was unrelated 
to other isolates tested and identified in separate cluster. Moreover, the  
remaining isolates had PFGE profiles with a similarity of < 85% and were 





Detection of ESBL-producing K. pneumoniae can be difficult. The reasons include: 
the hyperproduction of non-ESBL β-lactamases, SHV-1 or SHV-11, due to high 
gene copy number or a single base pair change in promoter sequence, or 
modifications in outer membrane proteins co-existing with TEM-1, SHV-1 and 
SHV-11. These resulted in increased MICs and confer an ESBL similar phenotype 
causing false positive results (Podbielski, Schonling et al. 1991a; Rice, Carias et al. 
2000; Wu, Siu et al. 2001).  
 
Klebsiella pneumoniae produces species-specific class A chromosomal β-l ctamases 
that confer resistance to ampicillin, amoxicillin, carbenicillin and ticarcillin. Three 
families of chromosomal β-lactamases, including SHV, LEN and OKP, have been 
identified in clinical K. pneumoniae isolates (Lee, Cho et al. 2006). The SHV-type 
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ESBLs were successful and widely distributed in K. pneumoniae. A survey from 
seven countries (South Africa, Argentina, Australia, Turkey, USA, Taiwan and 
Belgium) shown that SHV-type ESBLs were occurred in 49/73 of the isolates 
collected in 1996/7 from all of the countries, SHV-5 being the most common 
genotype (Paterson, Hujer t al. 2003). 
 
K. pneumoniae isolates are expected to present an intrinsic resistance to ampicillin 
(Heritage, M'Zali et al. 1999), but only 90% (54/60) of tested strains in this study 
were positive by PCR for SHV genes. Similar resistance findings reported that 95% 
(178/187) of K. pneumoniae isolates collected from Portugal showed reduced 
susceptibility to ampicillin (Mendonca, Ferreira et al. 2009). In an Australian study, 
the blaSHV was identified from all 21
 Klebsiella pneumoniae isolates obtained 
between 1991 and 1995. Of these 13 strains were ESBL-positive (6 carried blaSHV-2a 
gene and 7 carried the blaSHV-12 gene) and 8 strains were ESBL-negative (7 strains 
carried blaSHV-11 and one strain carried blaSHV-1
 gene) (Howard, van Daal et al. 2002). 
 
Consistent with previous results by Lee, Cho et al. (2006), the blaSHV-11 was the most 
prevalent gene described in this study in 21 isolates (17 isolates alone plus 4 isolates 
associated with blaSHV-12 and blaSHV-80). The blaSHV-11 has been described most often 
in K. pneumoniae (Nuesch-Inderbinen, Kayser t al. 1997), and may be the ancestor 
of blaSHV-2a and blaSHV-12 (Kim, Shin et al. 2002; Ford and Avison 2004). The non-
ESBL phenotype conferred by SHV-11 shows that the Leu35Gln substitution 
between SHV-11 and SHV-1 has little or no significance with respect to hydrolysis 
of expanded-spectrum cephalosporins, and therefore its appearance is likely to be due 
to drift rather than antibiotic selection (Howard, van Daal et al. 2002).  
 
Using direct sequencing, 3 isolates producing SHV-type β-lactamases showed mixed 
sequences from blaSHV-11 (Leu35→Gln), and blaSHV-12 (Leu35→Gln, Gly238→Ser, 
Glu240→Lys) and one isolate showed blaSHV-11 (Leu35→Gln) and blaSHV-80 
(Leu35→Gln, Ala146→Thr ). The possibility of multiple alleles in a single isolate 
has previously been reported previously. Lee, Cho et al. (2006) showed that K. 
pneumoniae strains carrying blaSHV-11 on the chromosome abundantly express 
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plasmid-derived SHV-12, concluding that blaSHV-11 was transferred from the 
chromosome by an IS26 originating from a blaSHV-12 element which showed a direct 
relationship between IS26 and blaSHV. Furthermore, 4 isolates from 13 ESBL-
positive strains were carried copies of a non-ESBL-encoding gene either blaSHV-1 or 
blaSHV-11 in addition
 to the blaSHV-2a or blaSHV12 gene (Howard, van Daal et al. 2002). 
 
The blaSHV-80 has substitution Ala146→Thr and showed unusual resistance to 
meropenem. The substitution of Ala146→Val was observed before in blaSHV-38 
which considered the first example of an SHV-1 derivative that had reduced 
susceptibility to several expanded-spectrum cephalosporins and imipenem. The 
author indicated that the Ala146Val substitution is located at the N terminus of an 
alpha helix, neither in the β-lactam binding site nor in the catalytic site. It is parallel 
to the region from positions 161 to 164 of the omega loop structure known to play a 
key role in β-lactam hydrolysis at a distance of 3.1 Å. The amino acid Ala146 is 
oriented toward the solvent and may significantly disturb the conformation of the N-
terminal part of the helix (Poirel, Heritier t al. 2003). On the other hand, the authors 
whose first described blaSHV-80 did not mention any resistance toward imipenem or 
meropenem (Mendonca, Ferreira et al. 2009).  
 
Almost all SHV-derived ESBLs have a G→A mutation which specifies a glycine-to-
serine substitution at amino acid 238. In this study the blaSHV-12 was detected in 8 
strains (1 alone, 1 together with qnrA1, 3 together with blaCTX-M-15 and blaTEM-1 genes 
and 3 together with blaTEM-1). SHV-12 was first identified in 1997 in Switzerland 
(Nuesch-Inderbinen, Kayser t al. 1997). The blaSHV-12 evolved from the branch of 
blaSHV-2a by evolutionary analyses (Ford and Avison 2004). The blaSHV-12 later 
reported from various continents and there has been a predominance of SHV-12 in 
south-east Asia (Lee, Cho et al. 2006), Spain (Diestra, Juan et al. 2009) and Italy 
(Carattoli, Miriagou et al. 2006). 
 
The plasmid-encoded SHV-5 was first identified in K. pneumoniae in 1989. SHV-5 
tends to hydrolyse most penicillins, narrow-spectrum and extended-spectrum 
cephalosporins, less on aztreonam and inhibited by β-lactamase inhibitors (clavulanic 
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acid, sulbactam, and tazobactam) (Gutmann, Ferre et al. 1989). In this study the 
SHV-5 was identified in one strain only. This result is in contrast to the previous 
studies until the late 1990s, European surveys of extended-spectrum β-lactamases 
(ESBLs) almost exclusively found TEM and SHV enzymes especially SHV-2 and 
SHV-5 which largely found in Klebsiella spp. (Livermore, Canton et al. 2007). Also, 
previous studies have demonstrated that SHV-5 is the most frequent ESBL in several 
enterobacterial species recovered from hospitalized patients in Mexico (Garza-
Ramos, Davila et al. 2009).  
 
My results are quite different from that was observed before in Scotland, in which 
SHV-2 and SHV-5 were detected in clinical isolates of K. pneumoniae collected at 
the Royal Infirmary of Edinburgh between May 1999 and March 2000 (Dashti, Paton 
et al. 2006). Moreover, 38 patients colonized with multiply-resistant ESBL blaSHV-2 
producing K. pneumoniae, were discharged from hospital to 22 nursing or resid ntial 
homes during a hospital-based outbreak, in the Grampian region, Aberdeen, Scotland 
(Bird, Browning et al. 1998). Another study linked between the qnrA1 gene and 
blaSHV-5 from K. pneumoniae isolates collected in 2006 (Hamouda, Vali et al. 2008).   
 
These findings are consistent with the English study where, the sequence analysis 
identified TEM-1, SHV-1/28, SHV-11, CTX-M-15 or CTX-M-33 variants among the 
K. pneumoniae isolates, and TEM-1, SHV-12 or KPC-4 in the Enterobacter spp. 
isolates from among clinical reference submissions received between April 2006 and 
March 2007 (Doumith, Ellington et al. 2009). In another study, 11 of 15 qnrA-
positive isolates, including single isolates of E. coli and C. freundii, 4 K. pneumoniae 
and 9 E. cloacae recovered during 2003-2005 in Liverpool were carried class 1 
integrons and expressed the ESBL blaSHV-12 (Corkill, Anson et al. 2005).  
 
On the other hand, the results show dissimilarity with the another English study, 
where SHV-2 (n=4), SHV-5 (n=3), and SHV-4 associated with TEM-15, and TEM-
26 (n=1) were identified from 10 distinct ESBL-producing strains of K. pneumoniae 





It is well-known that SHV ESBLs are plasmid associated in K. pneumoniae because 
an ESBL-conferring mutation in the poorly expressed chromosomal gene will not 
confer a phenotype (Hammond, Harris et al. 2008; Turner, Andersson et al. 2009). 
The conjugation results showed that the majority (29/3 ) of K. pneumoniae isolates 
harbour transferable blaSHV. These results highlight that most of these genes w re 
plasmids associated and characterized by high transferability. These findings 
enhance the possibility of mutational changes and pro uction of ESBL phenotypes. 
In addition, the strain 195 which carry blaSHV-11 and contain the large SHV 
transposon was failed to conjugate with the recipient strain. This result indicates a 
chromosomal location which agrees with other findings that the large SHV 
transposon is chromosomal location (Turner, Andersson et al. 2009). Furthermore, K. 
pneumoniae strain 208 possessed blaSHV-12 could not be transferred by conjugation 
indicating a nonconjugative plasmid location.  
 
Dissemination of SHV ESBLs may be largely mediated by plasmids or insertion 
sequences. The prevalence of K. pneumoniae isolates with more than one β-
lactamase has increased in recent years because high mobilization of ESBLs genes 
from genome to plasmid mediated by insertion sequences especially IS26 (Ford and 
Avison 2004). The close association of insertion sequences with antibiotic resistance 
genes strongly suggests an active role for these sequences in the evolution or 
dissemination of antibiotic resistance genes (Kim, Shin et al. 2002). IS26 was found 
associated with a class 1 integrons which considered as a critical step in the evolution 
of diverse multiresistance plasmids found in clinical enterobacteria (Miriagou, 
Carattoli et al. 2005). IS26 generates 8 bp target duplication upon transposition 
(Mollet, Iida et al. 1983). IS26 has been associated with several antibiotic resistance 
genes, including aphA1 in Tn2680, a blaT–aac5 operon in plasmid pUZ3644, an IAB 
operon in plasmid pBWH77, dhfrVIII in plasmid pLMO226 and dfr13, aadA4, 
blaTEM-1 and sul2 gene in plasmid pUK2381 (Kim, Shin et al. 2002).  
 
All isolates but one were found to carry the small SHV transposon. IS26 insertion in 
this study was identified in the blaSHV promoter with 14bp target duplication. It is 
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known that the small SHV transposon has a strong promoter that was generated by 
insertion of IS26 into the blaSHV promoter region through the introduction of a 
different –35 region (Kim, Shin et al. 2002; Turner, Andersson et al. 2009). The 
previous findings reported that the IS26 sequence was inserted immediately upstream 
of blaSHV-11, blaSHV-2a and blaSHV-12 genes generates the hybrid promoter consisting of 
the –35 region derived from IS26 and the –10 region from the blaSHV promoter itself. 
The IS26-insertion generated a hybrid promoter in which the TTGTGA –35 region of 
the blaSHV-12 promoter was replaced by the –35 sequence TTGCAA provided by the 
left inverted repeat of IS26. This hybrid produced an efficient promoter and 
increased β-lactam resistance (Podbielski, Schonling et al. 1991). 
 
In this study by PCR the insertion sequence IS26 couldn’t amplify associated with 
blaSHV-5 gene. The similar findings indicated that copies of IS26 are present, but not 
immediately adjacent to the region of homology with pACM1 carrying blaSHV-5 gene 
(Preston, Venezia et al. 2004). In contrast to this result, IS26 insertion was found 2 
kbp upstream in the plasmid-mediated SHV-5 enzyme (Gutmann, Ferre t al. 1989).  
 
The large SHV transposon-borne promoters (IS26-lacY-recF-SHV) were amplified 
from only one isolate harboured non-transferable blaSHV. The sequence from the
 
large SHV transposon-containing isolate was identical to the blaSHV promoter 
sequence reported by (Rice, Carias et al. 2000). This promoter has enhanced activity, 
due to a C→A mutation in the –10 region (Turner, Andersson et al. 2009). 
 
Seven of the 8 blaSHV-12 genes were located in IncN and IncFII plasmids but one 
isolate was assigned to be IncN plasmids. On the otr hand, it was not possible to 
determine the incompatibility group of the other one with the set of primers used. 
These results are in agreement with another study that correlated blaSHV-12 with a 
diversity of IncI1, IncK, IncFII and IncH12 (Diestra, Juan et al. 2009). Whereas 
other study linked blaSHV-12 with IncFII, IncI1
 and IncA/C plasmids (Carattoli, 




The plasmids carrying blaSHV-5 gene were assigned to be IncFII and IncN replicons 
types. Similar to these results, the blaSHV-5 gene was located in IncFII plasmid and its 
environment was surrounded by a gene encoding a putative RecF protein upstream 
and the gene coding the putative DEOR transcriptional regulator downstream 
(Diestra, Juan et al. 2009). Moreover, the plasmid p1658/97 carrying blaSHV-5 gene 
was found to bears two replication systems, IncFII and IncFIB (Zienkiewicz, Kern-
Zdanowicz et al. 2007).  In 2004, blaSHV-5 was identified on a compound transposon 
flanked by IS26 insertion sequences in the pACM1 plasmid from K. oxytoca 
obtained from an outbreak in 1993 in USA (Preston, Venezia et al. 2004). 
Subsequently, the compound transposon was found on Salmonella enterica pSEM 
plasmid isolated from October 2000 to February 2001 from infants with 
gastroenteritis in Romania (Miriagou, Filip et al. 2002). Also, blaSHV-5 was identified 
on a compound transposon in p1658/97 plasmid from a clonal E. coli outbreak in a 
Warsaw, Poland, hospital in 1997 (Zienkiewicz, Kern-Zdanowicz et al. 2007).  
 
Integrons play an important role in the dissemination of antimicrobial resistance 
through horizontal transmission. The integrons platform is composed of a gene (intI) 
encoding an integrase (that catalyzes the gene cassette movement by site-specific 
recombination), a recombination site (attI1), and a functional promoter (Pc) that 
directs transcription of the inserted gene cassettes. G ne cassettes are small mobile 
units composed of one coding sequence and a recombination site, attC. Integrons 
exchange gene cassettes through integrase-catalyzed site-specific recombination 
between attI and attC sites, resulting in the insertion of the gene cassette at the attI 
site, or between two attC sites, leading to the excision of the gene cassette( ) from 
the gene cassette array. To date, more than 130 gene cassettes have been described, 
conferring resistance to almost all antibiotic classes. Integrons are divided into two 
major groups: the resistant integrons (RI) and the super-integrons (SI). At present, 
five classes of resistant integrons are known to have a role in the dissemination of 
antibiotic-resistance genes. Class 1 integrons is the commonest; this is followed by 
class 2, whereas class 3 is rare. Class 4 and class 5, have been identified through their 
involvement in the development of trimethoprim resistance in Vibrio species. The 
superintegrons have been identified in a distinctive class of integrons in the 
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Vibrionaceae and in a branch of the pseudomonads genome and is not known to be 
associated with antibiotic resistance (Machado, Canton et al. 2005; Jove, Da Re t al. 
2010). 
 
In the present study I observed a high frequency of occurrence of integrons among 
ESBL-positive K pneumoniae. Results of class 1 integrons tested from 28 ESBLs-
positive strains by PCR revealed that 26/28 (93%) were positive, 2 (7%) isolates 
were negative. Three isolates (11%) were found positive for class 2 integrons; these 
isolates were found positive for class 1 integrons as well.  
 
The corresponding findings reported that Class 1 integrons were more frequently 
found (67%) among E. coli producing-ESBL collected over 12 years in a single 
hospital in Madrid, Spain (Machado, Canton et al. 2005). Moreover, the presence of 
integrons was demonstrated in 29/100 (29%) of E. coli isolates from healthy humans 
in Spain. The intI1 gene was identified in 26 of these isolates, the intI2 gene in 1 
isolate and both the intI1 and intI2 genes in 2 additional isolates (Vinue, Saenz t al. 
2008). In another study, class 1 integrons were present in 78 isolates (34.2%) in 
clinical K. pneumoniae isolates collected from Taiwan (Chang, Fang et al. 2009).  
 
The dfrA12 + aadA2, aadA2, aadA1 and dfrA12 + ereA2 gene cassettes have been 
identified by sequencing within the variable region f class 1 integrons in K. 
pneumoniae isolates collected, which confer resistance to trimethoprim, 
streptomycin/spectinomycin and erythromycin respectiv ly.  
 
To our knowledge, this the first to report the presence of arrangement of d rA12 - 
ereA2 gene cassette identified within K. pneumoniae isolates. 
 
Previous reports identified frA1 + aadA1, aadA, dfrA17 + aadA5, dfrA7, dfrA5, 
dfrA1 and dfrA12 + orfF + aadA2 gene cassettes. Most of them corresponded to 
different variants of dfrA and aadA genes (43% and 54%, respectively). The author 
also concluded that dfrA1 + aadA1 was the combination most frequently detected not 
only in his study but also in E. coli isolates recovered from healthy and sick humans, 
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animals and foods in other studies (Vinue, Saenz et al. 2008). Furthermore, (aadA1), 
(dfrA12-orfF-aadA2), (dfrA1-aadA1), (dfrA16-aadA2), (aadA2) were identified in 
another spanish investigations (Machado, Canton et al. 2005). In addition, 26 
different gene cassettes were identified from a study in Taiwan including resistance 
genes to trimethoprim (dfr1, 5, 7, 12, 17), erythromycin (ereA2), chloramphenicol 
(cmlA, catB3, catB8), ampicillin (blaOXA-30), carbenicillin (blaCARB-8), rifampin 
(arr3), and aminoglycosides (aadA1, 2, 5 for streptomycin, aadB for gentamicin, and 
aac(6′)-Ib, aac(6′)-Ib-cr, aac(6′)-Il, aac(6′)-II, aac(6′)-IIc for aminoglycoside-6′-N-
acetyltransferase) with different arrangements. A class 1 integron carrying the dfr12–





The data, showing the emergence and spread of new SHV variants in K. pneumoniae, 
is at variance with what has been found before in Scotland. The blaSHV-80 detected in 
this study may be considered of particular interest. In agreement with others, the 
presence of the IS26 element upstream of blaSHV genes described in this study 
strongly suggests an active role for these sequences in the evolution and 
dissemination of antibiotic resistance genes. Moreover, population structure analysis 
has revealed the presence of highly transfer broad-h st-range plasmids, IncN, 
harbouring the ESBL β-lactamases genes which able to disseminate within different 
clones. Finally, class 1 integrons are highly frequent among ESBL-producing K. 
pneumoniae clinical isolates. However, they encode resistances that currently affect 














































Antimicrobial resistance genes in pathogenic bacteria are considered the most rapidly 
evolving DNA sequences. The diversity of blaSHV-1 and blaSHV-11 genes based on the 
presence or absence of the non-synonymous mutation T92A was investigated. A total 
of 88 blaSHV-1 and blaSHV-11 genes was used in this study. Among the blaSHV genes 
studied, 47 were identified as blaSHV-11 and 41 were blaSHV-11 gene. Synonymous 
nucleotide mutations A402G, G705A, C786G and C324T were the most frequent. A 






The SHV enzymes are distributed worldwide. SHV-1 is the most prevalent β-
lactamase in K. pneumoniae, but it is also present as a plasmid-borne gene in various 
other species (Livermore 1995; Bradford 2001). Non-sy onymous nucleotide 
substitutions of the parental b aSHV-1 gene led to the emergence of ESBL enzymes, 
which are responsible for higher levels of resistance to extended-spectrum 
cephalosporins (Paterson and Bonomo 2005). The blaSHV-1 and blaSHV-11 genes differ 
by one synonymous nucleotide substitutions T92A coding for non-synonymous 
mutation corresponding to the Leu35Gln substitution. This substitution are found in 
many blaSHV genes (Nuesch-Inderbinen, Kayser et al. 1997). In the SHV family, 
ESBL activity is most frequently associated with a Gly238Ser substitution, and 
activity is frequently increased by a Glu240Lys substitution. The TEM situation is 
much more complex and less frequently involves Gly238 (Bradford 2001; 
Hammond, Harris et al. 2008).  Until now, 119 SHV enzymes have been identfi d 
but several of them do not code for ESBL enzymes (http://www.lahey.org/studies/).  
 
The aim of this study was to analyse the diversity of nucleotide sequences of 88 
SHV-encoding genes. The analysis of this diversity allowed predicting the 
emergence of new resistant variants.  
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6.3. RESULTS AND DISCUSSION 
 
β-lactamases offer one of the best examples of protein diversification and evolution 
as a mechanism of rapid adaptation of bacterial populations to diverse environments 
(Gniadkowski 2008). Nucleotide sequence analysis showed that CTX-1 enzyme 
(conferred resistance to cefotaxime) had arisen by the accumulation of point 
mutations in the gene encoding a TEM β-lactamase and consequently, CTX-1 is now 
named TEM-3. Similarly, SHV-1 has also been called PIT-2 (Heritage, M'Zali et al. 
1999).  
 
Here I didn’t study evolution of all blaSHV family but described the mutations only 
within SHV-1 and SHV-11 variants. A total of 88 blaSHV genes was used in this 
study were 14 (12 SHV-11 and 2 SHV-1) sequenced from our collection and 74 
downloaded manually from NCBI GenBank database (Table 6.1) which designated 
either SHV-1 or SHV-11. All these isolates do not cnfer resistance to broad-
spectrum cephalosporins. The blaSHV-1 gene sequence, as found in the GenBank 
database (accession number AF148850), was used as reference for the development 
of the framework classification. A nucleotide sequence of 861 bp from each blaSHV 
gene analysed in this study (beginning at nucleotid 1 of the coding region, 
according to standard nucleotide numbering. Nucleotid s sequences of whole gene 
were found in all isolates but 4 isolates. All sequnces were aligned without 
insertion-deletion events, and there were no missing or ambiguous data with Multi-
alignment online website Multalin (http://www.toulose.inra.fr/multalin.html). The 
nucleotide substitutions were calculated manually.   
 
The previous reports classified the blaSHV gene family based on the following 
principle: for gene blaSHV-1-X-1v or -11v, X is the gene number that has already been 
attributed to the blaSHV gene and corresponding enzyme; 1 or 11 indicates that this 
gene derived from either blaSHV-1 or blaSHV-11 parental genes; the number attributed to 
“v” indicates the framework variant according to the order of appearance in 
GenBank and literature. Ford & Avison (2004), named different gene sequence 
frameworks “v1” to “v4” following the name of the blaSHV gene (ex: blaSHV-1v4). 
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Mendonca, Nicolas-Chanoine t al. (2009) identified 83 different blaSHV gene 
sequence frameworks from (1 to 83). These frameworks resulted from the 
combination of both synonymous nucleotide mutations at 39 different nucleotide 
positions and the T92A non-synonymous mutation. 
 
Among the 88 blaSHV gene sequences tested, 47 (53.4%) were blaSHV-1 gene, 
characterized by a T residue at position 92 resulting in amino acid Leu at position 35, 
41 (46.6%) were blaSHV-11 gene with the non-synonymous mutation T92A encoding 
amino acid substitution Leu35Gln. Similar to these results, Mendonca, Nicolas-
Chanoine et al. (2009) identified 45 blaSHV gene sequence frameworks were based on 
the parental gene blaSHV-1, 38 were based on the blaSHV-11 gene. On the other hand, 
(Lee, Cho et al. 2006) reported that 62% blaSHV-11 genes and 35% blaSHV-1 among 
142 blaSHV genes studied.  
 
Alignment of all nucleotide sequences obtained showed 19 polymorphic sites dose 
not implied amino acid changes. One nucleotide substit tion observed occurred at 
sites G846A among 3 K. pneumoniae isolates sequenced in this study. Synonymous 
nucleotide mutations A402G (91%), G705A (57%), C786G (62.5%) and C324T 
(40%) were the most frequent observed in this study. The corresponding figures 
indicated that the appearance of these mutations were A402G (90%), G705A (60%) 
and C786G (66%) (Mendonca, Nicolas-Chanoine et al. 2009). In addition, (Nuesch-
Inderbinen, Kayser et al. 1997) reported that 59% of 34 blaSHV genes had 




The study of genes evolution and evolutionary forces acting on the genetic 
diversification can provide the ability to predict the emergence of new resistant 
variants. They also provide the opportunity for continuing basic scientific research to 


























AF148850 C T G C C A C C G G G G G C T G C C G 
Nucleotide 
changed 
T A C T T G T T A A A C A G C A G T A 
Time of change 1 47 1 35 22 80 1 3 1 8 50 10 1 4 18 1 55 16 3 
Percent of 
change 
1.1% 53.4% 1.1%  40% 25% 91% 1.1%  3.4%  1.1% 9% 57% 11.4%  1.1% 4.5%  20.5% 1.1% 62.5% 18% 3.4% 
 
Table 6.1: Polymorphic nucleotides site mutations ad percentage of these mutations within parental bl SHV-1 and blaSHV-11. The 
accession numbers used in this study are: AF148850, AF124984, FJ668818, FJ668813, FJ668802, DQ478720, GU 83598, GQ389703, 
DQ219472, AY826416.1, FJ668814, FJ668811, FJ668810, FJ668809, GQ389701, EU418908, X98099, EU280315, X98100, Y18299, 
FJ483937, DQ219477, X98098, GU083599, AY528717, EF035561, EF035557, GQ389706, EU418909, DQ219473, 
AF462396,GQ387358, DQ219475, DQ219476, DQ219474, EF035567, HM363638, EU376965, AY293069, EF035562, EF035560, 
EF035563, FJ668804, EF035564, FJ668800, FJ668799, EF035558, GQ463148, GQ463147, DQ166780, DQ166779, GQ389707, 
GQ389705,DQ166782, GQ389704, GQ389702, GU211012, EF035565, DQ219478, GU197545, AF187732, AF117743, GU197549, 
GU197543, GU197542, GU197544, GU197546, GU197548, GU197547, HM590432, GQ470430, GQ470428. The isolates numbers 
B31, 206, 91, 205, 204, 215, 69, 210, 213, BV, 73, 195, MB. 115, 138, 85 were sequenced and used from this study.   
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CHAPTER - 7:  
 
 
































A new blaLEN-25 from the K. pneumoniae (KpIII) phylogenetic group was identified 






LEN-1 is a chromosomally encoded β-lactamase found in many strains of K.
pneumoniae. Nucleotide sequence analysis shows that the gene encoding LEN-1 is 
very closely related to the nucleotide sequence of the blaSHV-1 and OHIO-1 genes 
(Heritage, M'Zali et al. 1999). K. pneumoniae strains have been classified into KpI, 
KpII and KpIII clusters according to the intrinsic β-lactamases they express. More 
than 80% of strains belong to group KpI, which exprss SHV enzymes, groups KpII 
and KpIII each account for 10% of the population and express OKP and LEN 
enzymes, respectively (Brisse and Verhoef 2001; Haeggman, Lofdahl et al. 2004). 
LEN-1 may confer resistance to ampicillin, amoxicillin, carbenicillin, and ticarcillin, 
but not to extended-spectrum β-lactams. In addition, LEN enzymes have been 





7.3.1. PCR and DNA sequencing of β-lactamase gene  
 
The blaLEN gene was identified and sequenced with blaSHV primers (Kp-SHV_for and 
Kp-SHV_rev) allowing the complete sequence of the blaLEN gene to be determined, 
as described earlier in section 5.3.1 (Chapter-5).  
 
A new blaLEN variant was detected in ESBL-negative strain 172. This β-lactamase 
contained 286 amino acids and shared 99.3% identity w h LEN-2 (GenBank 
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AY037780). It showed 6 nucleotides coding for 3 amino acid differences in 
comparison to blaLEN-2 (Val84→Leu, Thr114→Ala and Ile257→Leu), according to 
the standard numbering scheme of (Ambler, Coulson et al. 1991). The substitutions 
Thr114→Ala was firstly described in this study. Threonine  position 114 does not 
shown significant influence to the resistance to third-generation cephalosporins. The 
deduced enzyme was designated LEN-25 according the nomenclature proposed in 
http://www.pasteur.fr/recherche/genopole/PF8/betalac _en.html.  
 
None of other transferable class A β-lactamases, such as the TEM and CTX-M 
genes, were identified from this strain. This is similar to other reports where 
individual isolates did not co-express SHV and LEN enzymes (Haeggman, Lofdahl 
et al. 2004). 
 
7.3.2. Susceptibility testing 
 
As shown in Table 9.1 (Page 173), the antimicrobial susceptibility of the strain 
harbouring LEN-25 presented lower resistance values to cefotaxime (0.03 mg/L), 
ceftazidime (0.25 mg/L) and ceftriaxone (0.03 mg/L) keeping this type of β-
lactamases remained susceptible to all cephalosporins. These characteristics are 
typical of LEN-β-lactamases (Bush, Jacoby et al. 1995). No synergy with 
ceftazidime and the β-lactamase inhibitor was detected, indicating that is strain was 
a non-ESBL producer. Additionally, this isolate was sensitive for meropenem (MIC 
= 0.015 mg/L) and cefoxitin (MIC = 2 mg/L). 
 
Interestingly, high MICs of ciprofloxacin (4 mg/L) and nalidixic acid (32 mg/L) to 
the LEN-25 β-lactamase isolate were observed. By PCR this isolate was found to 
carry qnrB6 gene. The presence of the qnr gene increased the MICs of nalidixic acid 
and fluoroquinolones by four- to eightfold (Martinez-Martinez, Pascual et al. 1998; 
Mammeri, Van De Loo et al. 2005). Other Quinolone resistance mechanisms such as 
loss of outer membrane permeability, mutations of gyrA and parC genes, efflux 




7.3.3. Gene transfer 
 
It is known that LEN-type β-lactamases are chromosome-encoded enzymes. In 
comparison with chromosome-encoded β-lactamases, plasmid-encoded β-lactamases 
are highly reproducible and can transfer resistance more easily. Transference of 
β-lactam resistance gene was tested as previously decrib d in the Material and 
Methods chapter. The blaLEN-25 carrying isolate was successfully transconjugated to 
the recipient strain, which implies that the gene ecoding for this β-lactamase is 
located on a transferable plasmid. Consistent with my result Chen, Zhang et al. 
(2005) identified the first LEN-5 encoded by a plasmid of more than 48 kbp co-
expressed with blaCTX-M-14 gene in a clinical isolate of K. pneumoniae from China.  
 
7.3.4. Characterization of blaLEN 
 
The strain positive for chromosomal blaLEN gene was belonged to the KpIII-type. 
This result was in agreement with the previous findings that strains belongiong to the 
KpIII type harbour and express the LEN enzymes (Brisse and Verhoef 2001; 
Haeggman, Lofdahl et al. 2004). 
 
The plasmid carrying blaLEN-25 gene was designated to the IncN replicons type. 
Unfortunately the size of plasmid was not determined in this work. Furthermore, this 
isolate was positive for class 1 integrons and found to carry Sul1 and qacE∆1 genes 
in the 3 conserved sequence.  
 
Using PFGE, this isolate was unrelated to other isolates tested and identified in 
separate cluster (Fig 5.7). 
 
7.3.5. Nucleotide sequence accession number 
 
The new blaLEN-25 sequence was submitted to the GeneBank Sequence Database 










The new blaLEN-25 enzyme showed 3 amino acid differences in comparison to LEN-2, 
neither of these changed the enzyme to be ESBL. This result is the second to report 
that blaLEN gene was carried in transferable plasmid suggesting more complications 












CHAPTER- 8:  
 
First report of a novel extended-spectrum beta-lact amase 
KOXY-2 producing Klebsiella oxytoca that hydrolysis 































Objectives: The aim of this study was to study the broad-spectrum resistance of the 
blaOXY-2 producing Klebsiella oxytoca. 
Methods: K. oxytoca strains MU946294N and MB193997E were isolated from urine 
and blood specimens from patients in Scotland. The isolates were tested for 
antimicrobial susceptibility by the agar double dilution method. The identification of 
the strains was by the nucleotide sequences of the rpoB and gyrA genes. The strains 
were genotyped by pulsed-field gel electrophoresis (PFGE) to determine their clonal 
relationship.  
Results: Strain MU946294N was resistant to pencillins, monobactams, 
cephalosporins including cefotaxime and ceftazidime but was not inhibited by 
clavulanic acid. Isolate MB193997E displayed a β-lactam resistance phenotype 
consistent with chromosomal β-lactamase overproduction. No common transferable 
β-lactamase genes, for TEM, SHV, and CTX-M, could be amplified in either strain. 
However, positive amplification by PCR was found with primers for the blaOXY-2 
gene. Sequencing of this β-lactamase gene in MU946294N revealed it differed by 
one mutation from the all other blaOXY genes previously reported, with an amino acid 
substitution Ala237→Thr, which enhances the binding of cefotaxime. Strain 
MB193997E showed mutations at positions 255 and 283, neither of which affect the 
function. Based on rpoB and gyrA characterization, both strains were assigned to be 
KoII phylogenic group. However, the two isolates were completely dissimilar from 
each other by PFGE.  
Conclusions: The present study is the first to report the substitution of alanine to 
threonine at position 237 in the OXY-2 β-lactamase and this enhances resistance to 




Klebsiella oxytoca is an important opportunistic pathogen causing serious infections 
especially among neonates and intensive care units (Podschun and Ullmann 1998; 
Fevre, Jbel et al. 2005).  The K1 β-lactamase, first identified from a sick child 
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infected with Klebsiella aerogenes (Klebsiella pneumoniae) 1082E in Glasgow, 
Scotland. In 1986, this strain was renamed Klebsiella oxytoca SC10,436 based on 
changes in Klebsiella nomenclature (Arakawa, Ohta et al. 1989; Granier, Leflon-
Guibout et al. 2002).  
 
The chromosome of wild-type K. oxytoca carries a β-lactamase gene, which is 
constitutively expressed at low levels and usually confers low-level resistance to 
amino- and carboxy-penicillins (Livermore 1995; Fournier and Roy 1997). In 
addition, the overproduction of the chromosomally-encoded β-lactamase is due to 
up-mutations in the promoter sequence of the genes, K. oxytoca isolates have been 
found to be resistant to broad-spectrum cephalosporins (cefotaxime and ceftriaxone) 
and monobactams (Fournier, Arlet al. 1994; Fournier, Lu et al. 1995; Wu, 
Dornbusch et al. 1999). The in vivo selection of K. oxytoca strain conferring 
resistance to ceftazidime due to Proline167Serine substitution was recently reported 
(Mammeri, Poirel et al. 2003).  
 
The DNA sequence of blaOXY of K. oxytoca differs from those of blaTEM and blaSHV 
by more than 50% and is completely unrelated to blaAmpC (Arakawa, Ohta et al. 
1989). (Fournier, Roy et al. 1996) divided the β-lactamases of K. oxytoca into two 
main groups: blaOXY-1 and blaOXY-2. These two genes share 87% nucleotide sequence 
identity. Four other groups of K. oxytoca genes have recently been reported and 
named; blaOXY-3, blaOXY-4 (Granier, Leflon-Guibout et al. 2003), blaOXY-5 and blaOXY-6 
(Fevre, Jbel et al. 2005). These β-lactamases have been placed in functional group 
2be in Bush's scheme and in class A of Ambler's clasification (Ambler, Coulson et 




8.3.1. Bacterial strains 
 
Strains MU946294N and MB193997E, identified by routine testing (API System; 
bioMerieux, France) as K. oxytoca were obtained, both in 2007, from two patients 
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hospitalized in the Royal Infirmary of Edinburgh, Scotland. Strain MU946294N was 
obtained from a patient with a urinary tract infection and strain MB193997E was 
isolated from blood of encephalopathy patient who had been treated with meropenem 
for 7 days and then improved after the medication was changed to ciprofloxacin.  
 
8.3.2. Antimicrobial susceptibility 
 
As shown in Table 8.1, the strain MU946294N showed an unusual resistance 
phenotype characterized by resistance to cefotaxime, and ceftazidime. This strain 
also expressed high levels of resistance to amoxicillin, piperacillin, cephalexin, 
cefuroxime, and naladixic acid, moderate resistance to aztreonam, ceftriaxone and 
cefoxitin and was susceptible to meropenem.  
 
On the other hand, isolate MB193997E was resistant to amoxicillin, piperacillin, 
cephalexin, cefuroxime, ceftriaxone, sensitive to nalidixic acid, ceftazidime, 
meropenem and was border-line resistant to cefotaxime (0.5 mg/L) by MIC, and (28 
± 1 mm) by disc diffusion test (BSAC guideline: 20 mm). Both strains were 
previously reported resistant to cefotaxime by the Vit k 2 system.   
 
Results obtained from cloned strains without promoters shown that the two strains 
revealed identical phenotypic resistance to amoxicillin, piperacillin, ciprofloxacin, 
ceftriaxone, aztreonam and cefoxitin. The strain MU946294N conferred ceftazidime 
insuceptibility 2-fold higher than strain MB193997E, cefotaxime resistance was 
found 4 to 16 fold higher in strain MU946294N than that observed in strain 
MB193997E.  
 
The mutation in the promoter confers at least a 4 to 9 fold increase in MIC (Fournier, 
Gravel et al. 1999); however, it proved impossible to clone the gene with its 
promoter. 
 
The synergy between cefotaxime, ceftazidime and clavulanate was observed in both 
strains as seen in Fig. 8.1.  
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8.3.3. PCR and Nucleotide sequencing 
 
DNA amplification with a crude extract of K. oxytoca as the template was performed 
by PCR with consensus primers OXY-F (ATG ATA AAA AGT TCG TGG C) and 
OXY-R (TTA AAG CCC TTC GGT CAC) which amplified the ntire blaOXY-2 gene 
based on the alignment of previously published nucleotide sequence of the blaOXY-2 
genes. PCR conditions were as follows: 5 min at 94°C, 30 cycles of 30 sec at 95°C, 
45 sec at 50°C, and 1 min at 72°C, and final extension of 7 min at 72°C. The 
sequence of entire coding region were amplified by PCR using the combination of 
primers OXY-R primer and A1- (GAA CAT AGC GGC TCC TTA T) at position 
(145 to 163) according the sequence previously published (Fournier, Roy et al. 
1996). 
 
As indicated in Fig. 8.2, the nucleotide sequencing of K. oxytoca strain MU946294N 
revealed a blaOXY-2 gene which differed by one mutation from the other all blaOXY 
genes reported previously, with an amino acid substit tion Alanine, Serine or 
Glycine to Threonine at position 237 following the numbering scheme for class A β-
lactamases. This mutation has produced the first cefotaxime-resistant OXY-2 β-
lactamase producing K. oxytoca enzyme.  
 
There were two mutations in strain MB193997E; Aspartic acid to Asparagine at 
position 255, and Alanine to Threonine at position 283. Neither mutation appeared to 
affect the phenotype resistance of the strain. 
 
The deduced enzymes were designated OXY-2-9 form isolate MU946294N and 
OXY-2-10 from isolate MB193997E according the nomenclature proposed in 
http://www.pasteur.fr/recherche/genopole/PF8/betalac _en.html.  
 
8.3.4. Association with other β-lactamases 
 
None of transferable β-lactamases (CTX-M, TEM, SHV) enzymes and plasmid-
mediated quinolone (qnr) genes were amplified in either strain.  
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Amoxicillin >256 >256 >128 >128 
Piperacillin >256 >256 >128 >128 
Nalidixic acid >128 4 - - 
Ciprofloxacin 0.5 0.015 0.03 0.03 
Ceftriaxone 64 4 0.12 – 0.25 0.12- 0.25 
Cefotaxime 8 0.5 0.12 - 1 0.03 – 0.06 
Ceftazidime 4 0.25 0.5 - 1 ≤ 0.5 
Aztreonam 32 128 0.5 - 1 0.5 - 1 
Cefuroxime >128 >128 - - 
Cephalexin >128 32 - - 
Meropenem 0.03 0.03 - - 
Cefoxitin 16 2 4 4 
 
 
Fig 8.1: synergy disc diffusion test. A; isolate no. MU946294N. B: isolate no. 
MB193997E. C: K. oxytoca standard sensitive strain. D: K. pneumoniae resistant 
strain no. 115. Ceftazidime, amoxiclav and cefotaxime antibiotic discs are arranged 
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MU946294 MIKSSWRKIAMLAA-VPLLLASGALWASTDAIHQKLTDLEKRSGGRLGVALINTADNSQILYRGDERFAMCST  
MB193997 --------------A---------------------------------------------------------- 
SG77     ------------------------------------------------------------------------- 
KH11     ------------------------------------------------------------------------- 
SG43     ------------------------------------------------------------------------- 
SB136    --------------A---------------------------------------------------------- 
SB175T   --------------A---------------------------------------------------------- 
SL911    --------------A---------------------------------------------------------- 
SG176    --------------A-------S-------------------------------------------------- 
SC103436 --------------A-------S-------------------------------------------------- 
Strain B --------------A----------------------------------------------------------                                                                                 
                 80                                                         140    
                 .                                                           .     
MU946294 SKVMAAAAVLKQSESNKEVVNKRLEINAADLVVWSPITEKHLQSGMTLAELSAATLQYSDNTAMNLIIGYLGG 
MB193997 ------------------------------------------------------------------------- 
SG77     ------------------------------------------------------------------------- 
KH11     ------------------------------------------------------------------------- 
SG43     ------------------------------------------------------------------------- 
SB136    ------------------------------------------------------------------------- 
SB175T   ------------------------------------------------------------------------- 
SL911    ------------------------------------------------------------------------- 
SG176    ------------------------------------------------------------------------- 
SC103436 ------------------------------------------------------------------------- 
Strain B -------------------------------------------------------------------------                                                                                 
                                           180                                     
                                            .                                      
MU946294 PEKVTAFARSIGDATFRLDRTEPTLNTAIPGDERDTSTPLAMAESLRKLTLGDALGEQQRAQLVTWLKGNTTG 
MB193997 ------------------------------------------------------------------------- 
SG77     ------------------------------------------------------------------------- 
KH11     ------------------------------------------------------------------------- 
SG43     ------------------------------------------------------------------------- 
SB136    --------H---------------------------------------------------------------- 
SB175T   ------------------------------------------------------------------------- 
SL911    ------------------------------------------------------------------------- 
SG176    ------------------------------------------------------------------------- 
SC103436 ----------------------------------------------------N-------------------- 
Strain B ----------------------S--------------------------------------------------                                                                                 
                            237                                      280          
                             .                                        .           
MU946294N GQSIRAGLPESWVVGDKTGTGDYGTTNDIAVIWPEDHAPLVLVTYFTQPQQDAKNRKEVLAAAAKIVTEGL 
MB193997E -------------------A---------------N---------------------------T------- 
SG77      -------------------G--------------------------------------------------- 
KH11      -------------------A--------------------------------------------------- 
SG43      -------------------A--------------------------------------------------- 
SB136     -------------------A--------------------------------------------------- 
SB175T    -------------------A--------------------I------------------------------ 
SL911     -------------------A--------------------------------------------------- 
SG176     -------------------A--------------------------------------------------- 
SC103436  -------------------A---------------N----------------------------------- 
Strain B  -------------------S--------------------------------------------------- 
 
Fig 8.2: Alignments of the amino acid sequencing of strains MU946294N and 
MB193997E with those of OXY-2-1, OXY-2-2, OXY-2-3, OXY-2-4, OXY-2-5, 
OXY-2-6, OXY-2-7, OXY-2-8 and strain B of K. oxytoca. The amino acids are 




8.3.5. Isoelectric focusing 
 
By isoelectric focusing, one band of pI 5.6 was observed for the strain MU946294N 
(OXY-2-9); the band for strain MB193997E (OXY-2-10) was of pI 5.8 as shown in 
Fig. 8.3.  
 
The IEF gel was overlaid with varying concentration of clavulanic acid. The IC50 of 
the β-lactamase inhibitor clavulanate was at least 200-fold higher in both strains 
MU946294N and MB193997E than those for the inhibitor susceptible strain. 
 
 
Fig 8.3: IEF polyacrylamide gel of OXY-2 β-lactamases of strains MU946294N, 
MB193997E. Lane 1, 7: standard marker. Lane 2, 8: isolate no. MB. Lane 3, 9: 
blaSHV-1 standard strain. Lane 4, 10: blaTEM-1 standard strain. Lane 5, 11 isolate 







8.3.6. The blaOXY-2 promoter 
 
The promoter regions for the β-lactamase genes from the two isolates were 
sequenced and compared with the promoter sequence of wild-type blaOXY-2 
(TTGTCA for -35 and GATAGT for -10), the blaOXY-2 promoter of both strains 
MB193997E and MU946294N had a substitution (G→A) of the fifth base in the -10 
consensus sequence (GATAAT).  
 
8.3.7. KOXY β-lactamase sequence comparison and phylogenetic tre e 
 
The amino acid sequences of the OXY-2 β-lactamases of strains MU946294N 
(OXY-2-9), MB193997E (OXY-2-10), strain B (accession number AY303807) and 
strains (SB136, SB175, SG77, KH11, SG43, SG176, SL911, and SC10,436) 
previously published that corresponding to OXY-2 β lactamases (OXY-2-1, OXY-2-
2, OXY-2-3, OXY-2-4, OXY-2-5, OXY-2-6, OXY-2-7, OXY-2-8) according to 
(Fevre, Jbel et al. 2005) were aligned with ClustalW software 
(http://www.ebi.ac.uk/Tools/clustalw2/). 
 
The nucleotides sequences of the rpoB and gyrA previously published and those of 
the strains MU946294N and MB193997E were aligned by using ClustalW 
(http://www.ebi.ac.uk/Tools/clustalw2/). The phylogenetic tree was built with 
Geneious software (http://www.geneious.com/). As shown in Fig. 8.4, both strains 
were assigned to be KoII based on rpoB and gyrA characterization. The 940-bp 
fragment of the rpoB gene of the strain MU946294N showed 100% of identity w th 
strain SB136 (KoII) and 99% with strains SB175T, ATC13182 (2 nucleotides) and 
SB23833 (3 nucleotides). Strain MB193997E was 99% identical to all previous 
strains and the difference was in 1 to 4 nucleotides.  
  
The identity between strain MU946294N and strain MB193997E of the rpoB gene 




The two strains differed by only two nucleotides baed on gyrA characterization, and 




Fig. 8.4: Phylogeny of the K. oxytoca rpoB genes sequences. The neighbour-joining 
tree was rooted using no outgroup. Seven rpoB genes belong to each KoI, KoVI and 




The clonal relationship between the two isolates wa studied by pulsed-field gel 
electrophoresis (PFGE). Plugs were digested with 30U of Apa1 (Promega, UK). As 
indicated from the result of PFGE in Fig 8.5, the two isolates were completely 




Fig. 8.5: PFGE patterns of K. oxytoca strains MU946294N and MB193997E. Lane 1 
and 6: Lambda DNA marker; lanes 2 and 4: repeated strain MU946294N; lanes 3 
and 5: repeated strain MB193997E. 
 
 
8.3.9. Outer membrane proteins  
 
The outer membrane proteins of the isolates were studied as detailed in Material and 
methods section and described by Bossi and Figueroa-Bossi (2007). The results 
shown in Fig 8.6 and highlighted by arrows revealed that the outer membrane 
profiles were identical in two K. oxytoca isolates studied, except for the MU946294N 
strain, which exhibited reduced expression of the 36-kDa outer membrane protein on 
a sodium dodecyl sulphate-polyacrylamide gel (SDS-PAGE). This loss might explain 







Fig 8.6: SDS-PAGE of outer membrane protein. Lane 1 and 3: isolate MU946294N. 
Lane 2 and 4: isolate MB193997E. Lane 6: K. pneumoniae isolate 175. Lane 7: K. 
pneumoniae isolate 187. The right lane is protein marker (range 23 to 175 kDa). The 
white arrow indicates OpmK34, the black arrow indicates OmpK35/36, the lower 
white arrow indicates loss of minor band. 
 
8.3.10. GenBank accession numbers 
 
The blaOXY-2-9, blaOXY-2-10 genes and the rpoB gene partial sequences of strains 
MU946294N and MB193997E have been registered in GenBank database under 










Chromosomal β-lactamases are overproduced from bacteria by several mechanisms: 
by increased gene copy numbers, by promoter mutations or acquisition of insertion 
sequences, or by mutation in a regulator gene (Fournier, Gravel et al. 1999). The 
OXY-2 β-lactamase group hydrolyzes several β- actams including carbenicillin, 
cephalothin, ceftriaxone, and aztreonam better thane OXY-1 β-lactamase group 
(Fournier and Roy 1997). The ability of the K. oxytoca β-lactamases to hydrolyze 
extended-spectrum β-lactams is a result of over-production of the enzyme (Fournier, 
Arlet et al. 1994). 
 
Strain MU946294N, described here, is the first OXY-2 producing K. oxytoca that 
confers resistance to both cefotaxime (8 mg/L) and ceftazidime (4 mg/L) when 
compared with other OXY β-lactamases previously published.  
 
An interesting result is a replacement of Alanine, S rine or Glycine at position 237 in 
the strain MU946294N by Threonine. The substitution Threonine 237 that occurred 
in the signal sequence affects the catalytic properties of the enzyme. Mutagenesis 
experiments have shown that Asparagine as well as Threonine substitutions increase 
catalytic efficiency on cephems over penems (Healey, Labgold et al. 1989). Residue 
237 belongs to the oxyanion pocket. This pocket polarizes the β-lactam’s carbonyl 
group, which is strongly attracted by the hydrogen bo ding of backbone NH amide 
groups of amino acids at positions 70 and 237. The sid  chain at residue Alanine237 
is on the outer, exposed side of the B3 β-strand that forms the right edge of the 
binding site. Cefotaxime, with its branched oximino substituent, is unable to form a 
hydrogen bond to the Alanine at position 237, but replacement of Alanine237 with a 
hydrogen bond acceptor such as Threonine enhances the binding of cefotaxime 
(Knox 1995; Fournier and Roy 1997). On the other hand, the substitution located at 
position 237 could be also responsible for the reduc  susceptibility to ceftazidime. 
This is the case for some TEM-, SHV- and CTX-M-type ESBLs (Decre, Burghoffer 




The substitution of Threonine at position 237 was ob erved in plasmid-mediated 
extended-spectrum β-lactamases, TEM-5, TEM-24, TEM-86, TEM-114, TEM-121, 
TEM-130, TEM-131 and TEM-136 (http://www.lahey.org/Studies/). All these 
β-lactamases had higher levels of resistance to ceftazidime ranging from (>32 to 512 
mg/l). The cefotaxime MICs were clearly increased in TEM-5, TEM-24, TEM-86, 
TEM-131 (4 to 64 mg/l) (Petit, Sirot et al. 1988; Chanal, Sirot et al. 1989; Kruger, 
Szabo et al. 2004; Baraniak, Fiett et al. 2005). However, TEM-121 has lost 
hydrolysis activity against cefotaxime and ceftriaxone due to a loss of its affinity for 
these substrates (Poirel, Mammeri et al. 2004).  
 
The blaOXY-2 promoter of strains MB193997E and MU946294N had a substitution 
(G→A) of the fifth base in the -10 consensus sequence. Th  mutation (G→A) led to 
a four- to nine fold increase over the wild type promoter strength (Fournier, Gravel et 
al. 1999). The resistance phenotype of the strain MB193997E displayed a β-lactam 
resistance pattern identical to that displayed by K. oxytoca strains overproducing β-
lactamase. The nucleotide substitution Asp255→Asn acid has been previously 
published in isolates SC10,436 and K. oxytoca strain KER (Sirot, Labia et al. 1998; 
Granier, Leflon-Guibout et al. 2002). The Ala283→Thr mutation has not been 
previously published in any of OXY, TEM, SHV, and CTX-M β- lactamases.  
 
In this study I reported on the resistance of K. oxytoca strains MU946294N and 
MB193997E to amoxicillin-clavulanate. This resistance pattern is similar to that 
observed when an inhibitor-resistant TEM (IRT) enzyme is produced. However, 
there were no TEM derivatives in strains MU946294N and MB193997E, as 
identified by PCR and further confirmed by pI value, pI 5.6 and pI 5.8 respectively. 
These investigations were consistent with previous literatures in which, (Sirot, Labia 
et al. 1998) reported the first K. oxytoca strain conferred resistance to inhibitors and 
was due to the amino acid substitution Ser130→Gly. The resistance had been due to 
the use of amoxicillin-clavulanate (3g/day) for 10 days.  
 
The substitution of Alanine to Glycine or Serine to Alanine at position 237 modifies 
susceptibility to clavulanic acid, but not to tazobactam. Also, the presence of 
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Threonine at this position could be responsible for the relatively high inhibitor 
concentration of clavulanic acid required to give 50% inhibition (IC50s) observed for 
the K. oxytoca β-lactamases (Fournier and Roy 1997; Mammeri, Poirel et al. 2003). 
 
The neighbour-joining trees obtained based on the sequence of the 940-bp fragment 
of the rpoB gene and 441-bp fragment of the gyrA gene were very similar. The 
nucleotide variation at these two housekeeping genes was in very close similarity 
with the phylogeny for the OXY-2 β-lactamase genes. These results were in 
agreement with the previous findings, in which the chromosomal bla gene of K. 
oxytoca is able, like housekeeping genes, to classify the K. oxytoca groups. Also, 
strains harbouring blaOXY-2 gene fall into a clearly distinct phylogenetic group 
(Granier, Leflon-Guibout et al. 2003; Fevre, Jbel et al. 2005).  
 
The PFGE was used to measure strain similarity, this method has been used for 
epidemiological studies and is one of the most discriminative genotyping methods 
for typing various bacterial genera including Klebsiella spp (Hansen, Skov et al. 
2002). Results obtained from neighbour-joining trees based on rpoB and gyrA were 
different from PFGE results, this might be due to the fact that PFGE can detect 
chromosomal rearrangements, which may be caused by mo ile elements with rapid 




This is the first report of an Ala→Thre substitution at Ambler position 237 in an 
OXY-types β-lactamases. The present study is the first to report that the blaOXY-2 
gene family can confer resistance to extended-spectrum β-lactams (cefotaxime, 
ceftazidime). Beside ESBL resistance, the same isolate confer resistance to 
amoxicillin-clavuanate. This could represent emergence of CMO (Complex Mutant 
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Objectives: This study aimed to determine the prevalence of qnr genes and their 
association with the presence of ESBLs in clinical K. pneumoniae isolates from 
Scotland. 
Results: Of the 219 isolates tested, 18 (8.2%) were found to be positive by PCR for 
the qnr genes. These positive isolates were further assessed by PCR where 11 
possessed the qnrB1 gene, 2 harboured the qnrB6 gene and 5 contained the qnrA1 
gene. None of qnrS genes were identified. All of the 18 qnr positive isolates were 
found to be resistant to nalidixic acid and ciprofloxacin. Ten of the qnrB1 positive 
isolates were associated with CTX-M, SHV and TEM, one isolate with TEM and 
SHV-types β-lactamases. All qnrA1 positive isolates were associated with TEM and 
SHV. All isolates were found to carry IncN and/or IncFII plasmids bearing class 1 
integrons possess intI1 gene encoding for the integrase enzyme and qacE∆1 and sul1 
genes. 
Conclusion: These findings indicate the higher prevalence of qnr genes than in 
previous studies but still low in general. Also, these findings indicate the co-
expression of fluoroquinolone and extended-spectrum β-lactam resistance among 
Klebsiella pneumoniae isolates in Scotland.  
 
 
9.2. INTRODUCTION  
 
Quinolone resistance results from mutations in the c romosomally-encoded type II 
topoisomerases, and via the upregulation of efflux p mps, or porin-related genes 
(Drlica and Zhao 1997; Tran, Jacoby et al. 2005). The plasmid-mediated qnr genes 
(qnrA, B, S, C and D) play an emerging role in the dissemination of fluoroquinolone 
resistance. The first plasmid-mediated quinolone resistance protein Qnr was 
identified in a Klebsiella pneumoniae isolate in 1994 (Martinez-Martinez, Pascual et 
al. 1998), where the presence of the qnr gene increased the MICs of nalidixic acid 
and fluoroquinolones by four- to eight-fold (Martinez-Martinez, Pascual et al. 1998; 
Tran and Jacoby 2002; Wang, Sahm et al. 2004; Mammeri, Van De Loo et al. 2005). 
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The qnrA gene has been identified in complex In4 family class 1 integrons, known as 
complex sul1-type integrons that may act as a recombinase for mobilisation of the 
antibiotic resistance genes located nearby (e.g., qnr, blaCTX-M and ampC) (Mammeri, 
Van De Loo et al. 2005; Nordmann and Poirel 2005; Robicsek, Jacoby et al. 2006). 
The qnrB1 located in a multi resistance plasmid in an integron-like structure near 
orf513 (orf1005) gene (Jacoby, Walsh et al. 2006). Unlike qnrA and qnrB, qnrS 
genes have been reported that it is not part of a sul1-type integron and not as a form 
of a gene cassette in a common class 1 integrons (Hata, Suzuki et al. 2005). 
Recently, two other plasmid-mediated quinolone resistance genes, namely, qnrC and 
qnrD, have been identified from China (Cavaco, Hasman et al. 2009; Wang, Guo et 
al. 2009). In addition, an association of quinolone resistance with the production of 
ESBLs has been reported. This study aimed to determin  the prevalence of qnr genes 
and its association with the presence of ESBLs in clinical K. pneumoniae isolates 
from Scotland (Nordmann and Poirel 2005). 
 
 
9.3. RESULTS  
 
9.3.1. Initial PCR results 
 
In this study, different sets of already published primers as shown in Table 2.2 
(Materials and Methods) were used in multiplex PCR for detection of qnr genes 
(Cattoir, Poirel et al. 2007; Cattoir, Weill et al. 2007; Hopkins, Wootton et al. 2007; 
Park, Kang et al. 2009). The number of qnr genes identified by PCR was 47/219 
with a percentage of (21.5 %). These results are considered as a high percentage of 
prevalence. This result was confirmed by several repeats of the PCR amplification. 
After sequencing of these amplifications, the most of them came up as hypothetical 
proteins (false positive results). The actual number of qnr genes confirmed after 
sequencing was 18 (5 qnrA and 13 qnrB) genes. My results indicate that there is a 





9.3.2. Prevalence of quinolone resistance 
 
Of all K. pneumoniae isolates tested, 18/219 (8.2%) were found to be positive by 
PCR and DNA sequencing for the qnr genes. From these isolates, 16/32 (50%) qnr 
genes were found in ESBL-producing isolates. The 18 qnr positive isolates were 
further assessed by PCR, where 13 possessed the qnrB gene, 5 contained the qnrA 
gene, none of isolates were found to harbour the qnrS genes. Out of 13 qnrB positive 
isolates sent for sequencing, 11 of them were assigned to be qnrB1 and two isolates 
were qnrB6. All qnrA-positive isolates sent for sequencing were confirmed to be 
qnrA1 (Tables 9.1 and 9.2).  
 
None of these genes (qnrB, qnrA and qnrS ) were identified from K. oxytoca isolates.  
 
Resistance to nalidixic acid was found in all 18 qnr positive isolates with MIC ranges 
from 32 to >128 mg/L. As well, all isolates were resistant to ciprofloxacin but one 
(border-line resistance) with MICs range (0.5 - >128 mg/L) as shown in Table 9.1. 
 
9.3.3. Association between qnr genes and extended-spectrum β-
lactamase 
 
As shown in Table 9.1, twelve of 13 qnrB genes were associated with SHV-types 
β-lactamases. Only one isolate carrying qnrB6 was associated with new LEN-type 
β-lactamase. All of the qnrB1 positive isolates were found to carry the TEM-1 
β-lactamase, both the qnrB6 positive isolates were negative for the TEM-1 
β-lactamase. Furthermore, 10 isolates were found to be associated with the 
CTX-M-15 β-lactamase.  
 
Four of qnrA positive isolates were found to be associated with the TEM-1 
β-lactamase, all qnrA positive isolates were associated with either SHV-11 or SHV-
12 β-lactamases. However of the isolates those were test d none were found to 
harbour blaCTX-M and the qnrA genes. 
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Table 9.1: antimicrobial susceptibility of qnr-producing K. pneumoniae isolates 
 I D Qnr gene NA CIP CFR CTX CAZ MEP CFX β-lactamases 
69 Mu 936 327 N qnrB1 >128 >128 >128 128 64 0.03 8 TEM-1, SHV-11, CTX-M-15 
73 Mu 936 619 A qnrB1 >128 >128 >128 128 64 0.03 8 TEM-1, SHV-11, CTX-M-15 
175 Mg 768 689 P qnrB1 >128 >128 >128 128 128 0.03 16 TEM-1, SHV-12, CTX-M-15 
187 Mu 949847 W qnrB1 >128 >128 >128 >128 128 2 64 TEM-1, SHV-12, CTX-M-15 
197 Mu 950618 L qnrB1 >128 >128 >128 >128 128 0.06 64 TEM-1, SHV-5, CTX-M-15 
210 Mu 956764 R qnrB1 128 >128 >128 128 128 0.03 8 TEM-1, SHV-11 
213 Mu 960 478 qnrB1 >128 >128 >128 128 64 0.06 8 TEM-1, SHV-11, CTX-M-15 
215 Mu 966 491 T qnrB1 >128 >128 >128 >128 128 0.25 64 TEM-1, SHV-11, CTX-M-15 
MB Mb141078 qnrB1 >128 >128 64 64 >128 0.06 16 TEM-1, SHV-11, CTX-M-15 
B7 B143279 qnrB1 >128 >128 128 64 128 0.06 16 TEM-1, SHV-11, CTX-M-15 
BV B14124V qnrB1 >128 >128 128 64 >128 0.03 16 TEM-1, SHV-11, CTX-M-15 
138 Mu 943 892 B qnrB6 32 2 0.06 0.06 0.12 0.03 2 SHV-11 
172 Mu 948 095 C qnrB6 32 4 0.03 0.03 0.25 0.015 2 LEN-25 
106 Mu 939 649 W qnrA1 32 0.5 16 8 64 0.03 8 TEM-1, SHV-11 
135 Mu 943 702 T qnrA1 >128 8 16 16 128 0.03 8 TEM-1, SHV-11 
204 Mu 953545 C qnrA1 >128 8 8 8 128 0.03 4 TEM-1, SHV-11 
206 Mu 956107 Q qnrA1 128 4 8 8 128 0.015 4 TEM-1, SHV-11 


























 class 1 
integrons 
69 Mu 936 327 N qnrB1 + + + + + +  I 1k 
73 Mu 936 619 A qnrB1 + + + + + + + I 1k 
175 Mg 768 689 P qnrB1 - + + + + +  I 1k 
187 Mu 949847 W qnrB1 + + + + + +  I 1k 
197 Mu 950618 L qnrB1 + + + + + +  I 1k 
210 Mu 956764 R qnrB1 - - - + + +  I 2k 
213 Mu 960 478 qnrB1 + + + + + +  I 1k 
215 Mu 966 491 T qnrB1 + + + + + +  I 1k 
MB Mb141078 qnrB1 - + + + + +  I 1k 
B7 B143279 qnrB1 + + + + + +  I 1k 
BV B14124V qnrB1 + + + + + +  I 1k 
138 Mu 943 892 B qnrB6 + - + + + +  I -ve 
172 Mu 948 095 C qnrB6 + - + + + +  III 1.5-2k 
106 Mu 939 649 W qnrA1 + + + + + +  III 1.5-2k 
135 Mu 943 702 T qnrA1 + + + + + +  III 1.5-2k 
204 Mu 953545 C qnrA1 + + + + + +  III 1.5-2k 
206 Mu 956107 Q qnrA1 - - + + + +  III 1.5-2k 





Fig 9.1: Association between qnr genes and ESBL enzymes. All of the qnrB1-positive 
isolates were co-expressed TEM, SHV/LEN β-lactamases, whereas 10 isolates were found to 
be associated with the CTX-M-15 β-lactamase. In contrast, none of   qnrA-producing isolates 
were found to harbour blaCTX-M 
 
9.3.4. Phylogenetic typing 
 
The phylogenetic types of the isolates were performed using gyrA restriction 
endonuclease as indicated in Table 9.2. All isolates b long to qnrB was assigned to 
phylogenetic type I (KpI) except one isolate which arry qnrB6 and blaLEN was 
assigned to be KpIII. In contrast to qnrB, four of qnrA1 positive isolates were 
assigned to be KpIII except one isolate was found to be KpI phylogenetic type.  
 
9.3.5. Incidence of class 1 and class 2 integrons 
As shown in Table 9.2, all qnr-producing isolates were found located in complex 
sul1-type integrons and were positive for intl1, sul1, and qacE∆1 genes which confer 
resistance to sulphonamide and quaternary ammonium compounds. Additionally, all 
isolates but one was positive for conserved sequence carrying gene cassettes. 
 
Interestingly, all qnrA-positive isolates were found to harbour the same gene cassette 
dfrA5-ereA2 genes, whereas qnrB-producing isolates were not.  













































9.3.6. Plasmid profile  
 
Analysing the plasmid electrophoretic profiles of qnr-positive isolates, all but one 
qnrA1-positive isolates showed identical plasmid profile (Fig 9.2). The plasmid 
patterns of qnrB1 and qnrB6-positive isolates were different. 
 
The plasmid typing was performed using primers as described by (Carattoli, Bertini 
et al. 2005). As shown in Table 9.2, all qnrB1-positive isolates, except isolate 210, 
were assigned to be IncFII plasmid type. qnrB6-positive isolates were negative for 
IncFII plasmid, all but one qnrA1-positive isolates were IncFII negative plasmid 
type. IncN plasmid type was amplified by PCR from all isolates except two isolates 
harbouring qnrB1 gene. 
 
Using S1 nuclease digestion followed by PFGE for some isolates showed that all 
qnr-positive clinical isolates possessed 1 to 2 plasmid  of varying sizes. 
 
9.3.7. Conjugation and transformation 
 
Transfer of qnrA gene to E. coli J62-2 isolate confirmed that four of five qnrA1-
positive isolates were successfully transconjugated. Ten of 13 qnrB-positive 
transconjugant isolates were obtained (Fig 9.3). This is indication of highly 
transferable plasmids carrying qnr genes. blaCTX-M-15, blaSHV-, and some of blaTEM 
were found to be cotransferred with qnr genes.  
 
9.3.8. Clonal relationships among isolates  
 
Finally, the clonal relationship among the isolates in this study was assessed by 
studying the PFGE genomic DNA profiles. As shown in Fig 9.4, qnrB1-positive 
samples were grouped in two major clonally related clusters. However, the isolates 
producers for qnrB6 were separated in individual clones. In addition, four of five 
qnrA1-positive isolates were all clonally related. 
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Fig. 9.2: Gel electrophoresis of Pst1 restriction endonuclease. Lane 1, 18: Lambda 
DNA/HindIII Markers. Lanes 2, 3, 4 and 15: qnrA1-producing isolates 135, 204, 206 
and 214. Lanes 5 and 6: qnrB6-producing isolates 138 and 172 respectively. Lanes 7, 
8, 9, 10: qnrB1-producing isolates. Lane 11: isolate 32. Lane 12: isolate 84. Lane 13: 
isolate 114. Lane 14: isolate 208. Lane 16: isolate U54. Lane 17: isolate 115. 
 







Fig 9.3: Gel electrophoresis shown PCR amplification of qnrA and qnrB genes from 
transconjugated isolates. Lanes (1 to 10): qnrB gene from isolates 69, 73, 175, 187, 
210, 197, 213, MB, 215 and BV respectively. Lane 11: molecular marker of 100 bp. 
Lanes (12 to 16) qnrA1: isolates no. 106, 135, 206, 204 and 214 respectively.   
 
 177 























































































Fig 9.4: PFGE dendrogram showing the clonality of 18 qnr genes harboured K. 
pneumoniae isolates. A band position tolerance of 2.0% was used in PFGE pattern 






Resistance to fluoroquinolones by family Enterobacteriacae became common and 
widespread shortly after the introduction of these ag nts (Tran, Jacoby et al. 2005). 
Until now there are many mechanisms identified respon ible for quinolone 
resistance.  These mechanisms include i) the Qnr proteins (QnrA, QnrB, QnrS, QnrC, 
and QnrD) which protect the DNA gyrase and topoisomerase IV from inhibition by 
quinolones, ii) the aminoglycoside acetyltransferas variant, aac(6′)-Ib-cr, capable of 
acetylating and reducing the activity of norfloxacin and ciprofloxacin, iii) the 
recently described fluoroquinolone-specific efflux pump protein, QepA, involved in 
pumping fluoroquinolones out of bacterial cells  (Poirel, Cattoir et al. 2008; Cavaco, 
Hasman et al. 2009).  
 
This study reported on the distribution of the qnrA, qnrB and qnrS among a 
collection of 219 K. pneumoniae isolates tested by PCR. The prevalence of qnrA, B 
and S genes were 5 (2.28%), 13 (5.9%) and 0 (0%) respectively with an overall 
distribution of 8.2%.  
 
None of these genes were identified from K. oxytoca or from E. cloacae.  
 
The previous study concerning the prevalence of qnr genes in Scotland reported that 
only 2 qnrA gene were found to be associated with blaSHV-5 from K. pneumoniae 
isolates collected in Edinburgh in 2006 (Hamouda, Vli et al. 2008).  
 
In the UK, the prevalence of qnr genes was completely different from what found in 
this study. Where (Corkill, Anson et al. 2005) found a high prevalence of qnrA 
(32%) in multidrug resistant Enterobacteriacae recov red during 2003-2005 in 
Liverpool. In another study, only six S. enterica strains isolated in the UK belonging 
to four serotypes (Stanley, Typhimurium, Virchow and Virginia) were positive for 




These investigations were consistent with previous literatures worldwide in which, 
the qnrA was estimated to be 7.7% in ciprofloxacin-resistant E. coli isolates collected 
from 2000 to 2002 in Shanghai, China (Wang, Tran et al. 2003). Additionally, in 
China 29 (8.0%) of 362 phenotypic ESBL-producing isolates were positive for qnr 
genes, with qnrA-, qnrB- and qnrS-type alleles detected in 5 (1.9%), 4 (1.5%) and 5 
(1.9%) E. coli isolates, and in 8 (8.1%), 4 (4.0%) and 4 (4.0%) K. pneumoniae 
isolates respectively (Jiang, Zhou et al. 2008).  
 
The high prevalence of qnr genes was found among 106 K. pneumoniae isolates in 
U.S.A, whereas qnrA and qnrB were detected in 15 (14%) and 6 (6%) respectively 
(Robicsek, Strahilevitz et al. 2006).  
 
In contrast, the low incidence of the qnr gene was detected in 1 of 297 nalidixic-acid 
resistant E. coli strains (0.3%) in France (Mammeri, Van De Loo et al. 2005). In 
another study, qnrA-positive Enterobacter spp. and Citrobacter freundii isolates were 
detected in four patients in two intensive care units among 703 cephalosporin-
resistant or fluoroquinolone-resistant Enterobacteriac ae which were tested from 34 
German intensive care units from 2000 to 2003 (Jonas, Biehler et al. 2005). 
Moreover, the prevalence of qnr among enterobacterial clinical isolates carrying 
ESBLs between 2003 and 2004 in Barcelona was 4.9%. The qnrA1 was the most 
prevalent, whereas only one qnrS and no qnrB were detected (Lavilla, Gonzalez-
Lopez et al. 2008). 
 
All qnr-positive isolates reported in this study were resistant to ciprofloxacin (MIC 
range 0.5 to >128 g/L) and naldixic acid with (MIC range 32 to >128 g/L). The 
corresponding finding from Scotland showed that 32 of the 69 ESBL-producing K. 
pneumoniae (46.4%) were found to be resistant to ciprofloxacin, 11 (15.9%) were 
intermediate and 26 (37.7%) were sensitive (Dashti, Paton et al. 2006).  
 
Previous reports demonstrating that qnr alone did not confer resistance to 
fluoroquinolones; however, its presence promotes the selection of additional 
chromosomally encoded quinolone resistance mechanisms. Also, qnr  may facilitate 
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further selection from low-level to high-level resistance with the usage of quinolones 
(Mammeri, Van De Loo et al. 2005; Robicsek, Jacoby et al. 2006; Robicsek, 
Strahilevitz et al. 2006; Poirel, Cattoir et al. 2008). Moreover, the expression of 
qnrA1 considerably increased the mutant prevention concentration compared to 
strains without this gene (Rodriguez-Martinez, Velasco et al. 2007a). Additionally, 
the detection of qnr genes among nalidixic acid and fluroquinolones susceptible 
isolates has also been described in other studies (Cattoir, Poirel et al. 2007; Hopkins, 
Wootton et al. 2007).   
 
From this point, the fluoroquinolone resistance in our strains was probably due to 
mutations in genes coding for chromosomally encoded type II topoisomerases, efflux 
pumps (QepA), aminoglycoside acetyltransferase variants such as aac(6′)-Ib-c2 or 
porin-related proteins; determination of the exact mechanism of resistance was 
beyond the scope when I started this project.  
 
In the present study, qnr genes were found in 18/32 (56.25%) of the ESBL-producing 
isolates. The prevalence was higher in our ESBL colle tion. The results indicated 
that all qnr-positive isolates, but 3, carried blaTEM. These 3 isolates were associated 
with either SHV-11 or SHV-12 or LEN- β-lactamases. Additionally, in 10 isolates, 
the qnr genes co-existed with blaCTX-M-15. The association of qnr-positive genes, 
ESBLs and plasmid-mediated cephalosporinases (AmpC) have been described 
elsewhere (Wang, Sahm et al. 2004; Corkill, Anson et al. 2005; Mammeri, Van De 
Loo et al. 2005; Nordmann and Poirel 2005; Jacoby, Walsh et al. 2006). Moreover, 
the significant association rate of qnr genes with ESBL genes was reported before 
(Robicsek, Jacoby et al. 2006).  
 
To explain co-expression of qnr genes and ESBLs, (Rodriguez-Martinez, Velasco et 
al. 2007b) indicated that qnrA1 and blaFOX-5 genes would be located in different 
structures (4.1 kb and 3.0 kb fragments) in the same conjugative multi-resistance 




In this study all isolates were found located in complex sul1-type integrons and were 
positive for intl1, sul1, and qacE∆1 which confer resistance to sulphonamide and 
quaternary ammonium compounds. Consistent with the previous reports in the 
finding that qnrA and qnrB genes has been identified in complex In4 family class 1 
integrons, known as complex sul1-type integrons. These genetic structures possess 
one 5`-conserved segment (5`-CS) which contains intI1 gene encoding for the 
integrase enzyme and duplicated 3`-conserved segments (3`-CS) each of them 
contains qacE∆1 and sul1 genes. The two 3`-CS surround a common region (CR) 
which contains the ISCR1 (orf513) and a unique region. Usually, a single or double 
copy of ISCR1 is found downstream from qnrA1 (Mammeri, Van De Loo et al. 
2005; Nordmann and Poirel 2005; Garnier, Raked et al. 2006; Jacoby, Walsh et al. 
2006; Robicsek, Jacoby et al. 2006; Toleman, Bennett et al. 2006; Rodriguez-
Martinez, Velasco et al. 2007b).  
 
In my work, four of five qnrA1-positive isolates were successfully transconjugated. 
Ten of 13 qnrB-positive transconjugant isolates were obtained. This is indication of 
highly transferable plasmids carrying qnr genes. 
 
The plasmid typing was done using primers as described by Caratrolle. All qnr-
positive isolates but one were assigned to be IncN. In contrast, IncFII was described 
from 14 isolates. Interestingly, qnrB6-positive isolates were negative for IncFII 
plasmid. The IncN plasmids has been shown to carry qn S in S. enterica isolates 
from UK (Hopkins, Wootton et al. 2007). 
 
One isolate was not typed with the set of primers we used and this may indicate that 
either this isolate not correspond to any of replicon types or lack of primers we used. 
In this respect, plasmids isolated from S. enterica from the UK as well as the 
pAH0376 plasmid from Shigella flexneri from China were also negative for all these 
18 replicons (Hopkins, Wootton et al. 2007). Additionally, blaCTX-M-15 and aac(6′)-Ib 
and/or aac(6′)-Ib-cr located on a 340-kb plasmid that was negative for all the 







These findings indicate the prevalence rate of qnr genes is higher than previous 
studies but still low in general. In contrast to what has been reported before, all 
isolates that expressed qnr gene were found to be resistant to ciprofloxacin and 
naladixic acid. These findings indicated that there is a need to ascertain specific 
primers to identify qnr genes. In fact, the results showed higher-prevalence a d co-
expression of fluoroquinolone resistance among ESBL-producing K. pneumoniae 
isolates in Scotland than elsewhere. Furthermore, qnrB genes were more frequent 
among the isolates collected and are more often associated with ESBL-encoding 
genes than qnrA. Additionally, all isolates were located in complex sul1-type class 1 
integrons. Finally, association of the qnrB and qnrA gene with IncN and IncFII 























































The β-lactam antibiotics are most widely used to treat infections caused by Gram-
negative bacteria. The β-lactamases are, by far, the most important mechanism of 
resistance to β-lactam antibiotics, whereas production of ESBLs in particularly by E. 
coli and Klebsiella spp. confers resistance to third and fourth generation 
cephalosporins (Paterson and Bonomo 2005; Livermore, Canton et al. 2007). Until 
2003, Klebsiella spp. are the most common ESBL-positive bacteria with mutant 
forms of blaSHV and blaTEM genes (Potz, Hope t al. 2006). Hospital outbreaks and 
the inter-hospital dissemination of resistant strains of K. pneumoniae are frequently 
reported (Diancourt, Passet et al. 2005). 
 
The results presented in this thesis answer several important questions, such as the 
distribution of resistance to extended-spectrum cephalosporins and fluoroquinolones? 
Which variants promote the resistance to β-lactamases? What is the role of amino 
acid substitutions and their function in the resistance mechanism? How the CTX-M 
family is disseminated in clinical isolates of K. pneumoniae in community and 
nosocomial environments?  
 
At the end of each chapter, the results are discussed and conclusions are drawn; 
however, an overall conclusion of the different chapters is needed to put this thesis in 
context. 
 
This study is the first general surveillance in Scotland because the previous studies 
had only entered ESBLs isolates in their surveillance. ESBL production was detected 
in 35/223 (15.7%) of the strains determined by MICs and confirmed by combination 
and synergy double disc methods with cefotaxime, cetriaxone and ceftazidime as 
indicator for ESBLs production. The β-lactamases found in this study represented a 
low percentage of resistance if compared with higher pr valence worldwide.  
 
Carbapenems, such as imipenem and meropenem, have a very broad spectrum of 
activity and resist hydrolysis by ESBLs and derepressed chromosomal AmpC β-
lactamases (Walther-Rasmussen and Hoiby 2006). Compared with other 
antimicrobial agents tested in this study, all ESBL-producing strains were found 
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susceptible to meropenem, keeping this the drug of ch ice in treatment of multi-
resistant isolates. These results are in agreement with different studies worldwide 
that carbapenems were active against all ESBL-positive enterobacteria (Goossens 
and Grabein 2005; Luzzaro, Mezzatesta et al. 2006). 
 
My findings of this thesis indicate that ESBL-producing K. pneumoniae were seen in 
greater proportions in urine than blood. This was in consistent with many reports 
from USA, Canada, and Spain. On the other hand, this was in contrast to what found 
previously in London and south-east England where, ESBL-producing 
Enterobacteriaceae were seen in greater proportions in blood than urie (Potz, Hope 
et al. 2006).  
 
Until 2003, the most ESBL-producing Klebsiella spp. were almost exclusively 
nosocomial, often from specialist units (Potz, Hope et al. 2006). The ESBL-
producing Enterobacteriaceae have increased among community-acquired strains. 
Community-acquired bacteraemia was defined as a positive blood culture taken on or 
within 48 hours of admission into hospital (Ko, Paterson et al. 2002). The 
community-acquired findings, with its limitations, hown here were occurred in 
significant numbers 11 (31.4%) among K. pneumoniae isolates submitted by GPs. 
The similar figure from 42 UK centres is 70 (24%) Of 291 CTX-M-producing E. coli 
isolates studied were reported from community patients (Woodford, Ward et al. 
2004).  
 
Also, this study has confirmed that identification f Klebsiella using gyrA PCR-
RFLP is a simple, reliable, cheaper and rapid genotypic method to identify Klebsiella 
species and phylogenetic groups. Moreover, VITEK2 had the highest sensitivity, 
specificity and accuracy to identify the Klebsiella spp than the other phenotypic 
methods. That is because biochemical tests like API 20E may fail to differentiate 
between K. pneumoniae and K. oxytoca (Kovtunovych, Lytvynenko et al. 2003). 
 
Another main issue studied in chapter 4 was the production of CTX-M enzymes by 
K. pneumoniae isolates. The CTX-M β-lactamases constitute one of the most rapidly 
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growing ESBL families. Over the last decade CTX-M types have replaced TEM and 
SHV mutants as the predominant ESBLs in numerous contries. They have evolved 
from an entirely different route from the SHV/TEM ESBLs in that they derived from 
the movement of a chromosomal β- actamases of Kluyvera spp. through conjugation 
into Klebsiella and E. coli plasmids (Bonnet 2004). 
 
In this study, I identified 16 isolates carrying CTX-M enzymes and this is considered 
to be the first report of the emergence of this family of β-lactamases in K. 
pneumoniae in Scotland. Only CTX-M-15 enzyme was described in this study 
associated with five different clones, in contrast to he UK situation where, CTX-M-
15 first reported from E. coli in the UK in 2003, co-existed with CTX-M-9, CTX-M-
14, they all belong to an epidemic clone of E. coli sequence type ST131 and serotype 
O25:H4 (Woodford, Ward et al. 2004; Livermore, Canton et al. 2007; Lau, 
Kaufmann et al. 2008). 
 
Overall, this surveillance detected 50% of CTX-M-15 enzymes among 32 ESBL-
producing K. pneumoniae isolates which is similar to the moderate rates showed by 
other surveillance studies in Europe (Edelstein, Pimkin et al. 2003; Mugnaioli, 
Luzzaro et al. 2006); (Eisner, Fagan et al. 2006); (Mesko Meglic, Koren et al. 2009). 
However, higher rates, such as 100% were reported in Spain and Scandinavia (Oteo, 
Cuevas et al. 2009; Lytsy, Sandegren et al. 2008).  
 
The CTX-M genes are frequently located downstream of an insertion sequence 
ISEcp1, which played an important role in the mobilization a d expression of these 
genes (Karim, Poirel et al. 2001; Cao, Lambert et al. 2002). The ISEcp1 was 
identified 48 nucleotides upstream in all strains but one. This result was consistent 
with a 48bp sequence previously described for blaCTX-M-15 from India and previously 
named as the W sequence (Karim, Poirel et al. 2001; Poirel, Decousser t al. 2003; 
Eckert, Gautier et al. 2006). 
 
CTX-M enzymes are borne on plasmids that enable intra- and inter-species 
horizontal spread. These plasmids may carry other resistance determinants (Bonnet, 
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2004). In this study the IncN plasmid by PCR is always present when blaCTX-M-15 
gene was identified even in the absence of IncFII. As the IncN plasmid is the only 
type present, these results are the first to indicate the role of IncN replicon types in 
the dissemination of the blaCTX-M-15 genes in K. pneumoniae. The plasmids carrying 
CTX-M-15 genes had previously been identified to incompatibility groups IncFII, 
IncFI, IncR and IncFIIk and IncL/M (Lavollay, Mamlouk et al. 2006; Coque, Novais 
et al. 2008; Carattoli 2009; Oteo, Cuevas et al. 2009; Coelho, Gonzalez-Lopez t al. 
2010).  
 
In chapter 5, only 90% (54/60) strains were positive by PCR for blaSHV genes. In K. 
pneumoniae, the SHV-type ESBLs through the 1990s were successful and widely 
distributed worldwide. K. pneumoniae isolates are expected to present an intrinsic 
resistance to ampicillin (Heritage, M'Zali et al. 1999).  
 
Although SHV ESBLs have been reported in Scotland, only two SHV variants, 
SHV-2 and SHV-5, were more common. These data showed th  emergence and 
spread of new SHV variants in K. pneumoniae. Among the new SHV enzymes 
identified in the country SHV-1, SHV-11, SHV-5, SHV-12 and SHV-80. The 
SHV-12 ESBL, not uncommon in Scotland, was found, but more surprising was the 
discovery that 3 of the 8 isolates carried CTX-M-type β-lactamases suggests a 
prominent potential for this determinant to spread among different plasmid replicons. 
The blaSHV-12 has been reported to the predominant SHV enzyme in south-east Asia 
(Lee, Cho et al. 2006), Spain (Diestra, Juan et al. 2009) and Italy (Carattoli, 
Miriagou et al. 2006). SHV-80 possessed an amino acid substitution Ala146→Thr 
and expressed unusual resistance phenotype to meropenem and co-expressed CTX-
M. An amino acid substitution, Ala146→Val, described before in SHV-38 which had 
carbapenem hydrolytic activity (Poirel, Heritier et al. 2003). 
 
During the course of this study, it was demonstrated that a number of strains carried 
both non-ESBL encoding gene (SHV-11) and ESBL (SHV-12 or SHV-80) genes. 
The prevalence of K. pneumoniae isolates with more than one β-lactamase has been 




In agreement with others, the presence of the IS26 element upstream of blaSHV genes 
described in this study strongly suggests an active rol  for these sequences in the 
evolution and dissemination of antibiotic resistance genes (Ford and Avison 2004). 
All isolates but one were found to carry the small SHV transposon. IS26 insertion 
was identified into the blaSHV promoter with 14bp target duplication which provides 
a strong promoter. The large SHV transposon-borne promoters (IS26-lacY-recF-
SHV) were amplified from only one isolate harboured non-transferable blaSHV. This 
promoter has enhanced activity, due to a C→A mutation in the –10 region (Turner, 
Andersson et al. 2009).  
 
Additionally, class 1 integrons are highly frequent 26/28 (93%) among ESBL-
producing K. pneumoniae clinical isolates. Three isolates (11%) were found positive 
for class 2 integrons; these isolates were found positive for class 1 integrons as well. 
The dfrA12 + aadA2, aadA2, aadA1 and dfrA12 + ereA2 gene cassettes have been 
identified by sequencing within the variable region f class 1 integrons. They 
encoded resistances currently correspond to old antibiotics, keeping them without 
significant contribution of ESBL dissemination.  
 
Furthermore, in chapter 6 I focussed on the differences within SHV-1 and SHV-11. 
Among 88 SHV enzymes tested, the synonymous nucleotide mutations A402G, 
G705A, C786G and C324T were the most frequent. A new ucleotide substitution 
G846A was observed within 3 isolates sequenced from our collection. This study 
could help in future understanding of the evolution processes of SHV enzymes.  
 
LEN-1 is a chromosomally encoded β-lactamase found in many strains of K.
pneumoniae (Heritage, M'Zali et al. 1999). Until now, a reduced number of studies 
based on LEN β-lactamases have been published. In chapter 7, a new blaLEN- from 
the ESBL-negative K. pneumoniae (KpIII) phylogenetic group was identified in this 
thesis. It showed 3 amino acid differences in comparison to LEN-2 (Val84→Leu, 
Thr114→Ala and Ile257→Leu), the substitutions Thr114→Ala was firstly described 
in this study but does not shown significant influenc  to the resistance to third-
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generation cephalosporins. This result was only the second after (Chen, Zhang et al. 
2005) to report the carriage of the blaLEN gene on a transferable plasmid suggesting 
further complications of resistance in future.  
 
K. oxytoca is an important opportunistic pathogen causing serious infections 
especially among neonates and intensive care units (Podschun and Ullmann 1998; 
Fevre, Jbel et al. 2005). The chromosome of K. oxytoca carries a blaOXY gene, which 
is constitutively expressed at low levels and usually confers low-level resistance to 
amino- and carboxy-penicillins (Livermore 1995; Fournier and Roy 1997). The 
blaOXY first identified from a sick child infected with K. pneumoniae in Glasgow, 
Scotland (Arakawa, Ohta et al. 1989; Granier, Leflon-Guibout e al. 2002). 
 
In chapter 8, I studied two K. oxytoca isolates. One isolate showed resistance to 
cefotaxime and ceftazidime and has Ala237→Thr substitution. The present study is 
the first to report the substitution of Ala237→Thr in the blaOXY-2 and this enhances 
resistance to cefotaxime, and ceftazidime. This mutation has produced the first 
cefotaxime-resistant OXY-2 β-lactamase producing K. oxytoca enzyme. Also, the 
same isolate confer resistance to amoxicillin-clavuanate. This could represent 
emergence of CMO (Complex Mutant OXY) capable of conferring ESBL plus IRO 
(inhibitor resistance OXY) phenotype. The massive us of β-lactam plus β-lactamase 
inhibitor combinations in patients from the community and hospital environments 
also facilitates the appearance of these type of enzymes (Canton, Morosini et al. 
2008). 
 
The substitution of Thr237 was clearly increased cefotaxime MICs in TEM-5, TEM-
24, TEM-86, TEM-131 (4 to 64 mg/l) (Petit, Sirot et al. 1988; Chanal, Sirot et al. 
1989; Kruger, Szabo et al. 2004; Baraniak, Fiett et al. 2005). Also, the presence of 
Threonine at this position could be responsible for the relatively high inhibitor 
concentration of clavulanic acid (Fournier and Roy 1997; Mammeri, Poirel et al. 
2003). Recently, Pro167→Ser substitution of K. oxytoca strain conferring resistance 
to ceftazidime was reported (Mammeri, Poirel et al. 2003). The first K. oxytoca strain 
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conferred resistance to inhibitors was due to the amino acid substitution Ser130Gly 
(Sirot, Labia et al. 1998).  
 
In recent years, the plasmid-mediated qnr genes (QnrA, QnrB, QnrS, QnrC, and 
QnrD) which protect the DNA gyrase and topoisomeras IV from inhibition by 
quinolones have become a concern because of its frequent association with ESBL 
CTX-M and CMY-type enzymes (Lavilla, Gonzalez-Lopez t al. 2008); (Poirel, 
Cattoir et al. 2008; Cavaco, Hasman et al. 2009). Total of 45 (20.2%) and 30 (13.5%) 
isolates in all isolates were resistant to nalidixic acid and to ciprofloxacin. The high 
prevalence of ciprofloxacin-resistant strains found must be taken into account when 
designing treatment of an ESBL-producing E. coli urinary tract infection. 
 
In chapter 9, I reported on the distribution of the qnrA, qnrB and qnrS among a 
collection of 219 K. pneumoniae isolates. To our knowledge, this study constitutes 
the second to report on distribution of qnr genes in Scotland. The prevalence of qnrA 
and B genes were 5 (2.28%) and 13 (5.9%) respectively with an overall distribution 
of 8.2%. The qnr genes were expressed in 18/32 (56.25%) of total ESBL-producing 
isolates. In contrast, this finding indicated high-prevalence and different distribution 
than what reported previously in Scotland (Hamouda, Vali et al. 2008).  Even though 
other resistance mechanisms such as efflux pumps (QepA), aminoglycoside 
acetyltransferase aac(6′)-Ib-cr variants or porin-related proteins are likely to be 
present. 
 
Furthermore, consistent with the previous findings, all isolates were found in 
complex sul1-type integrons and were positive for intl1, sul1, and qacE∆1 genes. 
Finally, all qnr-positive isolates but one were assigned to be IncN. In contrast, IncFII 
was described from 14 isolates. The IncN plasmids has been shown to carry qnrS in 
S. enterica isolates from UK (Hopkins, Wootton et al. 2007). The association of the 
qnrB and qnrA gene with IncN and IncFII plasmids could help disseminate these 




Overall, during recent years, attention has been focused on the increment of E. coli in 
ESBL-production particularly in the community setting, whereas little work has been 
observed in previous studies in K. pneumoniae isolates. This study has confirmed 
that the maintenance of ESBL-producing K. pneumoniae isolates within hospitals 
and in the community. Also, the emergence and spread of new ESBL variants have 
detected. Moreover, the presence of high prevalence of CTX-M enzymes among 
ESBLs K. pneumoniae isolates as described for E. coli in UK.  
 
Finally, the issues studied in this thesis are of particular importance in understanding 
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